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G-protein coupled receptors (GPCRs) are surface membrane receptors that convey a diverse 
array of signals and control many physiological processes within cells. Several human disorders 
are as a result of mutations in these receptors and they are the targets of more than 40% of all 
drugs in modern medicine. This thesis is focused on GPR56, a member of the adhesion class of 
GPCRs that is the most abundantly expressed GPCR mRNA in human islets. GPR56 is also 
highly enriched in endocrine progenitors in the developing pancreas. Its function in islets, 
however, remains elusive. Previous studies have indicated that extracellular matrix collagen III 
is the ligand of GPR56 in the developing brain, where GPR56-collagen III interaction is 
important for maintaining pial basement membrane integrity and in the normal development of 
cerebral cortex. The aim of this project was to investigate the importance of GPR56 in islet 
functions. 
 
GPR56 mRNA was detected by RT-PCR in MIN6 β-cells and in mouse and human islets, while 
mRNA encoding collagen III was detected in islets but not in MIN6 β-cells. Islet GPR56 
expression was confirmed by detection of a 70kDa immunoreactive protein and 
immunohistochemistry revealed that it was strongly expressed by ductal and β-cells and faintly 
by exocrine acini cells. In the developing mouse pancreas, GPR56 was expressed by PDX1+, 
NGN3+ and SOX9+ endocrine progenitor cells. GPR56 was strongly expressed at the early days 
of pancreas development and became downregulated as the cells differentiated. It was then 
upregulated at the stage of β-cell replication between E18 and P9. Immunostaining revealed 
that collagen III was present in islet capillaries but not in endocrine cells. Acute exposure of 
islets to 100nM collagen III increased insulin output in a GPR56-dependent manner. In addition, 
pre-exposure of islets to collagen III for 48 h exhibited enhanced insulin secretion at stimulatory 
glucose concentration, without affecting insulin content.  
 
The role of GPR56 in regulating islet mass and β-cell proliferation was determined using GPR56 
knockout (KO) mice. Deletion of GPR56 did not affect mouse body weight. There was a trend of 
mild glucose intolerance in adult KO mice fed on normal diet compared with the WT mice, but 
there was no difference in islet insulin content. Quantification of islet size and proliferating β-





mice (P56) KO mice were smaller than WT islets and this was more pronounced in P9 mice, as 
a consequence of decreased β-cell proliferation as indicated by BrdU incorporation. Moreover, 
the number of β-cells actively replicating in the cell cycle, as determined by Ki67 staining, was 
greater in the WT islets compared to KO islets at P9, leading to less β-cells but higher numbers 
of α-cells in KO islets. However, there were no differences in islet capillary density or 
percentage islet nerve area. In addition, transient transfection of MIN6 β-cells, a mouse 
insulinoma cell line with functional similarity to mouse islets, with 1.2mg of GPR56 plasmids 
resulted in a 20 fold increase in GPR56 expression and this was associated with increased β-
cell proliferation and reduced apoptosis.  
 
In summary, the data presented in this thesis have demonstrated that GPR56 is expressed by 
mouse and human islets and collagen III is localised to islet blood vessels, suggesting that 
GPR56 may be regulated in a paracrine manner by local interaction with its activating ligand. In 
addition, GPR56 is differentially expressed during mouse islet development, where it is required 
at key stages of proliferation and differentiation of endocrine cells. However, GPR56 is not 
required for islet innervation and vascularisation of the developing endocrine pancreas. 
Evidence is also provided for the role for GPR56 in islet mass regulation, as a consequence of 


















Abbreviation   Definition 
[Ca2+]i     intracellular calcium 
°C     degrees centigrade 
Ab     antibody 
AC    adenylyl cyclase 
Ach     acetylcholine 
ADP     adenosine diphosphate 
Ag     antigen 
AGE     advanced glycation end products 
ANOVA    analysis of variance 
ATP     adenosine triphosphate 
BFPP     bilateral frontoparietal polymicrogyria 
BM     basement membrane 
bp     base pair 
BrdU     5-bromo-2’-deoxyuridine 
BSA     bovine serum albumin 
Ca2+     calcium ion 
cAMP     cyclic adenosine 3,5-monophosphate 
cDNA     complementary DNA 
CNS     central nervous system 
CO2     carbon dioxide 
Col I     collagen I 
Col III     collagen III 
Col IV     collagen IV 
cpm     counts per minute 
DAG     diacylglycerol 
DI H2O     deionised water 
DMEM     Dulbecco’s modified eagle’s medium 
DMSO     dimethylsulphoxide 





dNTPs     deoxynucleoside triphosphates 
DPP-4     dipeptidyl peptidase-4 
DTT     dithiothreitol 
E     embryonic 
ECL     enhanced chemiluminescence 
ECM     extracellular matrix 
EDTA     ethylenediaminetetraacetic acid 
ELISA     enzyme-linked immunosorbent assay 
ER     endoplasmic reticulum 
FBS     fetal bovine serum 
Fura-2 AM    fura-2 acetoxymethyl derivative 
GDP     guanosine bisphosphate 
GFAP     glial fibrillary acidic protein 
GLP-1     glucagon-like peptide-1 
GLUT-2    glucose transporter-2 
GLUT-4    glucose transporter-2 
GPCR     G-protein coupled receptor 
GPR56    G-protein coupled receptor 56 
GPR56C    G-protein coupled receptor 56 C-terminal 
GPR56N    G-protein coupled receptor 56 N-terminal 
GSIS     glucose stimulated insulin secretion 
H     hour 
HbA1c     glycated haemoglobin A1c 
HCl     hydrochloric acid 
Hobbit     homolog of blimp-1 in T cells 
IFN-γ     interferon gamma 
IL-1β     interleukin-1 beta 
INS1     rat insulinoma β-cell line 
IP3     inositol 1,4,5,-trisphosphate 
IP3R     inositol 1,4,5-trisphosphate receptor 





IRS    insulin receptor substrate 
K+     potassium ion 
KATP     ATP-sensitive potassium channel 
kDa     kilodalton 
Kir6.2     inward rectifier K+ channel 
KO     knockout 
LADA     latent autoimmune diabetes of adulthood 
MAPK     mitogen-activated protein kinase 
MEM     minimum essential medium 
MIN6     mouse insulinoma β-cell line  
ml     millilitre 
mM     millimolar 
MODY     maturity-onset diabetes of the young 
MOPS     3[N-morpholino]propanesulphonic acid 
MPCs     multipotent progenitor cells 
mRNA     messenger RNA 
Mwt     molecular weight 
NaOH     Sodium hydroxide 
NFAT     nuclear factor of activated T-cells 
ng     nanogram 
NGN3     neurogenin-3 
nM     nanonmolar 
OGTT     oral glucose tolerance test 
P     postnatal 
p     probability 
PAGE     polyacrylamide gel electrophoresis 
PBND     PCR buffer with non-ionic detergent 
PBS     phosphate-buffered saline 
PCR     polymerase chain reaction 
PDX1     pancreatic and duodenal homeobox 1 





PGC-1α4  peroxisome proliferator-activated gamma co-activator 1-alpha 4 
PI     phosphatidylinositol 
PI3K     phosphatidylinositol-3-kinase 
PIP2     phosphatidylinositol 4,5-bisphosphate 
PIP3     phosphatidylinositol-3, 4,5-trisphosphate 
PKA     protein kinase A 
PKB     protein kinase B 
PKC     protein kinase C 
PLC     phospholipase C 
PP     pancreatic polypeptide 
PPARγ     peroxisome proliferator-activated receptor-γ 
pSc     peri-islet Schwann cell 
PVDF     polyvinylidene fluoride 
qPCR     quantitative polymerase chain reaction 
RBD     Rho binding domain 
RIA     radioimmunoassay 
RNA     ribonucleic acid 
RRP     readily releasable pool 
RT     reverse transcription 
RT-PCR    real time polymerase chain reaction 
SDS     sodium dodecylsulphate 
SEM     standard error of mean 
SGLT-2    sodium-glucose transport protein 2 
siRNA     small interfering RNA 
SOX9     SRY-Box 9 
SPARC    secreted protein acidic and rich in cysteine 
SRE     serum response element 
SUR1     ATP-sensitive sulphonylurea receptor 
T1D     type 1 diabetes  
T2D     type 2 diabetes mellitus 





TG2     transglutaminase 2 
TM     transmembrane domain 
TNF-α     tumour necrosis factor alpha 
Tris     tris(hydroxymethyl)aminomethane 
tRNA     transfer RNA 
TZD     thiazolidinedione 
UV     ultraviolet 
v/v    volume in volume 
VEGF     vascular endothelial growth factor 
VGCC     voltage-gated Ca2+ channel 
w/v     weight in volume 
WHO     World Health Organization 
α     alpha 
β     beta 
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CHAPTER 4 THE IN VIVO FUNCTIONS OF GPR56 IN GLUCOSE HOMEOSTASIS, ISLET 
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Chapter 1 Introduction 
 
1.1 Diabetes mellitus 
Diabetes was first recognised by the ancient Egyptians around 1500 BC as a rare disorder 
where those affected urinate excessively and suffer from weight loss. The Greek physician 
Aretaeus was said to use the term ‘diabetes’, meaning ‘flowing through’ to imply that the 
patients were drained of fluid, while ‘mellitus’ was added by Thomas Willis to indicate that the 
urine of the sufferers had a sweet taste. Attraction of ants to urine was a way for identifying 
victims with the ‘honey urine’ by the ancient Indian physicians (MacCracken et al., 1997; 
Polonsky, 2012).  
 
From a rare disease in the Middle Ages, diabetes is now a global epidemic, with 415 million 
people currently living with the disease, and this is predicted to rise beyond 642 million by 2040, 
indicating that one person in ten will have diabetes if the current trend is allowed to continue 
(International Diabetes Federation, 2015). The main drivers of increased diabetes prevalence 
are over-nutrition coupled with sedentary lifestyle, as a result of urbanisation and increasing 
global transition to western lifestyles (Narayan et al., 2010). Low and middle-income countries 
are the worst hit, with majority of people suffering from diabetes younger than 60, in their most 
productive years. Globally, diabetes places immense economic burden on healthcare systems, 
with an estimated annual global expenditure ranging between $612 billion to $1099 billion (da 
Rocha Fernandes et al., 2016). 
 
Diabetes mellitus is a disorder of glucose homeostasis. According to the American Diabetes 
Association benchmarks, adopted by the World Health Organisation, diabetes is diagnosed if 
plasma glucose is ≥ 7mM after a fasting period of at least 8 h or if it is ≥11.1mM two hours after 
oral ingestion of 75g equivalent of glucose. Glycated haemoglobin (HbA1c) of ≥6.5% is also 
indicative of diabetes (Figure 1-1) (American Diabetes Association, 2011). Individuals who do 
not meet these thresholds but have high plasma glucose are referred to as prediabetics. Such 





as fasting glucose levels of between 5.6 and 6.9mM and glucose levels of 7.8 – 11mM two 
hours after consuming a sugar-rich drink respectively (American Diabetes Association, 2014).  
 
 
Figure 1-1 Diagnostic criteria for prediabetes and diabetes using fasting plasma glucose, oral glucose 




Traditionally, diabetes is classified into two main types: type 1 and type 2. Type 1 diabetes 
(T1D) is primarily due to autoimmune destruction of pancreatic β-cells, leading to severe insulin 
deficiency and total dependence on exogenous insulin administration. It accounts for about 5 - 
10% of diabetes cases and affects mostly young people. At the time of diagnosis, up to 80% of 
β-cells have been destroyed by infiltrating macrophages and CD8+ T cells (Notkins et al., 2001). 
Environmental factors may also drive the pathogenesis of T1D, as its incidence changes with 
seasons, with higher incidence observed in autumn and winter and lower in summer 
(Moltchanova et al., 2009). Type 2 diabetes (T2D), on the other hand, arises from insulin 
resistance and reduction in pancreatic β-cell mass that culminate in reduced insulin secretion. It 





where there is complete lack of endogenous insulin, in T2D, β-cells are still able to produce 
insulin but the target tissues such as skeletal muscles and adipose have become less sensitive 
to insulin. β-cells therefore compensate for increased resistance by producing more insulin. 
With increasing insulin resistance coupled with β-cells dysfunction, β-cells begin to fail, 
producing insufficient insulin, which eventually leads to a rise in circulating blood glucose.  
 
The classification of diabetes into type 1 and 2 is oversimplified, as other diabetes subtypes 
have been identified. When diabetes is first identified during pregnancy, it is called gestational 
diabetes and it is temporary in most cases. Although T1D is primarily diagnosed in children and 
adolescents, it has been proposed that up to 15% of T2D cases seen in adults, may in actuality, 
be T1D. A new class of diabetes to cater for this adult group, known as Latent Autoimmune 
Disease of Adults (LADA), has been suggested (Leslie et al., 2008). LADA, also referred to as 
slowly progressing insulin-dependent diabetes or type 1.5 diabetes, describes a subset of 
patients with features of T2D in addition with underlying autoimmunity (Leslie et al., 2016). 
However, lack of firm diagnostic criteria for LADA and genetic similarity with T1D has diminished 
enthusiasm for this ‘new’ class of diabetes. LADA is now regarded as a variant of T1D rather 
than a disease of its own (Rolandsson and Palmer, 2010). Another less common diabetes 
subtype is maturity onset diabetes of the young (MODY), which is also known as monogenic 
diabetes. It accounts for about 1-2% of all diabetes cases and is commonly diagnosed in 
children. It presents clinically like T2D and it is not dependent on insulin therapy. At least 13 
genes including hepatocyte nuclear factor (HNF) and glucokinase have been implicated in its 
onset, each having its own clinical presentation and management (Bishay and Greenfield, 
2016). 
 
T1D and T2D are complex disorders with social, environmental, genetic and behavioural factors 
contributing to disease onset (Tuomi et al., 2014). Unlike monogenic and neonatal diabetes that 
are single gene disorders, T1D and T2D are polygenic disorders, with several genes playing a 
role in disease development. In T1D, alleles at the human leucocyte antigen locus account for 
about 50% of all hereditary cases while such predominant genetic susceptibility locus has not 
been identified in T2D (Polonsky, 2012). Genome wide association studies have identified 





only account for 10% of the hereditability of T2D but can increase the risk of an individual 
developing T2D by up to 15% (Fuchsberger et al., 2016). 
 
1.1.2 Effects of chronic hyperglycaemia in diabetes 
Persistently elevated blood glucose, referred to as hyperglycaemia, is a common feature of all 
forms of diabetes, which causes microvascular and macrovascular complications observed in 
long standing diabetes. The risk of developing complications is influenced by genetic factors 
and the duration of hyperglycaemia. Increased insulin resistance, insulin deficiency and 
decreased insulin secretion mainly drive hyperglycaemia. As a result of insulin deficiency, 
catabolism is activated leading to increased hepatic gluconeogenesis. Moreover, increased 
circulating free fatty acids are also present in T2D and their inhibition of glucose uptake into 
muscles further contribute to elevated blood glucose.  
 
The long-term effect of diabetes on nerves, kidney and eyes causes neuropathy, nephropathy 
and retinopathy respectively, and they are termed microvascular complications. Cardiovascular 
and peripheral vascular diseases arising from the effect of chronic hyperglycaemia on heart and 
macrovasculature are classified as macrovascular complications. The complex cascades 
leading to cellular damage in prolonged hyperglycaemia are not fully understood, but generation 
of reactive oxygen species, activation of the polyol pathway and formation of advanced 
glycation end products (AGE) have all been implicated (Negre-Salvayre et al., 2009). During 
hyperglycaemia, intracellular glucose levels of tissues such as neurons, retina and glomerulus 
that do not require insulin for glucose uptake are raised, eventually leading to increased 
oxidative phosphorylation and production of free radicals. The amount of highly reactive radicals 
generated is considerably higher than what cellular anti-oxidants can handle, thereby damaging 
mitochondrial membrane and DNA. In addition, the polyol pathway is activated as a result of 
elevated intracellular glucose. Thus, aldose reductase reduces glucose to sorbitol, which 
accumulates within the cell because of its inability to diffuse out of cell membranes. By its 
osmotic effect, sorbitol depletes levels of intracellular myoinositol, a precursor of membrane 






Another mechanism of cellular damage in uncontrolled diabetes is the formation of AGE. AGEs 
are formed from non-enzymatic, irreversible attachment of circulating reducing sugars such as 
glucose and fructose to functional and structural proteins including albumin, globulin and 
collagen (Singh et al., 2014). Lipids and nucleotides are also susceptible to glycation. Glycation 
disrupts the normal function of molecules and interferes with receptor recognition. The 
attachment of reducing sugars to collagen causes arterial stiffness, diminished myocardial 
compliance and increased propensity for bone fracture (Saito et al., 2006). Accumulation of 
AGEs intracellularly causes generation of destructive radicals and receptor-mediated increase 
in apoptosis and inflammation (Persaud and Jones, 2003). 
 
1.1.3 Treatment of diabetes mellitus 
There are presently no cures for T1D or T2D. The main goal of treatment is to maintain blood 
glucose level within a range that will prevent or slow down the development of complications 
while preventing severe hypoglycaemic episodes. The mainstay therapy for people suffering 
from T1D is administration of exogenous insulin. To cater for daily fluctuations in plasma 
glucose or for post-prandial glucose correction, different insulin formulations have been 
developed, which are long-acting and short-acting insulin. Long-acting insulin, such as glargine 
and degludec, are meant to provide basal insulin throughout the day while short-acting insulin, 
such as lispro and aspart, are used when rapid reduction in plasma glucose level is required. 
Glargine and degludec are administered once daily and they both reduce the risk of nocturnal 
hypoglycaemia (Owens et al., 2014). Short-acting analogues have rapid onset of action and are 
usually given 15 min before meals. They achieve peak plasma concentration about 1 h after 
subcutaneous injection and can last for 4 to 6 h (Sanlioglu et al., 2013). 
 
The first step in the management of T2D is to set a glycaemic target that is appropriate for each 
individual patient, which is dependent on the availability of home-support systems, age, ability to 
self-care and other psychosocial factors. The current guideline sets a target of achieving HbA1c 
level of less than 6.5% (Handelsman et al., 2011). Lifestyle changes such as weight loss, 
calorie restriction and exercise, are recommended for improving glycaemic control. Patients are 
encouraged to eat balanced diet, food rich in fibre, legumes, whole grains, and less than 7% 





week (American Diabetes Association, 2011). Weight loss is an effective strategy for reducing 
incidence of T2D in individuals at high risk of developing diabetes (Feldman et al., 2017). 
However, maintaining weight loss is difficult as weight is normally gained back as a result of 
increased appetite and feeding. Dietary starches that are resistant to enzymatic digestion in the 
colon and hence available for fermentation by colonic bacteria producing short chain fatty acids, 
have been shown to reduce food intake and they may therefore be useful in long term weight 
maintenance (Nilsson et al., 2008; Guess et al., 2015). In addition to maintaining weight loss, 
fermentable carbohydrates have been shown to reduce ectopic fat in prediabetes and they 
mediate their beneficial effects by activating free fatty acid receptor 2 (FFAR2) to potentiate 
anorexic signalling in the gut (Guess et al., 2015; Brooks et al., 2017). Importantly, research 
efforts are underway to increase the resistant starch content of commonly consumed food so 
that the beneficial effects of fermentable carbohydrate on glucose homeostasis and weight loss 
can be felt at a population level (Petropoulou et al., 2016). 
 
For individuals with uncontrolled diabetes from lifestyle modifications, pharmacological 
intervention is the next line of action. It is a popular option for treatment of T2D, with many 
agents available commercially. Metformin is a commonly prescribed drug and it reduces hepatic 
gluconeogenesis by activating AMP-activated protein kinase. It is well tolerated, does not cause 
weight gain and rarely elicits hypoglycaemia, although it may cause gastrointestinal discomfort 
at a higher dose. Sulphonylureas, such as glibenclamide and glipizide, bypass metabolic 
coupling to stimulate insulin release by closing β-cell KATP channels, leading to membrane 
depolarisation.  They may however, cause weight gain and induce hypoglycaemia (Shimizu et 
al., 2012). Thiazolidinediones, on the other hand, provide glycaemic control by activating 
peroxisome proliferator-activated receptor γ with concomitant reduction in peripheral insulin 
resistance and inhibition of glucose production by the liver (DeFronzo, 2009). Sodium-glucose 
co-transporter 2 (SGLT2) inhibitors were recently approved for treatment of T2D. The kidney 
usually reabsorbs 120 – 140g glucose daily, via SGLT2 transporter proteins located in the 
proximal tubules. However, under conditions of hyperglycaemia the blood glucose may exceed 
the maximal renal reabsorption capacity of about 450g/day, and so the excess is excreted in 
urine. SGLT2 inhibitors increase renal glucose excretion by blocking the SGLT2 transporters 





resulting glucosuria does not cause hypoglycaemia, as the drugs become ineffective once the 
blood glucose reaches the minimum renal reabsorption capacity of approximately 80g per day. 
SGLT2 inhibitors also increase glucose uptake by the muscle, reduce systolic blood pressure, 
decrease hepatic gluconeogenesis and increase insulin sensitivity (Monami et al., 2014). Other 
available medications such as GLP-1 analogues and dipeptidyl peptidase IV (DPP-4) inhibitors 
including some advantages and disadvantages associated with their use are summarised in 
Table 1-1. 
 















events, rare occurrence of 
hypoglycaemia, improved 
lipid profile, they have been in 




Extensively used in the clinics Weight gain, 
hypoglycaemia 
Thiazolidinediones Pioglitazone Hypoglycaemia rarely 
occurred, longer lasting 
effects than metformin or 
glibenclamide, improved lipid 
profiles, pioglitazone is 
beneficial for coronary 
atherosclerosis, they have 
been in clinical use for 
decades 
Expensive, 
weight gain, heart 
failure, oedema, 
increased risk of 
bone fracture 
DPP-4 inhibitors Linagliptin, 
sazagliptin, sitagliptin 
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1.2 Islets of Langerhans 
Physiologically, the pancreas can be divided into exocrine and endocrine pancreas. The 
exocrine pancreas is the largest part of the pancreas. It is made up of acini cells arranged in 
small lobes. The exocrine pancreas secretes digestive enzymes such as proteases, lipase and 
amylase into the gut for breaking down protein, carbohydrate and lipid, while the endocrine 
compartment is made up of 2-3% of the total pancreatic volume. The endocrine pancreas is 
also known as the islets of Langerhans, and secretes mainly insulin, glucagon, somatostatin 
and pancreatic polypeptide. The islets of Langerhans are clusters of cells that are scattered 
throughout the pancreas (Figure 1-2 A) and were first described in 1869 by the German 
anatomy student Paul Langerhans. Islets are largely spherical in shape, with an average 
diameter of 100 - 200µm in mammals, irrespective of species, while pancreas size is dependent 
on species, increasing with body size (Jones and Persaud, 2010). Although islets have similar 
sizes, a healthy human pancreas contain up to a million islets while mouse pancreas has 
approximately 1000 islets (Bonnevie-Nielsen et al., 1983). However, only about 150 to 250 
islets are recovered following collagenase digestion of mouse pancreas.  
 
1.2.1 Islet cell types and morphology 
Islets are comprised of five different cell types each producing a unique hormone. They are the 
insulin secreting β-cells, glucagon-secreting α-cells, somatostatin-secreting δ-cells, pancreatic 
polypeptide expressing cells and ghrelin expressing ε-cells. Human islets have proportionally 
fewer β-cells and more α-cells compared to mouse islets. Mouse islets consist of approximately 
60–80% β-cells, 15–20% α-cells, <10% δ-cells, <5% PP cells and about 1% ghrelin cells while 
human islets contain about 50% β-cells, 40% α-cells, <10% δ-cells and few PP-cells (Cabrera et 
al., 2006; Steiner et al., 2010). Interspecies differences in the arrangement of the different islet 
cell types have been observed. In mice, islets are typically composed of densely packed β-cells 
located in the inner core, surrounded by a mantle of α-cells (Figure 1-2 B), while in human 
islets, β-cells are intermingled with other islet cells (Figure 1-3) (Kim et al., 2009). 
 
Islets are richly supplied with blood vessels, accounting for approximately 15% of the total 





and mouse islets differ in many features including their vascular architecture. Human islets have 
fewer capillary density and less tortuous capillary networks compared to mouse islets (Brissova 
et al., 2015). Unlike mouse islets with single basement membrane (BM), the blood vessels of 
human islets have duplex BM consisting of an outer parenchyma BM and an inner capillary BM 
(Virtanen et al., 2008). The implication of the double BM in human islets is speculated to provide 
extra protection against autoimmune insulitis, since rapid and massive lymphocyte infiltration 
was observed in islets of NOD mice compared with human islets at early stage of T1D 
(Otonkoski et al., 2008). 
 
Islets are also richly innervated, supplied by both sympathetic and parasympathetic nerve fibres 
containing the neurotransmitters norepinephrine and acetylcholine respectively. The 
sympathetic signal inhibits insulin and stimulates glucagon release to increase glucose supply in 
conditions of stress and anxiety. Sympathetic innervation is also necessary for pancreatic 
cytoarchitecture during islet development and functional maturation in mice (Borden et al., 
2013). Differences in innervation between human and mouse islets have been identified. In 
human islets, sympathetic fibres preferentially innervate vascular smooth muscles rather than 
endocrine cells thereby providing an indirect effect on islet functions (Rodriguez-Diaz et al., 
2011a). Generally, human islets are scarcely innervated with very few parasympathetic nerves 
in contrast with mouse islets with densely packed fibres. In human islets, α-cells secrete 
acetylcholine which exerts a paracrine effect on neighbouring β-cells and prime them for 







Figure 1-2: Anatomy of pancreas and islets of Langerhans from postnatal day 9 mice. A) The figure shows 
islets, identified by insulin immunostaining, scattered throughout pancreas as islands of cell clusters. Islets 
consist of about 2-3% of the total pancreatic volume. Scale bar = 100µm. B) Image of typical mouse islets 
showing β-cell core surrounded by a thin layer of α-cells, identified by glucagon immunostaining. Scale bar 
= 50µm. C). Somatostatin-producing δ-cells (green immunofluorescence) are scattered among other islet 





Figure 1-3: Human islets. A) Image shows the distribution of β-cells (red) and α-cells (green) in human 






islets, human islets contain proportionally fewer β-cells and a higher number of α-cells. B) Somatostatin-
containing δ-cells are also scattered among other islet cells. Scale bar = 50µm. Images obtained from 
(Cabrera et al., 2006). 
 
1.2.2 Intra-islet hormone communication 
The spatial arrangement and interaction of islet cells in rodents and humans have functional 
implications in their ability to rapidly and efficiently respond to changes in blood glucose as a 
single entity rather than individually. Thus, insulin secretion from intact islets upon glucose 
challenge is synchronous and several-fold higher than from isolated β-cells (Do and Thorn, 
2015). Islet cell types have co-ordinated mechanisms for maintaining glucose homeostasis via 
gap junctions, cell-cell contacts or through paracrine/autocrine signalling. Islet cells are 
functionally attached via gap junctions. Electron micrographs show that gap junctions such as 
connexin-36, tight junctions and E-cadherin are found along the membrane area where a β-cell 
meets another β-cell, allowing electrical activities and invariably intracellular calcium oscillation 
to spread from one cell to the other (Dahl et al., 1996).  In addition, cell-cell contact suppresses 
insulin secretion at low glucose by regulating trafficking of insulin granules to the cell membrane 
and exocytosis (Benninger et al., 2011). 
 
Moreover, islet cells can exert a functional influence on themselves or on neighbouring cells 
through the hormone that they secrete, by autocrine and paracrine signalling. For instance, 
glucagon is secreted from the α-cells at glucose concentrations of less than 3mM, and is 
inhibited by hyperglycaemia, when insulin secretion is stimulated. Insulin therefore inhibits 
glucagon secretion while glucagon stimulates insulin secretion. On the other hand, δ-cells 
regulate the secretory function of α- and β-cells by secreting somatostatin, which is a powerful 
inhibitor of glucagon and insulin secretion. Somatostatin receptors 2 and 5, Gi/o coupled 
GPCRs, are expressed on mouse and human α- and β-cells and their activation by somatostatin 
inhibits glucagon and insulin release (Gromada et al., 2001; Braun, 2014). The paracrine effect 
of islet hormones demonstrated in in vitro studies was, however, difficult to prove in vivo, as it 
had been noted that the amount of endogenous glucagon and somatostatin secreted into the 





and Thorn, 2015). Other molecules secreted by the endocrine cells such as cations, 
neurotransmitters and nucleotides also contribute to the intra-islet paracrine interactions.  
 
1.2.3 Islet-extracellular matrix interactions  
Islets are also regulated by components of extracellular matrix (ECM), which are present in 
three islet areas: the peri-islet basement membrane (BM), interstitial BM and vascular BM 
(Korpos et al., 2013). The peri-islet BM and interstitial BM form the peri-islet capsule that 
encases each islet. The distribution of the various components of ECM in islets has been a 
subject of debate. However, recent data have shown that the peri-islet BM is mainly composed 
of collagen IV, laminin, nidogen and heparan sulfate proteoglycans (Korpos et al., 2013), while 
the interstitial BM is composed mainly of collagen I and III. The vascular BM is made up of 
laminin and collagen III. Collagen III, which is a ligand for GPR56 in the brain, is expressed by 
blood vessels and is found in the lobar, lobular and acinar septa of human and rat pancreas. It 
is not present in between individual endocrine cells but it is found in the ECM surrounding 
human islets (Deijnen et al., 1994). The traditional function of collagens was to provide 
mechanical support to tissues but recent studies have provided insights into their crucial roles in 
matrix-receptor signalling. Before the discovery of the integrin family, cells were thought to be 
attached to collagens by cell-specific ‘glues’ known as nectins including osteonectin and 
chondronectin. Osteonectin which is now referred to as Secreted Protein Acidic and Rich in 
Cysteine (SPARC) is expressed in islets by fibroblast and endothelial cells and it inhibits β-cell 
proliferation and survival (Ryall et al., 2014).  
 
The peri-islet capsule provides a protective role against inflammatory assault. For example, in 
the NOD mouse model of T1D, the ECM component at the site of leucocyte infiltration at the 
peri-islet capsule is completely destroyed (Irving-Rodgers et al., 2008), which highlights the 








1.3 Glucose homeostasis 
The islets of Langerhans play an important role in ensuring that plasma glucose levels are 
maintained within a narrow range of about 3 to 5mM in healthy individuals, despite glucose 
fluctuations that arise from intermittent eating and fasting. Although the regulation of glucose 
homeostasis is complex and involves many organs including the liver, skeletal muscle, fat, and 
the brain, insulin is the primary hormone responsible for bringing down elevated postprandial 
glucose, through glucose uptake by insulin sensitive tissues and glucose storage. Insulin is 
generated in humans from enzymatic cleavage of proinsulin, a 9kDa peptide containing two 
chains of insulin (A chain: 21 amino acids and B chain: 30 amino acids) joined by a C-peptide 
(Liu et al., 2014). Mature insulin is stored in secretory vesicles together with C-peptides and 
other biologically active compounds. Following nutrient absorption from the gastrointestinal 
tract, β-cells sense increase in circulating glucose, and insulin granules are released by 
exocytosis into the interstitial space, where they are transported via the blood stream to target 
tissues. Insulin binds to insulin receptors (IR) on target tissues. IR, being a tyrosine kinase 
autophosphorylates downstream insulin receptor substrate protein leading to translocation of 
glucose transporter 4 (GLUT4) to the cell surface of skeletal muscles and adipocytes 
(Ottensmeyer et al., 2000). The increased number of GLUT4 on the plasma membrane 
facilitates glucose uptake via an energy-independent process. Insulin secretion is then switched 
off by β-cells once the circulating nutrients are depleted while glucagon may be turned on to 
prevent hypoglycaemia. Glucagon binds to the Gs coupled glucagon receptor to generate 
cAMP, which activates protein kinase A (PKA).  The eventual result is increased plasma 
glucose due to increased gluconeogenesis and glycogenolysis and decreased glycogen 
synthesis.  
 
1.3.1 Regulation of insulin secretion  
Insulin secretion is regulated by both nutrients e.g. glucose, amino acids and non-nutrients e.g. 
neurotransmitters, Glucose is a powerful regulator of insulin secretion from the β-cells. Unlike 
myocytes and adipocytes that utilises GLUT4 for glucose uptake, β-cells take up glucose via 
GLUT2 in rodents and GLUT1, 2 and 3 in humans (Mueckler and Thorens, 2013). GLUT2 is a 
high capacity, low-affinity glucose transporter, implying that it is functional only during periods of 





the β-cells, glucose is phosphorylated by glucokinase to glucose-6-phosphate in the glycolytic 
pathway. Glucokinase ensures that insulin release is proportional to circulating extracellular 
glucose that is within the range of 5 and 15mM (Guo et al., 2012). Pyruvate, the end product of 
the glycolytic pathway, is converted to ATP in the mitochondria through the tricarboxylic acid 
cycle. This increases ATP/ADP ratio within the cell where ATP binds to the ATP-sensitive K+ 
channel to close it (Ashcroft et al., 1984). In euglycaemia, inwardly rectifying potassium current 
maintains a resting membrane potential through potassium efflux; therefore, closure of the K+ 
channel prevents K+ efflux thereby causing membrane depolarisation. Depolarisation of β-cell 
membrane recruits Ca2+ intracellularly via the L-type voltage-gated calcium channel (VGCC) 
(Henquin, 2000). Increase in cytosolic calcium causes the ‘readily releasable pool’ of insulin 
granules to be docked to the plasma membrane for exocytosis leading to insulin secretion. This 
whole process is referred to as KATP channel dependent pathway or triggering pathway of insulin 
secretion and it accounts for the initial spike of insulin release seen in glucose stimulated insulin 
secretion perifusion experiments (Straub and Sharp, 2002). The initial spike, brought about by 
release of insulin granules from the immediately releasable pool is known as first phase insulin 
secretion. 
 
As insulin release follows a biphasic pattern, the initial spike is immediately followed by a sharp 
decline in insulin release before it picks up slowly until a plateau is reached. This slowly 
releasing phase of insulin secretion is known as the second phase and a KATP channel 
independent pathway controls it (Gembal et al., 1992). The amplifying pathway or KATP channel 
independent pathway increases the efficacy of intracellular calcium to increase insulin secretion. 
It requires glucose metabolism and is dependent on the triggering pathway. Although the 
mechanism of the amplifying pathway is not fully understood, apart from adenine nucleotides, 
activation of major second messengers such as PKA, PKC, PI3K, ATP and acyl CoA are not 
involved in its regulation of insulin secretion (Sato and Henquin, 2014). It has been suggested 
that targeting this pathway may be beneficial, as the process involved in the amplifying pathway 






Additional pathways involved in augmenting insulin secretion from β-cells are through the action 
of non-nutrients on receptors situated on their extracellular surface. Many of the non-nutrients 
signal by activating G-protein coupled receptors.  
 
1.4 G-protein coupled receptors 
G-protein coupled receptors (GPCRs) are the largest class of surface membrane receptors that 
convey a diverse array of signals and control many physiological processes. GPCRs have wide 
tissue distribution and more than 300 of them are expressed by human islets (Amisten et al., 
2013). They share several similarities, such as possession of a single polypeptide with an 
extracellular N-terminus. Linked to this is a seven transmembrane domain (TM1 – TM7), with 
three extracellular and three intracellular loops, and an intracellular C-terminus (Gether, 2000). 
GPCRs are sometimes interchangeably referred to as ‘7TM receptors’; however, there are 
receptors with seven transmembranes that do not signal via G-proteins. GPCRs are generally 
expressed at low levels with only 0.01% to 0.001% of the Expressed Sequence Tags 
corresponding to GPCRs (Fredriksson and Schiöth, 2005). They constitute less than 2% of the 
human genome despite their large numbers of about 800 (Banères et al., 2011). More than half 
of the GPCRs have sensory functions and they are referred to as odorant or sensory GPCRs. 
Odorant GPCRs are expressed on specific cell types where they respond to external stimuli 
such as light, taste, odour and pheromones. On the other hand, non-odorant GPCRs are widely 
expressed in different tissue types and they respond to diverse endogenous agonists that 
regulate various biological processes (Mombaerts, 2004; Gao and Chess, 1999).  
 
The first attempt to classify GPCRs made use of sequence similarities to group them into six 
classes. They were named by alphabets, as Class A (rhodopsin-like), Class B (secretin receptor 
family), Class C (metabotropic glutamate), Class D (fungal receptor), Class E (cyclic AMP 
receptor) and Class F (frizzled receptor). Of these, only classes A, B, C and F are found in 
vertebrates (Kolakowski, 1994). However, because of their abundance, this classification could 
not take into account the subtle differences between the GPCRs within the same group and an 
alternative system was developed to relate GPCRs structures to their functions and ligand 





classes: Glutamate, Rhodopsin, Adhesion, Frizzled/taste and Secretin, referred to as GRAFS 
classification (Fredriksson et al., 2003). 
 
GPCRs exert their effects mainly via heterotrimetric G-proteins containing α, β and γ subunits. 
Activation of GPCR releases GTP-bound Gα from the complex. There are four main types of 
Gα: Gαi, Gαs, Gαq/11 and Gα12/13 (Simon et al., 1991; Strathmann and Simon, 1991). The 
coupling preference of the GPCRs to any of these Gα subtypes determines their effect on 
insulin secretion. Generally, GPCRs that signal via Gαs or Gαq tend to increase insulin 
secretion while signalling via Gαi inhibits it (Ahrén, 2009). The effect of Gα12/13 on insulin 
secretion is not yet known. Recruitment of Gαs stimulates adenylyl cyclase leading to increased 
cyclic AMP. Coupling to Gαi inhibits adenylyl cyclase but stimulates mitogen-activated protein 
kinase (MAPK). Gαq/11 signalling activates phospholipase C (PLC) that breaks down PIP2 into 
diacylglycerol and inositol triphosphate. These second messengers increase intracellular 
calcium levels by releasing calcium from the internal stores and also stimulate protein kinase C 
(PKC). In addition, Gαq/11 increases phosphoinositol-3-kinase and Akt signalling. Activation of 
Gα12/13 leads to increase in Rho signalling and remodelling of actin cytoskeleton (Suzuki et al., 
2009). On the other hand, GPCRs can bind to non-G proteins such as β-arrestins to mediate 
distinct biological processes. β-arrestins bind to C-terminal domains of GPCRs that have been 
phosphorylated by a group of kinases called GPCR kinases, and causes them to be internalised 
and recycled or degraded (Oh and Olefsky, 2016).  
 
1.4.1 GPCRs as novel targets for T2D therapy 
GPCRs play important roles in modern medicine, as they are the targets of about 50% of all 
prescription drugs in clinical use (Cook, 2010). GPCRs are involved in growth, differentiation, 
secretion, maturation and survival of islet cells (Ahrén, 2009), therefore certain GPCRs have 
emerged as potential targets for treating islet dysfunction and T2D. The most well studied islet 
GPCR target is glucagon-like peptide 1 (GLP-1) receptor. GLP-1 is released by enteroendocrine 
cells upon nutrient stimulation into the blood stream, where it is largely degraded by dipeptidyl 
peptidase 4 (DPP-4) before it reaches the pancreas. GLP-1 has three main effects on islet 
functions. First, it increases insulin secretion via Gs and cAMP recruitment by binding to GLP-





substantially inhibit glucagon secretion. Secondly, since a small fraction of the released GLP-1 
reaches the pancreas, it has been suggested that endogenous GLP-1 may modulate islet 
function indirectly through the CNS by acting on enteroendocrine neurons. GLP-1 also improves 
islet function by inhibiting β-cell apoptosis and promoting β-cell proliferation (Preitner et al., 
2004; Xu et al., 1999; Doyle and Egan, 2007; Tourrel et al., 2001). Synthetic ligands of GLP-1R 
are available commercially as injectables for T2D and they include exenatide and liraglutide 
(Table 1-1). A strategy to increase the amount of GLP-1 that reaches the pancreas such as by 
inhibiting DPP-4 has also been developed (Oh and Olefsky, 2016). Other GPCRs that have 
received considerable attention for diabetes therapy include GPR40/FFAR1, GPR119, 
GPR120/FFAR4 and TGR5. In some cases, molecules targeting these GPCRs have either 
been discontinued due to lack of efficacy or currently undergoing clinical trials (Table 1-2). 
 
Table 1-2: Summary of GPCRs that have received considerable attention in diabetes therapy and the 








Effect of GPCR activation 
 
Clinical trials 
GPR40 Natural: long chain non-
esterified fatty acids 
Synthetic: TAK-875, AMG-
837, JTT-851, P11187 
Increased GLP-1, increased 
insulin, improved glucose 
tolerance 
None in clinical 
trials 




Increased GLP-1, increased 




to lack of efficacy 
GSK1292263: 
discontinued due 
to lack of efficacy 
PSN-821: Phase 
II 
GPR120 Natural: long chain non-
esterified fatty acids 
Synthetic: GW9508, TUG-
891, Compound A 
Increased GLP-1, decreased 
somatostatin, reduced 
inflammation 
None in clinical 
trials 
TGR5 Natural: bile acids 
Synthetic: SB756050 











1.4.2 Adhesion GPCRs 
The adhesion GPCR family is made up of 33 members with nine distinct subclasses (Table 1-
3). In addition to the canonical seven transmembrane segments common to other GPCRs, 
adhesion GPCRs have extended N-terminal and undergo self-cleavage during maturation at the 
GPCR proteolytic site (GPS) within the GPCR autoproteolysis-inducing (GAIN) domain. The 
GAIN domain is a unique evolutionarily conserved structure of adhesion GPCR that is required 
for self-cleavage (Prömel et al., 2013). The N and C terminals re-associate upon maturation and 
remain non-covalently attached. The GPS is found immediately upstream of the first 
transmembrane loop and is rich in cysteine residues alternating with tryptophan in a C-W-W-C-
C conserved sequence (Araç et al., 2012). The N-terminal of adhesion GPCRs contains mucin-
like motifs, which is suggested to help them in cell adhesion and cell-matrix interactions.  
Adhesion GPCRs are widely expressed in tissues such as the reproductive tract, neurons, 
stomach, lungs and various tumour cells, where they play varying roles in angiogenesis, cell 
adhesion, immune recognition and neuronal migration (Simundza and Cowin, 2013).  
 
 
Figure 1-4: Adhesion GPCR architecture. Adhesion GPCRs have unusually long N-terminal fragment 
(NTF) containing several adhesive motifs and it is joined non-covalently to the C-terminal fragment (CTF) 







1.4.3 Mode of signalling of adhesion GPCRs 
As mentioned earlier, N-terminal fragment of most mature adhesion GPCRs attaches non-
covalently with the membrane bound C-terminal fragment at the GPS, and the cleavage of this 
has been suggested to modulate receptor activity. The GPS is a highly conserved cysteine-rich 
sequence, found immediately upstream the first transmembrane strand. Increased activities 
were observed in studies involving GPR56, CD97 and BAI1 mutants where the N-terminal 
domains have been removed (Paavola et al., 2011; Ward et al., 2011; Stephenson et al., 2013). 
Based on this observation, two modes of signalling have been proposed for adhesion GPCRs: i) 
the extracellular domain acts as an inverse agonist of constitutive signalling, and its removal, 
whether by ligand binding or mechanical detachment, is necessary for receptor activation, and 
ii) a part of the extracellular domain buried in the GAIN segment acts as a tethered agonist, 
which is exposed to the 7TM upon ligand binding. The second scenario seems more likely, as it 
has been demonstrated in a number of adhesion GPCRs including GPR56, GPR126, GPR133, 
GPR64 and GPR114 (Wilde et al., 2016; Stoveken et al., 2015; Liebscher et al., 2014; Demberg 
et al., 2015; Kishore et al., 2016; Stoveken et al., 2017). 
 
1.4.4 Role of adhesion GPCRs in metabolic functions 
Many of the adhesion GPCRs are expressed in pancreas or islets but at low levels, except latrophilin 1, 
ELTD1 and GPR56 that are strongly expressed ( 
 
 
Table 1-3). More than two-thirds of adhesion GPCRs are still orphans with no known endogenous ligands. 
Studies using knockout mouse models are beginning to shed light on the biological effect of adhesion 
GPCRs on endocrine and metabolic functions. For instance, adipose tissue specific deletion of GPR116 
produced mice that were glucose intolerant and insulin resistant (Nie et al., 2012). PDX1 specific deletion 
of the adhesion GPCR Celsr2/3 produced mice that were glucose intolerant. However, the insulin 
secretory capacity of their β-cells was not affected. In addition to impaired glucose tolerance, loss of 
Celsr2/3 produced mice with severe pancreatic β-cell differentiation deficiency (Cortijo et al., 2012) while 
single nucleotide polymorphisms in Celsr2 have been correlated with reduced low-density lipoprotein 









Table 1-3: Expression profile of adhesion GPCRs in human pancreas (protein) and islets (protein or 
mRNA). Protein information for most of the GPCRs were from immunohistochemistry data from the human 
protein atlas project (Uhlen et al., 2015). RNA expression were from qPCR and RNA-Seq data (Amisten et 
al., 2013; Uhlen et al., 2015). Yes (+++): strongly expressed, Yes(++): moderately expressed, Yes(+): 
slightly expressed, No: not detected or unavailable data, (-): unknown or not yet investigated. 
 
            Adhesion GPCR 
Subgroup  
Expression in human? Ligands Phenotype in KO 
mice 





ADGRL1 (LPHN1) Yes Yes (+++) α-latrotoxin - 
ADGRL2 (LPHN2)  No Yes (+) α-latrotoxin - 
ADGRL3 (LPHN3) Yes No Fibronectin leucine rich 
transmembrane protein 3 
- 
ADGRL4 (ELTD1) No Yes (++) - - 
II ADGRE1 (EMR1) No No - - 
ADGRE2 (EMR2) No Yes (+) - - 
ADGRE3 (EMR3) No No - - 
ADGRE4 (EMR4) No No - - 
ADGRE5 (CD97) No Yes (+) - - 
III ADGRA1 (GPR123) No Yes (+) - - 
ADGRA2 (GPR124) No Yes (+) Glycosaminoglycans - 
ADGRA3 (GPR125) Yes Yes (+) - - 
IV ADGRC1 (CELSR1) No Yes (+) - - 
ADGRC2 (CELSR2) No Yes (+) - - 
ADGRC3 (CELSR3) No Yes (+) - Impaired β-cell 
differentiation 
V ADGRD1 (GPR133) Yes Yes (+) - - 
ADGRD2 (GPR144) No No - - 
VI ADGRF1 (GPR110) Yes No - - 
ADGRF2 (GPR111) No No - - 
ADGRF3 (GPR113) No Yes (+) - - 
ADGRF4 (GPR115) No Yes (+) - - 










VII ADGRB1 (BAI1) No No Phosphatidylserine - 
ADGRB2 (BAI2) No Yes (+) - - 
ADGRB3 (BAI3) No Yes (+) - - 
VIII ADGRG1 (GPR56) Yes Yes (+++) Collagen III, TG2, 
heparin, progastrin 
- 
ADGRG2 (GPR64) No No - - 
ADGRG3 (GPR97)  No Yes (+) Beclometazone 
dipropionate  
- 
ADGRG4 (GPR112) No Yes (+) - - 
ADGRG5 (GPR114) No Yes (+) - - 
ADGRG6 (GPR126) No Yes (+) Collagen IV - 
ADGRG7 (GPR128) No No - - 




GPR56, previously known as Cyt28, is a member of the adhesion class of GPCRs. It was 
recently renamed adhesion G-protein coupled receptor G1 (ADGRG1) when the nomenclature 
of the entire class of adhesion GPCRs was revised in 2015 (Hamann et al., 2015). GPR56 is 
located on chromosome 8 in mouse and chromosome 16 in human, suggesting a similar 
evolutionary origin involving gene duplication.  
 
GPR56 consists of 13 exons, with 693 amino acids in human and 697 in mouse. It undergoes 
alternative splicing to yield four isoforms namely GPR56687, GPR56692, GPR56523 and GPR56518 
(Kim et al., 2010). Consistent with other adhesion GPCRs, GPR56 has an usually long N-
terminal (GPR56N) segment consisting of 393 amino acids, which is further divided into four 
segments. The first 26 amino acids is a signal peptide, followed by the ligand binding site (27 – 
160 aa), the STP region  (108 – 177 aa), which is rich in serine, threonine and proline and the 
GPS. GPR56 agonist, collagen III, acts by binding to the ligand binding domain while another 
GPR56 binding partner, transglutaminase 2, binds to the STP segment. Deletion of the region 
between amino acids 97 and 143 on GPR56 completely abolished collagen III binding property 
(Li et al., 2008). GPR56N is heavily glycosylated with 7 glycosylation sites, which is important in 





expression or alters glycosylation pattern are linked to a rare human disease called bilateral 
frontoparietal polymicrogyra (BFPP) (Jin et al., 2007). 
 
1.4.5.1 Tissue distribution of GPR56 
GPR56 has a wide tissue distribution. It is expressed in thyroid gland, brain, pancreas, testis, 
lungs, placenta, muscle, kidney, liver, adipose and heart (Iguchi et al., 2008; White et al., 2014; 
Bjarnadóttir et al., 2004; Amisten et al., 2015; J. B. Regard et al., 2008). Because of its 
abundant expression in leukocytes and stem cells, GPR56 has been postulated to be a marker 
for cytotoxic T cells, haematopoietic and neural stem cells (Terskikh et al., 2001; Della Chiesa 
et al., 2010; Peng et al., 2011). GPR56 is expressed in the CNS where it plays a role in neural 
cells migration and cortical development (Singer et al., 2013). The hippocampus and the 
hypothalamus are particularly known for their high GPR56 mRNA expression (Liu et al., 1999). 
With this varied tissue expression ranging from brain cells to peripheral tissues, GPR56 may 
play a more general/basic cell function. However, it may play an important role in tissues where 
it is highly expressed, since it is well established that receptors that are abundantly expressed in 
a particular tissue play significant role in the functions of that tissue (Regard et al., 2008). 
GPR56 is the most abundant GPCR in human islets (Amisten et al., 2013). If the high mRNA 
expression of GPR56 identified in human islets translates to abundant protein level, GPR56 
may therefore serve as a key modulator of islet functions. 
 
1.4.5.2 Physiological functions of GPR56 
GPR56 was the first adhesion GPCR to be linked to a human disease known as BFPP. BFPP is 
an inherited human brain disorder involving improper lamination of the cerebral cortex, and 
arises as a result of loss of function germline mutation in GPR56. The four missense mutations 
which all occur at the N-terminal are R38W, Y88C, C91S and C346S. Patients with BFPP suffer 
from moderate to severe mental retardation, seizures, poor eye muscle co-ordination and 
cerebral hypoplasia (Piao et al., 2004; Parrini et al., 2009; Luo, Yang, et al., 2011). Studies in 
neuronal development in mice have indicated that GPR56 is critical for the proper formation of 
the cerebellum, as it allows the developing neurons to adhere to the ECM of pial basement 
membrane. Failure of this process leads to neuronal overmigration and ectopia. Moreover, loss 





oligodendrocyte precursor cells (Luo et al., 2011; Li et al., 2008). Outside the CNS, GPR56 
plays structural functions in seminiferous tubule development where its absence during 
embryogenesis leads to male infertility (Chen et al., 2010). GPR56 is highly expressed in 
NGN3+ endocrine progenitors in the developing pancreas (Gu et al., 2004), but its function in 
islet development is not yet known. The function of GPR56 in the brain is well established and it 
may provide clues about its role in islets. Although islets and the brain do not arise from the 
same developmental origin, they share several similarities such as the presence of similar 
evolutionary conserved elements, overlap of several metabolic pathways and gene expression. 
It is likely that GPR56 may play similar role in development, proliferation and migration in islets.  
 
1.4.5.3 Agonist and binding partners of GPR56 
It was postulated that adhesion GPCRs will have multiple interacting ligands due to their usually 
long N-terminal segment with adhesive motifs, and their broad expression in many tissues. 
Indeed, four binding partners have been identified for GPR56 and they include collagen III, 
transglutaminase 2, heparin, and progastrin. A synthetic peptide TYFAVLM/P7, that selectively 
activates GPR56 based on the stachel sequence present in its GAIN domain, has also been 
reported (Stoveken et al., 2015). 
 
Collagen III 
Collagen III was the first GPR56 agonist to be discovered. It binds to GPR56 to regulate cortical 
brain development. Collagen III activates GPR56 with an EC50 of 84nM (Luo et al., 2011). 
Collagen III, a fibril forming substance, is a major structural component of the ECM of many 
tissues. In the pancreas, it is found in islets vasculature and also in the lobar, lobular and acinar 
septa (Deijnen et al., 1994). An antibody directed against the N-terminal of GPR56 was also 
found to have similar agonistic effect as collagen III. The GPR56N antibody produced GPR56-
dependent SRE/NFkB and RhoA signalling (Iguchi et al., 2008) 
 
Transglutaminase 2 
Transglutaminase 2 (TG2) was identified as a putative binding partner of GPR56 by in situ 
receptor affinity probe. It binds to the STP region of GPR56N but it is unclear whether it acts as 





GPR56 is thought to play a part in suppressing melanoma tumour growth and metastasis (Xu et 
al., 2006). TG2, also known as tissue transglutaminase or high molecular weight GTP binding 
protein, is a ubiquitous protein with three distinct biological functions. First, it is a Ca2+ 
dependent transamidase serving as a cross-linking protein forming amide bonds between 
glutamine and lysine. Secondly, it functions as an intracellular G protein for many GPCRs, 
activating phospholipase C and, lastly, as an adaptor protein facilitating interactions between 
ECM and integrins to promote cell adhesion (Lorand and Graham, 2003). 
 
Report on the roles of TG2 on glucose homeostasis is conflicting. The transamidase activity of 
TG2 was suggested to modulate insulin exocytosis from isolated islets while inhibitors of TG2 
decreased glucose stimulated insulin secretion in a dose-dependent manner (Bungay et al., 
1986). Islets isolated from TG2 null mice were less sensitive to glucose and they secrete less 
insulin compared to wild type. In these mice, blood glucose concentration was considerably high 
after OGTT compared to wild type mice (Bernassola et al., 2002). In humans, TG2 was 
identified as a candidate gene for early onset diabetes. Missense mutations in TG2 gene were 
found in some Italian families with maturity onset diabetes of the young (Porzio et al., 2007). On 
the other hand, Iismaa and colleagues found no difference in the glucose stimulated insulin 
secretion in homozygous TG2 null mice compared to the wild type (Iismaa et al., 2013). 
Overexpression of the TG2 gene also showed no effect on glucose homeostasis. The animals 
used in the Bernassola study were cross-bred from different strains which the Iismaa group 
claimed would ordinarily make them develop insulin resistance. They argued that inhibitors of 
TG2, such as monodancylcadaverine used in previous experiments, would obviously decrease 
glucose-stimulated insulin secretion because those inhibitors prevent insulin exocytosis. On 
examining the pedigrees of the Italian families with missense mutations in TG2 encoding genes, 
they ruled out that the mutation is not fully penetrant and concluded that there is no association 
between tranglutaminase 2 and glucose homeostasis.  
 
Heparin 
Heparin is another high molecular weight binding partner of GPR56. It interacts with GPR56 
between amino acids 26 to 35 and 190 to 200, which partially overlaps with collagen III and TG2 





promotion of cell adhesion and migration. However, activation of downstream signalling 
molecules was not detected (Chiang et al., 2016). 
 
Progastrin 
It was recently shown that progastrin, a cleaved form of preprogastrin produced by the G-cells 
of the small intestine, binds GPR56 to promote proliferation and reduced apoptosis of colonic 
epithelial cells (Jin et al., 2017).  Gastrin is typically expressed in developing pancreas and it 
becomes turned off in adult islets (Larsson et al., 1976). Gastrin expression is switched on in 
adult islets exposed to severe hyperglycaemia, in rodents and humans with T2D, but 
disappears when glucose level is restored to normal, indicating that it could be a marker for 
reversible dedifferentiating β-cells (Dahan et al., 2016). Gastrin increases islet mass by 
stimulating β-cell neogenesis from transdifferentiated (from acinar to ductal cells) exocrine 
tissue (Rooman et al., 2002).  
 
1.4.5.4 Signalling pathways of GPR56 
Collagen III binds to GPR56 to activate RhoA through Gα12/13 protein in the developing brain. 
However, in β-cells, activation of GPR56 by collagen III has been shown to inhibit RhoA (Dunér 
et al., 2016), indicating that collagen III – GPR56 activation may have differential effects on 
RhoA signalling based on cell type. Rho protein family belongs to the Ras superfamily and 
include small GTPases such as Rho, Rac and Cdc42. They are involved in the formation of 
actin cytoskeleton, maintaining cell polarity and migration. In skeletal muscles, GPR56 couples 
to Gα12/13 to activate mammalian target of rapamycin (mTOR). In addition, GPR56 associates 
with Gq11, which is stabilized by the scaffolding proteins CD9 and CD81 (Little et al., 2004). 
The function of this interaction on GPR56 signalling is not yet known, but it is likely to couple to 
PKC. Full length GPR56 inhibits VEGF by suppressing PKCα while truncation of STP region of 
GPR56 or overexpression of GPR56C activates VEGF and PKCα, which in turn leads to 
increased angiogenesis in melanoma cells (Yang et al., 2011). Overexpression of GPR56 
induces the transcriptional activities of NFAT, NF-κB, TCF and E2F response elements while at 
the same time suppressing expression of c-myc and p53, suggesting that GPR56 may be 
involved in cell adhesion, proliferation and apoptosis (Iguchi et al., 2008; Kim et al., 2010; 








1.5 Aims  
The overall aim of this thesis is to identify the expression and function of GPR56 and collagen III 
in islets of Langerhans. Specifically, the objectives are to: 
ü Determine the mRNA and protein expression of GPR56, its agonist, collagen III, 
and its binding partners, CD81 and latrophilin 1 in islets. 
ü Investigate the role of GPR56 in islet development 
ü Investigate the effect of GPR56 on β-cell adhesion and pseudoislet formation. 
ü Investigate the effect of GPR56 on β-cell proliferation and apoptosis using gain-
of-function studies. The effect of GPR56 deletion on β-cell proliferation and islet 
mass will also be investigated using GPR56 KO mice 
ü Characterise the islet architecture, islet vascularisation/innervation and glucose 
handling properties of GPR56 KO mice 
ü Study the acute and chronic effect on collagen III on insulin secretion and 
determine whether it exerts its effect via GPR56 
























































Chapter 2 Materials and Methods 
2.1 MIN6 β-cell culture 
Cell culture is a common technique for the growth and maintenance of cells outside their normal 
environment. For cells to grow and replicate, they must be provided with the necessary nutrients 
to which they were exposed to in vivo. Culture media, therefore, are usually extracellular salt 
solutions to which appropriate nutrients for cell growth have been added. Such nutrients include 
amino acids, vitamins, inorganic salts, and glucose. Serum and antibiotics are also added to 
culture media. Serum provides grow factors and acts as a pH buffer while antibiotics prevent 
bacterial contamination.  
 
Pancreatic β-cell lines offer excellent alternatives to primary islets in the study of β-cell function. 
Although primary islets are the obvious gold standard model for clinically relevant studies on 
islet functions, they are not readily available and are laborious to isolate. Isolating human islets, 
for example, is labour-intensive, and expensive in terms of the facilities required for maintaining 
Good Manufacturing Practices. Human islets are also in short supply as they are prioritised for 
transplantation. Cell lines that share the necessary similarities with islets, such as the ability to 
secrete insulin upon glucose challenge, have therefore been developed. Such cell lines with 
close functional resemblance to primary β-cells include INS1 and MIN6 β-cells (Skelin et al., 
2010; Persaud, 1999). 
 
The MIN6 β-cell line used in this thesis was established from pancreatic tumour material derived 
from a transgenic mouse in which the insulin promoter drove SV-40 antigen expression and 
uncontrolled β-cell proliferation. MIN6 β-cells express Glut-2 and glucokinase, which are the 
primary determinants of functional β-cells for glucose entry and phosphorylation. However, 
despite their close functional resemblance to primary β-cells, cell lines also have their 





at high passage, usually above 55 (Hauge-Evans et al., 1999), so it is important to use these 
cells within a defined passage range to maximise the usefulness of the data obtained. 
 
2.1.1 Maintaining and sub-culturing MIN6 β-cells 
MIN6 β-cells were maintained in culture at 370C in Dulbecco Modified Eagle’s Medium (DMEM) 
containing 10% fetal bovine serum (FBS), 2mM L-glutamine and 100U/ml penicillin/0.1mg/ml 
streptomycin. Passages from 24 to 45 were used for the experiments described in this thesis. 
Phenol red was present in the DMEM: it acted as a pH indicator and changes in colour from 
orange to yellow when there was a build-up of acidic metabolites indicated that the cells were 
overgrown or that the medium had not been changed regularly.  
 
MIN6 β-cells were grown as monolayers in an aseptic environment and medium was changed 
every 3-4 days to replenish nutrients. Once the cells were about 70-80% confluent, they were 
sub-cultured by trypsinisation. Briefly, MIN6 β-cells were exposed to a solution of trypsin/EDTA 
(0.1%/0.02%) for about 2 min in an incubator at 370C. As MIN6 β-cells are adherent cells, they 
become detached from tissue culture flask in the presence of trypsin/EDTA. Trypsin digests the 
anchorage sites between cells and the flask while EDTA, being a chelating agent, binds to Ca2+ 
and makes it unavailable for calcium-dependent adhesion. Trypsin/EDTA is sufficient to lift cells 
from the flask, but in order to aid complete detachment of cells and to prevent excessive 
exposure of cells to trypsin, which can cause over-digestion, the flask was given a firm tap 
against the palm. Serum-containing DMEM was then added to stop trypsin’s action. After 
centrifugation at 1000rpm for 2 min, the MIN6 β-cell pellet was re-suspended in fresh DMEM 
and cells were sub-cultured in a T75 or T125 flask containing 15ml or 25ml media respectively. 
 
2.1.2 Cryopreservation and thawing of MIN6 β-cells 
MIN6 β-cells can be preserved for future use by freezing them in a cryoprotectant at -1960C. At 
this temperature, all biological and biochemical activities that can cause cell death are arrested 
and cells can be stored long term without affecting viability and function. Once MIN6 β-cells had 
reached a confluency of about 70 to 80%, they were trypsinised and re-suspended in 10ml of 
DMEM as described in section 2.1.1. After centrifugation, cells were re-suspended in freezing 





transferred into Nunc® cryovials. DMSO was used as a cryoprotectant, to prevent cell damage, 
which can occur from ice crystal formation at freezing temperatures. The cryovials were then 
transferred into a cryogenic freezing container called ‘Mr Frosty’ and placed in a -800C freezer 
overnight before being transferred into liquid nitrogen (-1960C) for longer storage. Mr Frosty has 
an outer compartment, which was filled with 100% iso-propranol that allows a uniform cooling 
rate of -10C/min. This is important for cell preservation as it controls the rate and size of ice 
crystal formation.  
 
To reconstitute cells from frozen storage, cryovials were retrieved from liquid nitrogen and 
quickly placed into a 370C water bath with gentle agitation to facilitate thawing. Once thawed, 
the cryovial contents were immediately transferred into sterile 15ml Eppendorf tubes followed by 
the addition of 10ml full DMEM and centrifuged at 1000rpm for 5 min. The supernatant was 
aspirated and cells were re-suspended in fresh growth medium before being transferred into a 
25cm3 tissue culture flask (T25). Cells were allowed to adhere overnight and medium was 
replaced to remove any non-adherent cells or residual DMSO. The cells were then cultured in 
an incubator (95% air/ 5% CO2) at 370C. 
 
2.1.3 Cell counting and viability 
MIN6 β-cell suspensions were mixed with 0.2% trypan blue in equal volumes and allowed to 
stand for 5 min, to enable compromised cells take up the dye. Trypan blue is a low molecular 
weight dye which allows viable cells to be distinguished from non-viable ones: viable cells with 
intact plasma membranes will not take up dye and they stain bright under a light microscope. 
However, dead cells appear dark blue as the dye is able to access the cell interior via the 
compromised plasma membrane. The haemocytometer chamber was created by placing a 
moistened cover slip over the slide and pressing firmly until Newton rings were observed. 10µl 
of the MIN6 β-cell-Trypan blue mixture was added to the chamber by capillary action. Using the 
10X objective of a phase-contrast inverted microscope, cells in the four 0.1mm3 corner squares 
(Figure 2-1) were counted and an average cell density was calculated. The total number of 






Total cell number/ml = Average cell number of the four corner squares x 104 x 2 (dilution 
factor) 
104 is the conversion factor to convert 10-4ml to 1 ml. 10-4ml is the volume of one large corner 
square which was obtained by multiplying the area of the square with the depth created by the 
cover slip.  
Therefore the volume of a corner square = 1mm2 x 0.1mm = 0.1cm x 0.1cm x 0.01cm  
     = 10-4 mm3 or 10-4 ml 
 
To estimate cell viability, the number of viable cells was expressed as a percentage of the total 




Figure 2-1: Haemocytometer grids showing the four corner squares used for cell counting. Cells in A, B, C 
& D were counted and an average was calculated. Each corner grid is 1mm by 1mm and the cover slip 














2.2 Islet isolation and maintenance  
2.2.1 Isolation and culture of mouse islets 
Islets were isolated from ICR and C57BL/6 mice (≥25g) aged 6 – 8 weeks. Mice were humanely 
killed by cervical dislocation before incisions were made to expose the abdominal cavity. 2 – 3 
ml collagenase solution (1mg/ml collagenase in Minimal Essential Medium) was injected via the 
bile duct into the pancreas after clamping the ampulla of vater, which is the point at which the 
bile duct empties into the small intestine (Figure 2-2). The distended pancreas was carefully 
dissected out and placed in a water bath at 370C for 10 min to aid the digestion of the exocrine 
tissue surrounding the islets.  Digestion was stopped by adding 25ml of MEM supplemented 
with 10% FBS and the digest was centrifuged three times at 1400 rpm for 1.15 min each. The 
supernatant was discarded and pancreas pellets were re-suspended in DMEM, vortexed and 
passed through a sieve that prevents non-digested fat and exocrine tissues >425µm from 
passing through. Islets were purified by histopaque gradient centrifugation at 3510rpm. 
Histopaque is a polysucrose solution with a density of 1.077g/ml. Islets at the interface of MEM 
and histopaque were retrieved, washed three times in MEM at 1500rpm before being 
handpicked and sterile-washed in RPMI (supplemented with 10% FBS, 2mM L-glutamine and 
100U/ml penicillin/0.1mg/ml streptomycin). Islets were maintained in culture at 370C 
(95%air/5%O2) prior to use. 
 
 
Figure 2-2: Steps involved in islet isolation. 1) The ampulla of vater was first located and clamped with a 





intestine. 2) A needle was inserted into the bile duct at the junction where hepatic and cystic ducts meet. 3) 
Collagenase solution was injected until the pancreas was distended and, 4) the collagenase-containing 
pancreas was retrieved by dissecting it away from the duodenum, stomach and spleen. Image taken from 
Li et al., 2009. 
 
2.2.2 Isolation and culture of human islets 
Human islets were provided by the Islet Isolation/Transplantation Unit of King’s College 
Hospital. They were isolated from healthy, non-diabetic, heart-beating cadaveric donors. 
Appropriate ethical approval was obtained from the Ethics Committee of King's College London 
and consent for research use was obtained from the relatives of donors. Islets were isolated by 
Liberase digestion of the exocrine pancreas and isolated islets were maintained in CMRL 
medium for 24 – 48h at 370C (95% air/ 5% CO2) prior to use. 
 
2.3 Gene expression 
Polymerase Chain Reaction (PCR) is a common technique used for detecting and quantifying 
gene expression. This was made possible by the invention of novel thermal cyclers that enable 
reproducible, cycle-by-cycle detection and quantification of accumulating PCR products. The 
success of this technique, however, relies on two earlier steps, which are the isolation of high 
quality RNA or DNA and, in the case of RNA, its conversion into complementary DNA (cDNA). 
 
2.3.1 Total RNA extraction 
Total RNA was extracted from MIN6 β-cells, mouse and human islets using the Qiagen RNeasy 
column kits. Isolated islets and MIN6 β-cell pellets were either stored at -80°C in RNAlater® 
solution prior to use or immediately lysed in 500µl of RLT buffer containing 2-mercaptoethanol 
(1%V/V). RLT buffer contains a high concentration of guanidine isothiocyanate (GITC), which 
denatures cellular proteins, including RNAses. MIN6 β-cells and islets have high concentrations 
of RNAses, and 2-mercaptoethanol (1% V/V) was added to enhance the inactivation of these 
enzymes.  
 
For mouse and human islets, up to 700µl of lysate was homogenised by being passed through 





hand, were pipetted up and down several times, which is sufficient to disrupt and homogenise 
the cells. Homogenisation is necessary as it reduces lysate viscosity and allows efficient binding 
of extracts to the RNA column. Equal volumes of 70% ethanol were added to the lysates, which 
were mixed thoroughly by pipetting and then transferred to RNeasy spin columns. The columns 
were centrifuged at 12,000rpm for 30 sec, flow-through was discarded and the columns were 
washed with 350µl of Buffer RW1. This buffer contains guanidine salt and ethanol, which 
enables the removal of carbohydrate, fat and protein from the RNA column. 
 
On-column DNase digestion was carried out by adding 80µl of DNase incubation mix, prepared 
by mixing 10µl of DNase 1 stock solution with 70µl buffer RDD. Each column was washed with 
Buffer RW1 and total RNA was eluted with 30µl of nuclease-free water. Total RNA 
concentration and purity, as measured by the 260/280 and 260/230 ratios, was determined 
using a Nanodrop spectrophotometer. Nucleic acids absorb maximally at 260nm, proteins at 
280nm and guanidine HCL, EDTA and phenolate ions (from TRIzol reagent) will absorb 
phenolate ions at approximately 230nm: comparing absorbance at these wavelengths provides 
an indication of the presence of contaminants. Ideally, a 260/280 ratio greater than or equal to 
2.0 is considered pure for RNA. A considerably lower ratio may indicate the presence of protein 
or other contaminants that strongly absorb near 280nm. When column-based RNA kits are 
used, carryover of GITC can lower the 260/230 ratio, which does not necessarily signify poor 
quality RNA. RNA was stored at -800C prior to cDNA conversion.  
 
2.3.2 cDNA synthesis 
RNAs were converted to cDNAs by reverse transcription using the High Capacity cDNA 
Reverse Transcription Kit. The kit uses random primers for initiating the first strand synthesis 
ensuring that cDNAs are made from all RNAs present in the sample, including mRNA and 
tRNA. A 2X reverse transcription master mix (Table 2-1) was mixed with an equal volume of 
total RNA, retrieved as described in section 2.3.1, and kept on ice until ready to load into a 
thermal cycler.  Reverse transcription was carried out using the conditions shown in Table 2-2. 









Table 2-1: Preparation of 2X reverse transcription (RT) master mix for a 20µl reaction. For each reaction, 
10µl of the master mix was pipetted into an Eppendorf tube and mixed with 10µl of RNA. 
 
Components  Amount  (µl) 
per reaction 
Final concentration 
10x Reverse Transcription buffer 2.0 1x 
25x dNTP mix (100mM) 0.8 4mM 
10x RT random primers 2.0 1x 
Multiscribe reverse transcriptase (50 
U/µl 
1.0 2.5 U/µl 
Nuclease-free water 4.2 - 
 
 
Table 2-2: Thermal cycling conditions for cDNA synthesis using the high capacity cDNA reverse 










Temperature(0C) 25 37 85 4 






2.3.3 Primer design and validations 
Primers (Table 2-3) were designed using the Primer3 tool at 
http://biotools.umassmed.edu/bioapps/primer3_www.cgi, followed by primer blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) to ensure that the primers are specific to their 
target DNA sequences. The MFold tool (http://unafold.rna.albany.edu/?q=mfold) was used to 
check that the primers do not contain significant secondary structure within the amplicon and 
primer regions, and a positive delta G value, which represents the free energies of all possible 
structures, was indicative of this. Primers were also designed to have similar annealing 
temperatures such that multiple real-time PCR could be performed at the same time with the 
same PCR programme. In most cases, intron-flanking primers were designed such that one 
primer was on one exon while the other was on a different one, separated by introns.  With this 
method, genomic contamination can easily be detected as the presence of a short intron will 
produce a longer PCR product while amplification will not occur if the intron is of thousands of 
bases long. For some experiments, quantitative PCR was performed using QuantiTech primers 






Table 2-3: List of primers used for PCR or qPCR including their forward (F) and reverse (R) sequences, 
and their amplicon lengths. Primers were designed to give short products of ~90-230bp as amplification of 
such short products occurs with very high efficiency. 
 
 Primer sequence 5’ -3’  Product 
length (bp) 
Human COL4A1 F- CCGTGGGACCTGCAATTACT 
R- ACGGCGTAGGCTTCTTGAAC 
89 
Human COL3A1 F- GACCCTAACCAAGGATGCAA 
R- GGAAGTTCAGGATTGCCGTA 
200 
Mouse COL3A1 F- GTCCACGAGGTGACAAAGGT 
R- GATGCCCACTTGTTCCATCT 
204 
Mouse GPR126 F- CTGGGAATCTCCACACGGTA 
R- CCACATCCGCACACTGAGA 
144 
Mouse CD81 F- CATGATCCACAGACCACCAG 
R- AGGCAAACAGGATCACAAGG 
202 
Human CD81 F-AGATCGCCAAGGATGTGAAG 
R- GGTTGCTGATGATGTTGCTG 
201 
Mouse GPR56 F- TTGCAGCAGCTTAGCAGGTA 
R-GATCCTCTAGACCGGCTGTG 
199 
Human GPR56 F- ATCCTGCTTCTGCAACCACT 
R- TAGTCCCGAGGTTTCCTCCT 
198 
Mouse Lphn1 F- CAACGGTGTGGTGAAAGTTG 
R- AGATGACAGGGTCCATGAGG 
200 
Human Lphn1 F- GTCCCCTACAAAGTGGAGCA 
R- CCACGAGGCATACTCAGTCA-3  
195 
Mouse β-actin F- AGCCATGTACGTAGCCATCC 
R- TCTCAGCTGTGGTGGTGAAG 
227 










2.3.4 Polymerase chain reaction (PCR) 
A large quantity of DNA is required in order to investigate the expression of a specific gene and 
this can be readily achieved by using the polymerase chain reaction (PCR) in which many 
thousands of copies of DNA can be produced from a single strand DNA. The process mimics 
the natural DNA replication that occurs within cells. It involves rapid sequential changes in 
temperature to allow primers to bind to specific sequences on template DNA (annealing), 
followed by elongation by a heat-stable DNA polymerase using deoxynucleotides and the 
dissociation of the newly formed products when the temperature is raised so that another cycle 
can begin. The combination of reverse transcription and polymerase chain reaction (RT-PCR) 
are powerful tools for identifying low abundance RNAs in samples. 
 
A PCR master mix was prepared (Table 2-4) and 17µl was pipetted into nuclease-free 0.2ml 
PCR tubes. 1µl of cDNAs from MIN6 β-cells, mouse or human tissue, together with 1µl of 
forward and reverse primers of the gene of interest, were added. cDNAs were not added to 
tubes containing distilled water or non-reverse-transcribed RNA and they served as negative 
controls to exclude possible contamination from genomic DNA. The cycling conditions were set 
as follows: initial denaturation at 940C for 2 min, denaturation at 940C for 40 sec, annealing at 
600C for 40 sec and extension at 740C for 1 min, repeated 32 times, followed by a final 
extension at 740C for 10 min. The PCR products and a DNA size ladder were separated on 
1.5% agarose gels at 100V for 30min and DNA was visualised under UV light. The sizes of the 















Table 2-4: Components of the PCR master mix used for cDNA amplification. 
 




Molecular grade water 10.0 - 
5x Green Go Taq flexi buffer 4.0 - 
PCR nucleotide mix (40mM) 0.8 1.6mM 
Forward primer (100µM) 1.0 5µM 
Reverse primer (100µM) 1.0 5µM 
MgCl2 (25mM) 2.0 2.5mM 






2.3.5 Quantitative PCR 
Real time PCR was performed on a LightCycler 480 96-well plate thermal cycler using the 
SYBR green-based method. cDNAs were diluted 1:5 with nuclease-free water and mixed with 
SYBR green master mix (Table 2-5). Primers were either designed in-house (Table 2-3) or 
Qiagen Quantitect validated primers were used. Primer efficiency was determined by absolute 
quantification using reference standards and primers with efficiency of greater than 98% were 
used in the experiments described in this thesis. Housekeeping gene normalisation with 
GAPDH was first carried out to determine the concentration of cDNA to be used for the 
quantification step. This entailed a pre-incubation at 950C for 5 min, cycling for 40 cycles: 950C 
for 10 sec, 600C at single mode acquisition for 30 sec, then a melt step was performed at 65-
970C. The dilution factor required to generate a GAPDH Ct (cycle threshold) value of 18 for 
each cDNA was calculated.  The Ct value is the number of cycles required for the fluorescent 
signal to exceed background noise.   Quantifications were performed by qPCR by screening 
each pair of desired primers against the various cDNAs, with pre-incubation at 950C for 5 min, 
cycling for 40 cycles: 950C for 10 sec, 600C at single mode acquisition for 30 sec and finally a 
melting analysis at 65-970C. Amplified PCR product specificity was determined for each run by 
melting curve analysis and by end-point agarose gel electrophoresis and expression of target 
gene transcripts were normalised against the reference gene GAPDH (Pfaffl, 2001). 
 
Table 2-5: SYBR green master mix for qPCR. 
 
Components  Amount  (µl) per reaction 
SYBR MasterMix 5 
cDNA  1 










2.4 Over-expression of GPR56 in MIN6 β-cells 
2.4.1 GPR56 plasmid DNA and bacterial transformation  
Full coding sequence of mouse GPR56 DNA cloned into pCMV-Sport 6 vector (Figure 2-3) was 
a gift from Dr Xianhua Piao of Children’s Hospital and Harvard Medical School, Boston. 50ng of 
GPR56 DNA was gently mixed with 50µl of E. coli competent cells and placed on ice for 10 min. 
Transformation, which is the process by which cells take up recombinant vector, was carried out 
by the heat shock method. The DNA / E. coli mixture was placed in a 420C water bath for 45 sec 
and immediately placed on ice for 2 min. 900µl of ice-cold SOC medium was added and the 
cells were allowed to grow at 370C for 1 h on a shaking incubator. This step allows the bacteria 
to generate protein for the antibiotic resistance gene encoded on the plasmid backbone such 
that they will be able to survive in the presence of antibiotic in subsequent steps. LB agar plates 
containing ampicillin were prepared (Table 2-6) and allowed to solidify. 50µl of the 
transformation mixture was plated on the agar plates and incubated at 370C overnight.  Only 
cells that picked up plasmid DNA with ampicillin resistance gene will be able to form colonies 
(Figure 2-4).   
 
 
Figure 2-3: pCMV-sport 6 vector showing multiple cloning sites where GPR56 DNA was inserted. The 









Table 2-6: Preparation of LB agar plates incorporating ampicillin antibiotics. LB agar powder was dissolved 
in distilled water and autoclaved. It was allowed to cool down to about 500C when ampicillin was added 
and mixed thoroughly. The solution was aliquoted to five 10cm petri dishes and allowed to solidify. 
 
Reagents  Amount    Final concentration/plate 
LB agar (3.7%) 3.7g 0.74g 
Distilled water 100ml 20ml 










Figure 2-4: Selecting bacteria with GPR56 plasmid DNA. Bacteria that picked up GPR56 plasmid DNA will 
be resistant to ampicillin because of their ampicillin resistance gene. They will therefore form colonies on 
nutrient agar containing ampicillin while non-transformed cells will die.  
 
 
2.4.2 Growth of bacterial culture and plasmid DNA purification 
A flask containing 3ml LB culture medium (Table 2-7) was inoculated with a single bacteria 
colony from the agar plate and incubated for 16 h at 370C with vigorous shaking. It is not 
recommended to grow the cells for more than 16 h. This is because the cells enter stationary 
phase and cell lysis will begin to occur which will lower plasmid yield. Using a QuickLyse tube, 
bacterial cells were pelleted from culture by centrifuging at 13,000 rpm for 1 min at room 
temperature and supernatant was discarded. Plasmid DNA purification was carried out using 






Table 2-7: Preparation of LB culture medium. LB broth was dissolved in distilled water and autoclaved. It 
was allowed to cool down to room temperature and ampicillin was added. 
 
Reagents  Amount 
LB broth 2.5g 
Distilled water 100ml 
Ampicillin (100mg/ml) 100 µl 
 
 
2.4.3 Transient overexpression of GPR56 in MIN6 β-cells 
MIN6 β-cells grown to about 80% confluent were lysed with trypsin/EDTA and seeded onto 6 
well-plate at a density of 3 x 105 cells per well. After overnight culture, MIN6 β-cells were 
transfected with 0, 12ng or 1200ng GPR56 plasmid DNA with lipofectamine 2000. 
Lipofectamine and Opti-MEM were mixed at 1:15 before been incubated with various 
concentrations of GPR56 plasmid DNA (Table 2-8) for 5 min. 150µl of the transfection mix was 
added to each well and incubated either overnight or for 3 days, and the degree of transfection 
was determined by qPCR as described in section 2.3.5. The effect of overexpressing GPR56 in 
MIN6 β-cells on insulin secretion, β-cell proliferation or apoptosis was carried out as described 






Table 2-8: Transfection procedure for GPR56 plasmid DNA. Mix 1 and 2 were incubated at room 
temperature for 5 min. The tubes were bulked up with pcDNA vector to ensure that each reaction mix has 
equal concentration of vector. 150µl of each reaction mix (0% = 0ng, 1% =12ng and 100% =1200ng 
PGR56 plasmid DNA) were added to the wells containing MIN6 β-cells. 
 
	 Volumes 
(µL) for 0% 
plasmid 
Volumes 






Mix 1  
Opti-Mem 150 150 150 
Lipofectamine-2000 10 10 10 
Mix 2  
OptiMem (make up to 150 µL) 147.79 
 
147.52 120.0 
pCMV-Sport mGPR56 A (dil 
1/10) (82.94 ng/µl) 
0 0.30 30.0 
pcDNA3 (1133.3 ng/µl) 2.21 (100%) 2.18 (99%) 0 
 
Combined volume 310 310 310 
 
 
2.5 Protein expression 
2.5.1 Protein extraction 
Cell lysis and protein solubilisation was carried out with RIPA (Radio-Immunoprecipitation 
Assay) buffer.  RIPA buffer is available commercially and is formulated to enable efficient cell 
lysis without altering the biological activity of the protein or causing protein degradation. The 
composition of RIPA buffer is shown in Table 2-9. To further preserve protein integrity, protease 
and phosphatase inhibitors are normally added to RIPA buffer before use. 
 
MIN6 β-cells were grown as monolayers until they were about 70 - 80% confluent. Lysis buffer 
was prepared by adding one tablet each of PhosStop phosphatase inhibitor and protease 
inhibitor cocktail to 10ml chilled RIPA buffer. Media was carefully aspirated from MIN6 β-cells 
and 500µl of lysis buffer was added. The flask was further incubated on ice for 5 min before the 
cells were scrapped and lysate was transferred into pre-chilled 1.5ml tubes. With isolated islets, 
approximately 300 islets were incubated in 100µl RIPA lysis buffer for 30 min on ice and 





for 10 min at 40C. The supernatant was carefully removed and either stored in 4% sample buffer 
at -200C or protein concentration was determined by the bicinchoninic acid method.  
 
Table 2-9: Components of RIPA lysis buffer. One tablet each of complete protease inhibitor and PhosStop 
phosphatase inhibitor was added to 10 ml of RIPA buffer. 
 
Reagents  Final concentration (pH 8.0) 
NaCl 150mM 
Tris 50mM 
IGEPAL® CA-630 1% 
Sodium deoxycholate 0.5% 
Sodium dodecyl sulphate 0.1% 
 
 
2.5.2 Protein quantification 
Quantification of protein concentration in cell lysates was carried out by the bicinchoninic acid 
(BCA) method. This is a two-step assay based on the reduction of cupric ion to cuprous ion, 
when copper is chelated by protein in an alkaline environment to form a light blue complex, a 
reaction known as the biuret reaction. In the second step, bicinchoninic acid reacts with the 
reduced cuprous ion to form an intense purple colour. The BCA/cuprous ion complex is soluble, 
with a strong absorbance at 560nm that increases linearly with concentration, allowing an 
increasing concentration of protein to be determined. The advantage of the BCA protein assay 
is that it is highly sensitive and selective to cuprous ion. Unlike the Coomassie-based methods, 
the universal peptide backbone contributes to colour formation in the BCA assay thereby 
minimising the effect of compositional differences of various proteins. 
 
A serial dilution of bovine serum albumin (from 2mg to 0mg/ml) in lysis buffer was made and 
this served as the standard. Samples, diluted to 1:10 and 1:100, were added as well as the 
standards in triplicates to a 96-well plate. 200µl of BCA working solution (solutions A and B in 
50:1) was added to each well and mixed briefly on a plate shaker while avoiding air bubbles. 





reader at 595nm – this wavelength was the closest available filter to 560nm. Figure 2-5 shows a 
typical standard curve generated by plotting absorbance against concentration. The 
concentration of samples was estimated from the standard curve.  
 
 
Figure 2-5: A typical BCA assay standard curve for determining protein concentration. The average 
absorbance of standards measured in triplicate at 595nm is plotted against concentration. Protein 
concentration of samples is extrapolated from the curve based on their absorbance. 
 
2.5.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Gel electrophoresis is an important technique for separating proteins based on their mass. 
When electric field is applied to charged particles in solution, they migrate to electrodes of 
opposite charge. Their rate of movement is determined by several factors including the ionic 
strength of the solution, pH, charge, size and nature of the separating matrix. The supporting 
matrix could be a semi-solid gel made from agar or polyacrylamide. The mass of the protein to 
be separated determines the percentage concentration of polyacrylamide to use – larger protein 
will separate faster in low percent polyacrylamide and vice versa (Table 2-10). In SDS-PAGE, 
sodium dodecyl sulphate, a strong detergent, is used to treat the samples to ensure a uniform 






Pre-cast NUPAGE® 12% gel was used to separate proteins of about 10 to 80kDa. In 
circumstances where different protein sizes were to be separated, 7.5% or 14% gels were 
freshly prepared (Table 2-11). Protein lysates from MIN6 β-cells, mouse or human islets were 
boiled in 1.5% SDS loading dye for 5 min before they were loaded on to gels along with 3.6 -
260kDa pre-stained molecular weight marker. The gel was placed in a mini-cell electrophoresis 
chamber filled with 1X MOPs running buffer (Table 2-12) and run at 150V for 1 – 2 h or until the 
dye front has reached the bottom of the gel. 
 
Table 2-10: Protein separation range based on percent concentration of polyacrylamide gel. 
 
























Table 2-11: Preparation of 7.5% and 14% polyacrylamide gels. The lower resolving gel was first made by 
mixing 4X resolving buffer, distilled water, 30% acrylamide, ammonium persulphate (APS), and TEMED 
and immediately poured between glass plates. The gel was overlaid with water and allowed to polymerise 
for 30 min. Water was removed and the resolving gel was overlaid with 4% stacking gel while a well former 
(comb) was gently placed in position and the gel was allowed to set. 
 
Reagent 4% 7.5% 14% 
Distilled water 6.1ml 19.4ml 10.7ml 
4X ProtoGel® Resolving Buffer 
(1.5M Tris-HCl, 0.4% SDS, pH 8.8) 
.......... 10.0ml 10.0ml 
ProtoGel® Stacking Buffer (0.5M 
Tris HCl, 0.4% SDS, pH 6.8) 
2.5ml .......... .......... 
30% Acrylamide 1.3ml 10.0 18.7 
10% APS 0.1 0.2 0.2 
TEMED 25µl 50µl 50µl 
Total volume (for 4 gels) 10.25 39.65 39.65 
 
 
Table 2-12: Preparation of 20X MOPS running buffer. The reagents were initially dissolved in 400ml 
distilled water and the volume was made up to 500ml with distilled water. 1x MOPS running buffer was 
used for gel electrophoresis. 
 




MOPS 104.6 1M 
Tris Base 66.6 1M 
SDS 10 69.3mM 







2.5.4 Western Blotting 
Western blotting, also known as immunoblotting, is used to identify specific protein from tissue 
lysate after the proteins have been separated by size using gel electrophoresis. The protein is 
first transferred from the gel unto a solid matrix with high protein binding affinity such as 
nitrocellulose or polyvinylidene fluoride (PDVF) membrane. Nitrocellulose is commonly used as 
it was the first to be discovered and it has excellent binding and retention properties. However, it 
is of less mechanical strength and unlike PDVF, it is not suitable for re-probing or for further 
processing such as sequencing.  
 
Following electrophoresis, a sandwich of gel, blotting membrane, filter papers and filter pads 
was made (Figure 2-6) and placed in a cassette. The cassette was then immersed in transfer 
buffer (Table 2-13) and allowed to run for 2 h at 90V. Protein transfer was confirmed by staining 
with Ponceau S, a reversible red stain that identifies the presence of protein on membrane. 
After few washes in PBS to remove the dye, the membrane was incubated in blocking buffer 
(5% w/v milk in TBST) for 1 h to reduce non-specific staining. The membrane was transferred to 
5ml blocking buffer containing appropriate amount of primary antibody and incubated overnight 
at 40C. The membrane was washed three times in TBST after which it was incubated for 1 h in 
blocking buffer containing secondary antibody conjugated to horse-radish peroxide. After 
washing off excess antibody thrice in TBST, immunoreactive protein was identified by 
chemiluminescent detection using ECL reagents (Amersham). Light emission produced by the 
ECL substrate was captured on a photographic film and the molecular weight of the targeted 






Figure 2-6: Assembly of western blot sandwich. The sandwich was made such that proteins can migrate 
from the gel to the membrane (from negative to positive electrode) when current is applied. Proteins are 
negatively charged and they will move towards the positive electrode. 
  
Table 2-13: Preparation of 1x transfer buffer. 
 
Reagent Amount (ml)  
Distilled water 849 










2.5.5 Immunohistochemistry  
Immunohistochemistry (IHC) is a method for identifying the expression and localisation of an 
antigen of interest in tissue sections using antibody directed against the antigen. IHC was used 
in this thesis to provide information on the expression of GPR56, collagen III and collagen IV in 
developing or adult pancreas as well as their colocalisation with insulin, glucagon, somatostatin, 
CD31 or TUJ1. Freshly retrieved mouse pancreases were fixed in 4% paraformaldehyde either 
overnight or for 3-5 h depending on tissue thickness, to arrest biological degradation by forming 
chemical bridges between proteins. Other aldehyde fixatives that could be used include 
formalin, 10% Neutral Buffered Formalin and glutaraldehyde. However, 4% paraformaldehyde is 
a better choice as it yields low background during immunostaining. After fixation, the pancreas 
was transferred into 70% ethanol and stored at 40C or processed immediately for paraffin 
embedding. The pre-embedding processes involve the complete removal of water from the 
cellular spaces of the tissues by passing them through a series of graded ethanol, xylene and 
then paraffin. The tissues were then embedded in paraffin wax and cut to 5µm thick with a 
microtome before being mounted on superfrost slides. 
 
Pancreases retrieved from embryos and postnatal mice were fixed in 4% paraformaldehyde and 
cryoprotected in 30% sucrose overnight at 40C or for few hours until the tissue sank. This 
occurs when water has been displaced from the cellular space and the tissue reaches a 
negative buoyancy. After the pancreas was frozen in OCT medium using absolute ethanol and 
dry ice, they were either stored at -800C until ready for sectioning or cut to 12µm thick using a 
cryostat at -200C. The sections were mounted onto superfrost slides and stored at -800C until 
use. 
 
2.5.5.1 Tissue de-waxing and antigen retrieval 
Paraffin preserves tissue morphology and allows thin sections to be made but it must be 
removed before immunostaining to allow antibodies to have complete access to the antigen of 
interest. Paraffin-embedded sections were de-waxed by heating at 560C for 30 sec and washed 
twice in xylene for 5 min each. Sections were then rehydrated in a series of ethanol washes 






As mentioned in earlier, paraformaldehyde fixation causes protein cross-linking which induces 
conformational changes that mask antigenic sites and make them unrecognisable by antibody. 
It is therefore necessary to restore antigenicity before adding primary antibodies. Antigen 
retrieval was carried out by heat-induced epitope retrieval method.   Slides were boiled in 10mM 
citric acid solution pH 6.0 (Table 2-14) in a pressure cooker for 15 – 20 min until a hissing sound 
was heard, and heating was continued for a further 2 min 30 sec. The slides were then washed 
in PBS. In experiments involving BrdU staining, additional antigen retrieval steps were carried 
out. In this case, sections were incubated with 2N HCl for 10 min at 370C and later neutralised 
by incubating sections in 0.1M borate pH8.5 for 10 min.  
 
Table 2-14: Preparation of 1M citric acid stock solution. The stock solution was made by dissolving citric 
acid in distilled water and stored at room temperature. Citric acid working solution was prepared by diluting 
8ml 1M Citric acid stock in 800ml distilled water and pH was adjusted to 6.0 with 5M NaOH. 
 
Reagent  Amount Final concentration 
Citric acid 105g 1M 
Distilled water 500ml - 
 
 
2.5.5.2 Detection method 
Fluorescent detection method was used for most of the immunostaining described in this thesis. 
Prior to adding primary antibodies of interest (Table 2-15), sections were blocked with 1% BSA 
and 10% normal goat serum in PBS containing 0.1% triton-X-100 for 1h at room temperature in 
a humidifying chamber. To keep the solution on the sections, wax pen was used to carefully 
draw circles around sections. After the blocking step, primary antibody of interest at the 
appropriate dilution was added and slides were incubated overnight at 40C in a humidifying 
chamber. For sections used as negative control, blocking buffer alone was added, without any 
primary antibody. After three washes in PBS, fluorophore-conjugated secondary antibody 
(Table 2-16) targeting the species in which the primary antibody was raised was added to the 
sections and incubated for 1h at room temperature in the dark. All onward steps were 
performed in the dark to prevent photo bleaching as secondary antibodies are sensitive to light. 





at room temperature, then washed in PBS and mounted with Fluoromount® aqueous mounting 
medium. Images were visualised with Nikon Eclipse Ti inverted microscope or with Nikon 
Eclipse TE 2000-U. 
 
For protocols involving 3,3’-diaminobenzidine (DAB) detection system, endogenous 
peroxidases were blocked by incubating sections in 3% hydrogen peroxide for 15min, after the 
antigen retrieval steps. Primary antibody was then added and subsequently, biotinylated 
secondary antibody or a universal biotinylated link antibody was added to the tissue section for 
30 min. Sections were washed briefly with PBS containing 0.25% (v/v) Triton-X-100 before 
being incubated with HRP-conjugated streptavidin for 30 min, followed by the addition of DAB. 
The development of a dark brown precipitate at the antigenic sites when DAB was added was 
monitored under a light microscope and the reaction was stopped by washing sections in PBS-T 
when adequate labelling has been reached.  
 
2.5.5.3 Quantification of β-cell mass 
Staining for insulin identified β-cells in mouse and human pancreas sections. β-cell mass was 
then measured using the area quantification tool of the NIS Elements 3.0 software on Nikon 




















The following primary antibodies were used for immunostaining: 
Table 2-15: A list of primary antibodies used for immunohistochemistry including their working 
concentrations, manufacturers and catalogue numbers. 
 
Primary antibody  Dilution Manufacturer/Catalogue number 
Rabbit polyclonal anti-GPR56 1:50 Abcam ab194881 
Mouse monoclonal anti-GPR56 1:25 Millipore MABN310 
Rabbit monoclonal anti-GPR56C  1:250 Piao’s lab (199) 
Rat monoclonal anti-BrdU 1:100 Bio-Rad OBT0030S 
Guinea pig polyclonal anti-insulin 1:200 Dako A0564 
Mouse monoclonal anti-glucagon 1:50 Sigma G2654 
Rat monoclonal anti-somatostatin 1:25 Abcam ab30788 
Rabbit polyclonal anti-collagen III 1:50 Abcam ab7778 
Rabbit polyclonal anti-collagen IV 1:100 Abcam ab6586 
Rabbit anti-neurogenin3 1:25 Abcam ab38548 
Rabbit polyclonal anti-Ki67 1:100 Abcam ab66155 
Mouse monoclonal anti-Ki67 1:100 BD Biosciences 550609 
Rat monoclonal anti-CD31 1:100 BD Biosciences 553370 
Rabbit monoclonal anti-TUJ1 1:1000 Covance MRB-435P 








Table 2-16: A list of secondary antibodies used for IHC at the indicated dilutions. The antibodies were 
made up in blocking buffer containing 1% BSA and 10% goat serum in PBS with 0.1% Triton-X-100 prior 
to use. 
 
Secondary antibody  Dilution  Manufacturer/Catalogue number 
Alexa-fluor 488 goat anti-mouse IgG 1:1000 Invitrogen A11029 
Alexa-fluor 594 donkey anti-guinea 
pig IgG 
1:100 Jackson immunolab 706-585-148 
Alexa-fluor 488 goat anti-rat IgG 1:1000 Invitrogen A11006 
Alexa-fluor 594 donkey anti-rat IgG 1:100 Jackson immunolab 712-585-150 
Alexa-fluor 488 anti-rabbit IgG 1:100 Jackson immunolab 711-545-152 
Alexa-fluor 546 anti-guinea pig IgG 
(highly cross-adsorbed) 
1:1000 Invitrogen A11074 
Alexa-fluor 555 goat anti-rabbit IgG 1:1000 Invitrogen A21428 




2.6 Measurements of insulin secretion 
2.6.1 Quantification of insulin content 
Quantification of islets insulin content was done by the acid ethanol method. 10 islets were 
incubated at 40C overnight in 250µl of acidified ethanol (prepared by mixing absolute ethanol, 
deionised water and concentrated HCL in 52:17:1 ratio respectively), after which they were 
sonicated on ice for 20 sec. The solution was centrifuged at 2000rpm for 1min and supernatant 
was diluted with borate buffer to 1:2500. Insulin content was determined by radioimmunoassay 






2.6.2 Static insulin secretion 
The acute effect of collagen III on insulin secretion from islets was determined in static secretion 
experiments. Mouse and human islets were cultured overnight in RPMI containing 10% NCS, 
2mM L-glutamine and 100U/ml penicillin/0.1mg/ml streptomycin at 370C in an atmosphere of 
95% air / 5% O2. Islets were pre-incubated for 1 h in a physiological buffer (Gey & Gey, 1936) 
supplemented with 2mM glucose (Tables 2-17 and 2-18). Three islets (small, medium and 
large) per replicate were transferred to 0.5ml Eppendorf tubes then exposed to 300µl of the 
physiological buffer containing either 2mM or 20mM glucose in the presence or absence of 
collagen III for another 1 h at 370C. Islets exposed to the muscarinic agonist carbachol (500µM) 
served as positive control. Islets were centrifuged at 2000rpm for 1 min at 40C and 100µl of 
supernatant was diluted 1:5 with borate buffer and stored at -20°C prior to insulin 
radioimmunoassay. 
 
In similar experiments to assess the effects on insulin secretion of chronic exposure of islets to 
collagen III and IV, islets were cultured on dishes coated with 100nM collagen III or IV for 48 h. 
To coat dishes with collagen, 100nM collagen III or IV was spread on petri dishes and incubated 
at 370C for 5 h. Any remaining liquid was carefully removed and the petri dishes were kept at 
40C in a sealed and sterile environment prior to use. After 48 h incubation, islets were retrieved 
and exposed to either 2mM or 20mM glucose for 1 h, after the initial pre-incubation in 2mM 
glucose. Insulin secretion was determined by radioimmunoassay. 
 
Table 2-17: Composition of stock physiological salt solution. The reagents were completely dissolved in 
1.5L distilled water after which the volume was made up to 2L and stored at 40C. 
 
Reagents  Amount (g/2L) Final concentration [mM] 
when diluted 
Sodium chloride  26.00 111.00 
Potassium chloride  1.48 5.00 















Table 2-18: Preparation of physiological salt solution for experimental use. The pH of the solution was 
adjusted to 7.4 with 5% CO2//95% air before use. 
 
Reagents  Amount  Final concentration 
2x stock solution 250ml 1x 
Distilled water  250ml - 
Glucose  0.18g 2mM 
Calcium chloride (1M) 1ml 2mM 
Bovine serum albumin 0.25g 0.05% 
 
2.6.3 Dynamic insulin secretion 
To determine the dynamic insulin secretory profile of islets to acute exposure to collagens III 
and IV, mouse and human islets were perifused with physiological buffer containing the agents 
of interest in a perifusion system (Figure 2-7). This system consists of 8-16 chambers 
maintained at 370C in a temperature-controlled environment. Each chamber was lined with 1µm 
pore size nylon membrane to make sure that islets cannot pass through. Groups of 40 mouse 
islets or 150 human islets were transferred to chambers using a micropipette and islets were 
pre-perifused for 1h with physiological buffer containing 2mM glucose at a flow rate of 
0.5ml/min. The perifusate was discarded during this period after which the islets were exposed 
to agents of interest at specific time intervals. Perifusates were collected every 2min and insulin 








Figure 2-7: The perifusion system. The perifusion system consists of a water bath to maintain buffer 
temperature at 37°C, islet chambers, pvc tubes and valves, and a peristaltic pump for delivering the 
buffers to the islets. The system was made air-free after loading the islets into the chambers. Islets were 
perifused with agents of interest and perifusates was collected every 2min for quantification of released 




Radioimmunoassay is a very sensitive method for quantifying the concentration of an antigen of 
interest in a biochemical assay by making use of radioisotopic labelling. This assay is based on 
the principles of antibody (AB) and antigen (AG) interaction, in the presence of a radiolabelled 
form of the antigen (AG*), which is the tracer. AG, the substance to be measured, and its 
corresponding AG* compete for the limited binding sites on the AB such that at equilibrium, the 
following equation applies: 
 
AB + AG + AG*    AB: AG + AB: AG* + AG + AG*     
 
Thus, based on the law of mass action, keeping the concentration of antibody (AB) and tracer 
(AG*) constant while increasing the concentration of antigen (AG), the equilibrium will be shifted 








AB: AG will decrease with a resultant increase in AB: AG* since more AB sites are available for 
AG* to bind. The amount of AB: AG* present at any given time can then be measured using a 
suitable radiometric detector. 
 
To measure insulin concentrations in experimental samples, a 10ng/ml insulin stock was diluted 
serially in triplicate with borate buffer (Table 2-19) to give a range of concentrations over which 
the assay is sensitive (10ng/ml to 0.04ng/ml). Samples were diluted with borate buffer and 
assayed in duplicates. The radioactive tracer was I125-insulin, and it was diluted with borate 
buffer to give an approximate count of 10,000cpm per tube while the antibody used was bovine 
anti-insulin, diluted 1/10. Reference tubes were also set up in triplicate to measure non-specific 
binding, maximum binding of the antibody as well as total γ emission of the tracer. Antibody and 
tracer were added to tubes containing experimental samples and standards (Table 2-20) and all 
tubes were left to equilibrate at 40C for 48 – 72h. Following the period of equilibration, 1ml 
precipitant (Table 2-21) was added to each tube except those measuring total γ emission, to 
precipitate the antigen-antibody complexes. The tubes were centrifuged at 3000rpm at 40C for 
15min and the supernatant was aspirated. The radioactivity of the pellet was determined by a 
Packard Cobra II γ counter in counts per min per ml (cpm/ml). Plotting cpm/ml against log 
concentration generated a standard curve from which the concentration of insulin in the 
samples was determined.  
Table 2-19: Preparation of borate buffer. The reagents were dissolved in 1.8L distilled water and the pH 
was adjusted to 8.0 with conc. HCl before the volume was made up with dH2O to 2L. BSA (100% w/v) was 
then added and allowed to dissolve before the buffer was stored at 40C. 
 

































200  100   
Maximum 
binding (MB) 
100 100 100   
Total 
radioactivity (T) 
  100   
Standards  100 100 100  
Samples  100 100  100 
 
 
Table 2-21: Preparation of the precipitant. The γ-globulin was dissolved in PBS before 30% PEG was 
added with continuous mixing, giving a concentration of 15% PEG in the precipitant. Tween-20 was added 
to the mixture to prevent γ-globulin from sticking to the tubes. The 30% PEG stock solution was prepared 
by dissolving 600g polyethylene glycol in distilled water and made up to 2L. 
 
Reagents  Amount (1L) Final concentration 
30% PEG 500ml 15% 
γ-globulin  1000mg 1% 











2.7 Cell adhesion, apoptosis and proliferation 
2.7.1 Colorimetric cell adhesion assay 
To determine the effects of collagens I, III, IV and fibronectin on the adhesion properties of 
MIN6 β-cells, a colorimetric cell adhesion assay was used. 96-well plates were coated with 
100nM each of collagen I, III, IV or fibronectin, or with 0.5% BSA and non-specific binding sites 
were blocked for 45 min with 0.5% BSA at 370C. BSA sticks to the part of the wells not covered 
by collagens. MIN6 β-cells were maintained overnight in serum-free DMEM and retrieved by 
trypsinisation (section 2.1.1). Groups of 30,000 cells were seeded into the coated plates and left 
to adhere at 370C for 90 min. Non-adherent cells were washed off with serum-free DMEM 
containing 0.1% BSA and the remaining adherent cells were fixed with 4% paraformaldehyde, 
and stained with crystal violet (5mg/ml in 2% ethanol). After five washes with distilled water, 
plates were allowed to air dry then adherent cells were lysed in 2% SDS for 30 min. The 
adherent cell density was determined by measuring absorbance at 595nm with a Chameleon 
plate reader. 
 
2.7.2 Caspase-Glo 3/7 apoptosis assay 
Apoptosis, a programmed cell death, is mediated by a set of proteases known as caspases. 
The initial cell death signal is induced by initiator caspases 8 and 10 and the ensuing cell death 
is carried out by effector caspases 3 and 7.  The caspase-Glo 3/7 Assay kit recognises the 
activation of caspases 3 and 7 within cells, and cleavage of a tetrapeptide sequence within a 
substrate following caspase 3/7 activation results in light emissions that can be detected using a 
plate luminometer. The intensity of light emitted is proportional to the amount of activated 
caspase 3/7 present within the sample. 
 
Groups of 20,000 MIN6 β-cells or 3-5 islets per well were cultured in media containing 2% FBS 
in the presence or absence of 100nM collagen III for 48 h, with a subsequent 20h incubation in 
the presence or absence of a cytokine cocktail (1U/µl TNF-α, 0.05U/µl IL-1β and 1U/µl IFN-γ). A 
working solution of the reagent was made by mixing caspase 3/7-Glo buffer with caspase 3/7-
Glo substrate and 25µl of the reconstituted reagent was added to each well (also containing 
25µl).  Plates were incubated at room temperature for 1 h and luminescence intensity, a 





2.7.3 BrdU ELISA 
Proliferation of β-cells in vitro was determined by BrdU incorporation using a colorimetric BrdU 
ELISA kit. 20,000 native MIN6 β-cells or MIN6 β-cells transfected with GPR56 plasmids as 
described in section 2.4.3 were seeded onto 96-well plate and incubated overnight at 370C in 
DMEM supplemented with 10% FBS. The cells were then serum-starved for 24 - 48h and 
labelled with 100µM BrdU labelling solution for 4h at 370C. Non-transfected cells grown in the 
presence of serum served as positive control. The cells were fixed and denatured for 30 min 
with a 200µl/well FixDenat solution after which the wells were dried by blotting. Anti-BrdU 
antibody was added to each well which bind to the BrdU incorporated into newly synthesised 
DNA. The wells were washed three times with PBS and 25µl of substrate solution was added. 
The well plate was placed on a shaker until sufficient colour developed, which took about 5 to 
10 min. Reaction was stopped by adding Stop solution (Sulphuric acid) and absorbance was 
read at 450nm on a microplate reader. 
 
 
2.8 Measurement and manipulation of second messenger generation 
2.8.1 Single cell calcium microfluorimetry 
The effect of collagen III and other agents of interest on intracellular calcium recruitment was 
carried out by single cell calcium microfluorimetry. This technique allows real time measurement 
of the changes in cytosolic calcium concentration within cells. Calcium signalling is a central 
factor in insulin secretion and data obtained from measuring changes in cytosolic calcium could 
provide information on β-cell health. To measure calcium, cells are incubated with fluorescent 
dyes such as Fura-2AM that causes a shift in excitation wavelength from 380nm to 340nm 
when the dye is bound to calcium. This therefore allows intensity measurement of Ca2+-free and 
Ca2+-bound form of the dye to be made. By expressing the level of [Ca2+]i as a ratio of these 
excitation wavelengths, changes in intensity as a result of factors unrelated to intracellular 
calcium such as dye leakage and changes in cell thickness is minimised. 
 
MIN6 β-cells (1.5 X105 cells) were seeded on acid-ethanol washed coverslip initially for 1 h for 
the cells to attach in serum free DMEM. Incubation buffer was changed to DMEM containing 





about 100 – 200 islets were partially dispersed (Figure 2-8) in 200µl accutase for 5min at 370C 
and mixed intermittently every 2 min before being seeded on acid-washed coverslip as 
described for MIN6 β-cells. The cells were then loaded with 5µM Fura2-AM for 30 min at 370C 
before being transferred to a temperature-controlled chamber maintained at 370C and perifused 
with physiological buffer supplemented with 2mM glucose. A shutter system was used to 
expose the cells alternatively to 340nm and 380nm while emission at 510nm was captured 
using an inverted epi-fluorescent microscope (Zeiss Axiovert 135). Cells of interest were 




Figure 2-8: Partially dispersed human islets. Human islets were incubated for 5min in accutase at 370C 








2.8.2 GTP-Rho pull down assay 
Native MIN6 β-cells or MIN6 β-cells transfected with GPR56 plasmid was serum-starved for 36 
h, after which the cells were stimulated with 100nM collagen III or 20mM glucose for 5, 10 and 
15min, and lysed in 300µl of lysis buffer. Isolated islets cultured overnight were incubated in the 
presence or absence of 100nM collagen III for 10 min and lysed in lysis buffer. After centrifuging 
for 10min at 12,000rpm, protein concentration was determined. Protein concentration was 
normalised and an aliquot was used as input loading control while the remaining supernatant 
was incubated with 25µg GST-RBD beads for 2h at 40C. The resin was washed twice with lysis 
buffer at 2600rpm for 30sec and boiled in Laemmli sample buffer. Input loading control and the 
resin were separated by SDS-PAGE and bound-RhoA was detected by immunoblotting.  
 
 
2.9 In vivo studies 
2.9.1 GPR56 knockout mouse model 
All in vivo studies involving GPR56 knockout (KO) mice were carried out at Children’s Hospital 
and Harvard Medical School, Boston, USA, and conformed to the guidelines of the Animal Use 
and Care Committee of Boston Children’s Hospital. GPR56 KO mice on a mixed 
129/BL6/FvB/Balb/c background were obtained from Genetech/Lexicon. The targeting strategy 
involves the replacement of exons 2 and 3 by LacZ/Neo, which leads to the deletion of the start 
ATG codon and causes a frame-shift. The TG2/GPR56 double KO mice used in this thesis were 
generated and maintained by Dr Paio’s lab and were different from the one mentioned in 
Chapter 1. 
 
2.9.2 Confirmation of gene knockout 
2.9.2.1 Genotyping 
To determine the genotypes of the transgenic mice, about 2mm of their tail tips were cut into 
200µl of PBND (PCR buffer with non-ionic detergent) buffer (Table 2-22) containing 10µl 
(100µg/ml) proteinase K and digested overnight at 550C. The tubes were further heated for 10 
min at 950C to inactivate proteinase K before being centrifuged at 12,000 rpm for 10 min. A 
master mix was prepared (Table 2-23) and Betaine/DMSO was added due to the high GC 





AAA GTA GCT AAG ATG CTC TCC-3’; Neo 3A, 5’-GCA GCG CAT CGC CTT CTA TC-3’; and 
91-111, 5’-GA CTT CCG CTT CTG TGG CCA G-3’. A touch-down PCR cycling protocol was 
used, where annealing occurred at 650C for the first 10 cycles and gradually decreases by 
10C/cycle to 550C. The next 30 cycles annealed at 550C.. PCR products were separated on 
1.5% ultrapure agarose gel at 200V for 1h. 
 
Table 2-22: Preparation of PBND buffer. The reagents were dissolved in 450ml deionised water and 
volume was adjusted to 500ml with deionised water, and autoclaved. It was aliquoted and stored at -20. 
Gelatin will not dissolve until after autoclaving. 
 
Reagents  Amount  Final concentration 
1M Tris-HCL stock, pH 8.3 5ml 10mM 
KCl 1.87g 50mM 
MgCl2.6H2O 0.255g 2.5mM 
IGEPAL 2.25ml 0.45% v/v 
Tween 20 2.25ml 0.45% v/v 
Gelatin 0.05g 0.1mg/ml 
 
Table 2-23: PCR master mix for 20 genotyping reactions 
 
Reagents  Volume (µl) 
Sterile double distilled water 248.5 
10x PCR buffer (15mM MgCl2) 50 
100mM dNTPs 2 
MgCl2 34 
Betaine (Sigma B0300) 130 
DMSO 6.5 
200µM primer DNA085-14 1 
200µM primer Neo3A 1 
200µM primer 91-111 1.5 








2.9.2.2 Immunohistochemistry staining 
The GPR56 KO mice described in this thesis were whole body knockout model. 
Immunohistochemistry was therefore performed on pancreatic sections to determine whether 
GPR56 protein in β-cells was also deleted. Wax-embedded pancreas sections from wild type 
(WT) and KO mice were processed as described in section 2.5.5 and stained for the c-terminal 
domain of GPR56.  Staining for insulin revealed β-cells. The GPR56 C-terminal antibody (199) 
was developed and validated previously in Professor Piao’s lab (Luo et al., 2011, 2014).  
 
2.9.3 Glucose tolerance tests 
Intraperitoneal glucose tolerance test (IPGTT) was carried out on adult mice from 8 to 12 week 
old. Mice were fasted overnight for a maximum of 16 h by removing food but allowed free 
access to water. Basal glucose level was measured with Accu-Chek glucose meter and strips 
prior to intraperitoneal administration of 30% glucose at 2g/kg. Blood was obtained by pinpricks 
to the tails of the animals using 27G needle. Plasma glucose concentrations were later 
measured at 15, 30, 60, 90 and 120 min. 
 
2.9.4 BrdU delivery 
Age-matched adult GPR56 WT and KO mice were given BrdU (50mg/kg) intra-peritoneally (IP) 
daily for 5 days while P9 mice were given 50mg/kg BrdU IP for 24 h prior to pancreas retrieval. 
The pancreases were fixed in 4% paraformaldehyde and processed either for paraffin 
embedding or fixed-frozen.  
 
2.10 Statistical analyses 
In all cases, normality of data distribution was evaluated using D’Agostino or Shapiro-Wilk tests. 
Normally distributed data were analysed using a two-tailed Student’s t-test or ANOVA, as 
appropriate. Repeated measurements in the same animal at different time points were 
determined by two-way repeated measurement ANOVA with appropriate post hoc tests. 
However, non-Gaussian data were analysed by Mann-Whitney U test. Statistical analyses were 
performed using GraphPad Prism 7. Data are presented as mean ± SEM and p<0.05 was 
considered significant. Immunohistochemistry images in Chapters 3, 4 and 5 were scored 






































Chapter 3 Characterisation of GPR56 expression in developing 
and adult pancreas 
 
3.1 Introduction  
The adhesion G-protein coupled receptor family is the second largest class of GPCRs in the 
mouse and human genome (Bjarnadóttir et al., 2004). These receptors are generally thought to 
be involved in cell adhesion and cell-matrix interaction because of the presence of several 
adhesive motifs on their N-terminals. Adhesion GPCRs are expressed in both central and 
peripheral tissues including the brain, reproductive tracts and lungs, where they play varying 
roles including cortical development (Li et al., 2008; Piao et al., 2004), cell migration (Iguchi et 
al., 2008) and immunity (Nijmeijer et al., 2016).  
 
GPR56 is a member of the adhesion GPCR family that has received considerable attention in 
the last decade, because it was the first adhesion GPCR to be associated with a human 
disease, known as bilateral frontoparietal polymicrogyria (BFPP). BFPP is a rare human brain 
disorder caused by germline mutations in GPR56, which presents as cognitive and motor 
dysfunctions manifesting in cerebral hypoplasia, seizures and mental retardation (Parrini et al., 
2009).. It arises as a result of improper neuronal migration during cortical development, 
suggesting that GPR56 is essential for cell migration (Fujii et al., 2013; Luo, Yang, et al., 2011).  
 
Similar to other adhesion GPCRs, GPR56 is ubiquitously expressed. Its expression has been 
reported in the brain, testis, thyroid, placenta, small intestine and stomach (Liu et al., 1999). 
GPR56 expression has also been detected in metabolically active tissues such as skeletal 
muscle, adipose, and liver (Amisten et al., 2015; Iguchi et al., 2008) and it is the most 
abundantly expressed GPCR mRNA in human islets (Amisten et al., 2013). GPR56 was found 
to be high at the protein level in pancreas and kidney, with medium expression reported in 
brain, liver and spleen (Huang et al., 2008). The broad expression of GPR56 in both central and 






It is thought that the unusually long N-terminal domain of GPR56 allows it to bind to many 
partners, including collagen III, transglutaminase 2 (TG2) and CD81. Collagen III is a ligand for 
GPR56 in the developing brain, where it couples to Gα12/13 and RhoA signalling (Iguchi et al., 
2008; Luo, Jeong, et al., 2011).  TG2 interacts with GPR56 to suppress melanoma growth and 
metastasis (Xu et al., 2006), but it is unclear whether TG2 is a traditional agonist as no 
downstream signalling has been identified. In addition, the tetraspanin protein CD81 acts as a 
scaffolding protein to stabilise the association of GPR56 with Gq (Tritarelli et al., 2004). The 
functional significance of this interaction is also not known. 
 
As stated above, GPR56 is a developmental gene. It is critical for the proper formation of the 
rostral cerebellum as it allows the developing neurons to adhere to the extracellular matrix of 
the pial basement membrane (Koirala et al., 2009). The failure of this process leads to neuronal 
overmigration and ectopia. In addition, loss of GPR56 leads to hypomyelination of the CNS as a 
result of defective development of oligodendrocyte precursor cells (Giera et al., 2015). Outside 
the CNS, GPR56 plays structural functions in seminiferous tubule development in mice where 
its absence during embryogenesis leads to male infertility (Chen et al., 2010). In the developing 
pancreas, GPR56 mRNA is robustly expressed in NGN3+ endocrine progenitors (Gu et al., 
2004), but its function in islet development is not yet known.  
 
GPCRs that are highly expressed in a given tissue are known to play important physiological 
role in those tissues. For example, opsins that are important for light detection are highly 
expressed in the eye, while the glucagon-like peptide 1 receptor, a major therapeutic target for 
treating diabetes, is abundantly expressed in islets (Regard et al., 2008). It is therefore likely 
that GPR56 may play an important role in islet function, if the abundant mRNA level already 
reported in islets translates to high protein expression. This chapter describes the expression of 
GPR56 and its binding partners in mouse and human islets, as well as their cellular localisation. 
The expression of GPR56 in endocrine progenitors and in different stages of islet development 







• Determine whether GPR56 is expressed in the developing pancreas and whether it 
colocalises with markers of pancreatic progenitors. 
• Quantify the expression of GPR56 at different stages of islet development 
• Determine whether deletion of GPR56 has any effect on proliferation and differentiation 
of endocrine progenitors. 
• Determine the expression of GPR56 and its binding partners in adult mouse and human 





Total RNAs from MIN6 β-cells, mouse islets, human islets, mouse and human exocrine cells 
were extracted and reversed-transcribed to cDNAs as described in Section 2.3.2. The mRNA 
expression of GPR56 and its binding partners was investigated by RT-PCR, using specific 
forward and reverse primers designed to amplify the targets of interest (Table 2.3). The 
amplified products were separated on 1.5% agarose gels containing 0.5µg/µl ethidium bromide 
and DNA bands were visualised under UV light. 
 
3.3.2 Western blotting 
Protein was extracted from mouse brain and MIN6 β-cell samples with RIPA buffer (Section 
2.5.1) and protein concentrations were determined by the BCA method. Following protein 
separation by SDS-PAGE, fractionated proteins were transferred to a blotting membrane and 
probed with a commercially available monoclonal antibody directed against GPR56. The 
membrane was further incubated with the corresponding secondary antibody and 







3.3.3  Fluorescent immunohistochemistry 
Freshly retrieved mouse pancreases were fixed in 4% paraformaldehyde overnight before being 
cryoprotected and frozen, or transferred into 70% ethanol and paraffin embedded. Fixed frozen 
or wax-embedded mouse pancreases and archived human pancreas blocks were cut to 10µm 
or 5µm sections respectively and IHC was carried out as described in Section 2.5.5. Pancreas 
sections were incubated overnight with antibodies directed against GPR56, collagen III, 
collagen IV, insulin, glucagon, somatostatin, NGN3, SOX9 or CD31. After incubating with 
fluorophore-conjugated secondary antibodies (Table 2-16) targeting the species in which the 




3.4.1   Expression of GPR56 mRNA by MIN6 β-cells, mouse islets, human islets and 
exocrine cells 
RT-PCR revealed that mouse and human endocrine and exocrine cells express GPR56 mRNA 
(Figure 3-1). The amplicons obtained correspond to the predicted sizes of the nucleotide 
sequence generated using the chosen primer pairs (199bp for mouse GPR56 and 198bp for 
human). As expected, no amplification was seen when MIN6 β-cell RNA, mouse islet RNA or 
distilled water were used instead of cDNAs, indicating that the amplified DNA bands were not 
due to genomic DNA contamination. The expression of GPR56 mRNA was stronger in mouse 
islets than in mouse exocrine cells while the expression level in human islets was comparable to 
that in human exocrine cells (Figure 3-1). However, it is not possible to quantify relative 








   
Figure 3-1 Detection of GPR56 mRNA in mouse and human pancreatic cells. cDNAs from the indicated 
tissues were amplified by reverse-transcriptase PCR. Amplified products were run on a 1.5% agarose gel 
containing ethidium bromide and DNA bands were visualised under UV light. GPR56 is expressed in MIN6 
cells, mouse and human islets, and in exocrine cells. A molecular size marker and RNAs from MIN6 cells 
and mouse islets, and distilled water containing mouse and human primers but no cDNA, were run on the 
same gel. Amplicons correspond to the predicted size of the nucleotide sequence generated using the 
chosen primer pairs. 
 
 
3.4.2 GPR56 protein expression 
Having detected GPR56 mRNA in β-cells, it was investigated whether GPR56 message is 
translated to protein. As protein is the primary determinant of cell phenotype and the mRNA 
level of a gene is not necessarily directly correlated to its protein level (Lundberg et al. 2010), 
western blotting was used to identify the expression of GPR56 protein in whole brain and MIN6 
β-cell lysate. Cell lysates were subjected to SDS-PAGE and the separated proteins were blotted 
on to PDVF membrane, before being immunoprobed with an antibody directed against the N-
terminal domain of GPR56. It is known that GPR56 can exist either as a full length protein or in 
a cleaved form, as during processing, the N-terminal segment of GPR56 is cleaved at the GPS 
motif (Xu et al., 2006). Consistent with a previous report (Iguchi et al., 2008), GPR56 was 
mainly expressed as the full length 70kDa protein in adult mouse brain, with lower expression of 
the 65kDa cleaved form (Figure 3-2A, left side). In MIN6 β-cells, GPR56 was expressed at 





This could mean that the cleaved form of GPR56 is not expressed by β-cells or that MIN6 β-
cells had lower GPR56 protein expression than in brain.  
 
The expression of GPR56 protein in human pancreas was investigated by fluorescence 
immunohistochemistry, Using the same antibody that had been used in the western blotting 
experiments, archived blocks of human pancreas were cut to 5µm thick and identification of 
GPR56 expression was carried out as described in Section 2.5.5. As shown in Figure 3-2B, 
GPR56 was strongly expressed in human islet cells, with apparently faint expression in the 
exocrine cells. However, consecutive sections that were subjected to the same immunostaining 
procedure but without GPR56 antibody also indicated background staining in the exocrine 
pancreas, indicating that this was non-specific staining (Figure 3-2B, right). The restriction of 
GPR56 expression to endocrine cells of the human pancreas is not consistent with detection of 
GPR56 mRNA in human acinar cells, suggesting that there may have been some endocrine cell 









Figure 3-2 Protein expression of GPR56 in whole mouse brain, MIN6 β-cells and human islets. A) Whole 
brain and MIN6 β-cell lysates were separated by SDS-PAGE and subjected to western blotting. 
Immunoreactive bands for GPR56 were seen at 70kDa in whole brain and MIN6 β-cell lysates. A second 
band appeared faintly at 65kDa in whole brain lysate. B) GPR56 expression was detected by 
immunohistochemistry in wax-embedded human pancreas sections. As expected, no immunoreactivity 
was observed in the negative control sections where GPR56 antibody was omitted. Scale bar = 50µm. 
 
 
3.4.3 Localised expression of GPR56 in mouse and human islets 
A careful analysis of the cellular localisation and expression pattern of a protein may provide 
useful clues pertaining to its functions in vivo. Previous studies that reported the protein 
expression of GPR56 in the pancreas have used methods such as western or northern blotting 
that cannot distinguish expression within the exocrine or endocrine parts of the pancreas or 
between individual endocrine cells (Huang et al., 2008; Liu et al., 1999; Shashidhar et al., 
2005). This may be due to non-availability of an appropriate antibody for immunostaining at the 
time of study or the fact that the primary aim of these papers was not islet focused.  
 
To confirm the cellular localisation of GPR56 in mouse and human islets, double 





from adult mouse and human pancreases. Immunostaining of mouse pancreas sections 
showed that GPR56 is expressed strongly by islets compared to the surrounding exocrine cells 
(Figure 3-3B, E & H). On the other hand, GPR56 expression was not detected in α and δ-cells 
(Figure 3-3C &I). 
 
It was observed from BLAST multiple alignment tests that mouse and human GPR56 share 
81% sequence homology, suggesting that the GPR56 localisation pattern in human pancreas 
may be similar to that of mouse. To test this, immunohistological staining was carried out on 
serial sections of wax-embedded human pancreas with antibodies specific to GPR56, insulin, 
glucagon or somatostatin. As observed previously (Figure 3-2B) GPR56 was strongly 
expressed in human islets, but unlike in mouse pancreas, there was little or no staining in the 
surrounding exocrine acinar cells (Figure 3-4). Comparable to mouse islets, it could be seen 
that GPR56 is expressed by human β-cells but it is absent in glucagon producing α-cells and 
somatostatin secreting δ-cells. In mouse and human islets, there was >95% co-expression of 
GPR56 and insulin in β-cells (Figure 3-5), suggesting that GPR56 may have β-cell specific 
functions in both mouse and man.  
 
Consistent with the literature, the pattern of expression of endocrine cells in mouse islets is 
different to that of human. Thus, unlike in mouse islets where β-cells are present in the core of 
the islets surrounded by a mantle of α-cells (Figure 3-3A), in human islets α-cells are scattered 








Figure 3-3 GPR56 is expressed by mouse β-cells. 5µm sections of paraffin embedded mouse pancreas   
were immunoprobed with GPR56 antibody and tagged with a fluorescent secondary antibody (B, E & H). 
Subsequently, sections were incubated with glucagon, insulin or somatostatin antibodies and tagged with 
corresponding secondary antibodies respectively (A, D & G). Images were merged (C, F & I) and co-









Figure 3-4 GPR56 is expressed by human β-cells. 5µm sections of paraffin embedded human 
pancreas were immunoprobed with GPR56 antibody and tagged with a fluorescent secondary 
antibody (B, E & H). Subsequently, sections were incubated with glucagon, insulin or somatostatin 
antibodies and tagged with corresponding secondary antibodies respectively (A, D & G). Images were 
merged (C, F & I) and co-localisation is indicated in yellow. Images are representative of five different 






Figure 3-5 Percentage of islet endocrine cells expressing GPR56 in mouse and human pancreas sections. 
GPR56+ islet cells in mouse and human islets were counted with ImageJ software. The number of 
individual islet cells expressing GPR56 is represented as a percentage of the total number of islet cells. 
Data are represented as mean + S.E.M, n = 5 sections. 
 
3.4.4 Expression of GPR56 in islet development  
It has been proposed that GPR56 may be involved in islet development because its mRNA 
transcript was highly expressed in endocrine progenitor cells (Gu et al., 2004). To identify 
expression of GPR56 during mouse islet development, immunohistological staining was 
performed on sagittal sections of mouse embryos and pancreases that were retrieved at E11 
and E13-E16 respectively.  The midgut was used to locate the position of the pancreatic 
primordium in E11 embryonic sections since the dorsal and ventral buds of the pancreas are 
evaginations of the midgut (Figure 3-6A & B). GPR56 protein was detected in the pancreas at 
the earliest available stage of development: at E11, when the dorsal and ventral buds are yet to 
fuse, it was present in both buds (Figure 3-7C). In addition, its expression was also evident in 
the pancreas at E13 and E16 (Figure 3-7D & E).   
 
Shortly after the fusion of the lateral and dorsal buds, the primitive pancreas undergoes 
significant structural changes that are marked by budding at the edges of the pancreas, also 
known as the tip region, and rearrangement of the cells at the inner or trunk region to form the 





at the trunk region predominantly give rise to endocrine and ductal lineages (Shih et al., 2013). 
As shown in Figure 3-6D, GPR56 was detected at the tip region (marked by rosette-like buds) 
and the trunk region at E13, with similar expression levels in both regions. At E16, when the 
islet structure is morphologically distinguishable from the exocrine cells, GPR56 expression was 








Figure 3-6 Expression of GPR56 in embryonic mouse pancreas. A) Image shows the lateral view of a 
mouse embryo at E13.5 stained with haematoxylin. Image was taken from (Saisawat et al., 2014). B) The 
midgut region of a mouse embryo at E10 was microsurgically dissected. Image shows the dorsal and 
ventral pancreas as outgrowths of the midgut, which are yet to fuse at this stage C) Wax-embedded E11 
mouse embryo was sectioned sagittally and immunoprobed for GPR56. GPR56 is expressed in both the 
ventral and dorsal buds of the pancreatic primordium. D) A sagittal section of a mouse embryo at E13 





pancreas. Li = liver, Mg =mid gut, Pa = pancreas, Vp= ventral pancreas, Dp = dorsal pancreas, Ki = 
kidney, Go = gonad, Lu = lung, Is = islet, Scale bar = 100µm for C, D & E only. 
 
As GPR56 expression was restricted to the β-cells in adult mouse and human islets (Figure 3-3 
- Figure 3-5), it was investigated whether this restriction started during islet development in the 
embryo or acquired after birth by carrying out double immunostaining of GPR56 and insulin in 
mouse embryonic pancreas sections at E18. At this stage of development GPR56 was 
expressed by β-cells and it colocalised with insulin (Figure 3-7C), consistent with what was 
observed in adult mouse and human islets. However, not all GPR56-expressing cells were 
positive for insulin (Figure 3-7B) and some insulin+ β-cells were negative for GPR56 (Figure 










Figure 3-7 GPR56 colocalises with insulin in developing islets at E18. Antigens were retrieved for 12 min 
and double IHC was performed on 10µm sections of E18 mouse pancreas for (A) insulin and (B) GPR56. 
C) GPR56 and insulin immunostaining were merged and colocalisation is indicated in yellow. GPR56 is 
expressed by some β-cells. Not all GPR56+ cells are positive for insulin and vice versa. (D-F) Images show 
non-detection of (D) insulin and (E) GPR56 when primary antibodies were omitted in the immunostaining 






To confirm the specificity of GPR56 and insulin antibodies, the immunostaining procedure was 
repeated with PBS replacing the primary antibodies, followed by incubation with the appropriate 
secondary antibodies. Using the same exposure time, no immunopositive signals were seen in 
the absence of the primary antibodies (Figure 3-7D-F), indicating that the signals in A & B are 
positive for insulin and GPR56 respectively. 
 
Double IHC was also carried out on E18 mouse pancreas sections using antibodies for GPR56 
and glucagon or somatostatin. Glucagon expressing α-cells were detected at E18, with no 
colocalisation with GPR56 (Figure 3-8D, E&F). As shown in Figure 3-8G, somatostatin positive 
δ-cells were expressed in embryonic mouse pancreas at E18. Similar to adult islets, no 
colocalisation between GPR56+ cells and somatostatin+ cells was observed (Figure 3-8I). Since 
GPR56 is only expressed by β-cells in embryonic islets (Figure 3-8C), the GPR56+ cells that do 
not co-localise with insulin are either progenitor cells that are yet to differentiate to β-cells or 
ductal cells. 
 
As shown earlier, GPR56 mRNA was detected in exocrine cells of adult mouse pancreas 
(Figure 3-1). Following a similar line of investigation, it was therefore determined whether 
GPR56 is expressed by developing mouse acinar cells. Pancreases were dissected from 
embryonic day 18 (E18) and 9-day-old mice (P9) and fixed-frozen. 10µm sections were 
immunoprobed for GPR56 and amylase, which is a marker for acinar cells. Consistent with the 
mRNA expression in adult mouse pancreas, GPR56 was faintly expressed in exocrine cells 
compared with endocrine and ductal cells where amylase was not present (Figure 3-9). At E18 
and P9, GPR56 was faintly colocalised with amylase while at P9, it was strongly expressed by 









Figure 3-8 GPR56 is not expressed by embryonic α-cells or δ-cells. Double immunostaining of GPR56 
(green) with insulin, glucagon or somatostatin (red) was performed on E18 fixed-frozen mouse pancreas 
sections. GPR56 is co-expressed by some insulin positive β-cells (A – C). GPR56 was not detected in α- 









Figure 3-9 GPR56 is expressed at low levels by the exocrine acinar cells in embryonic and post-natal 
mouse pancreas. Fixed-frozen mouse pancreas sections were immunoprobed for amylase and GPR56 at 
E18 and P9.. GPR56 faintly colocalised with amylase at E18 (A-C) and in early postnatal pancreas (D-F). 














3.4.5 Expression of GPR56 at different stages of mouse islet development 
E15 was the earliest time point at which it was possible to quantify expression of GPR56 in islet 
development, due to limited availability of tissues. GPR56 was abundantly expressed in both 
the exocrine and endocrine pancreas at E15 and it colocalised with insulin (Figure 3-10B&C). 
There was a gradual decline in the expression of GPR56 in exocrine cells as the mice mature 
from E15 to P9 (Figure 3-10B, E, H&K), while its expression in the islets was maintained. 
Overall, quantification of GPR56 expression by ImageJ analysis indicated that there was a 
decrease in GPR56 expression in the whole pancreas at E16 and this decrease was maintained 
till E18 (Figure 3-10M). Thereafter, GPR56 expression began to increase and at P9 it had 








Figure 3-10 Expression pattern of GPR56 in developing mouse pancreas. Fixed-frozen mouse pancreas 
sections were immunoprobed for GPR56 and insulin, and the expression levels of the two proteins were 
quantified by ImageJ. A-L) Representative images showing the expression of GPR56 and insulin at E15 to 
P9, with colocalisation indicated in yellow. Scale bar = 100µm. M) The graph shows the percentage area of 






















GPR56+ cells in the pancreas at different developmental stages. *p<0.05, n=10 sections, Kruskal-Wallis 






3.4.6 Expression of GPR56 by endocrine progenitor cells 
Endocrine progenitors are positive for neurogenin 3 (NGN3), a transcription factor expressed 
exclusively by pancreatic cells that will later form the islets. They differentiate terminally to form 
α-, β-, δ- and pancreatic polypeptide (PP) cells. To confirm that endocrine progenitor cells 
express GPR56, NGN3 expression was first assessed by IHC in fixed frozen or wax embedded 
pancreas sections from E18 mice. Figure 3-11 and Figure 3-12 show that, in mouse pancreas 
the subcellular localisation of NGN3 is both cytoplasmic and nuclear, consistent with what was 
observed in the hippocampus (Simon-Areces et al., 2010). 
 
NGN3 expression is tightly controlled during islet development, maintaining a balance between 
endocrine cell proliferation and differentiation. NGN3 is downregulated during differentiation. It 
was shown by lineage tracing that each endocrine cell transiently expresses NGN3 for up to 48 
h, after which the expression is switched off and the cells become terminally differentiated (Gu 
et al., 2002). Figure 3-11B and Figure 3-12B, E & H show that NGN3 is highly expressed in 
some cells in the developing pancreas, while it is weakly expressed in others. Dual staining with 
an insulin antibody indicates that NGN3 is expressed in some β-cells, while other insulin-
expressing cells are negative for NGN3 (Figure 3-11C). This suggests that the cells are in 
transition of their progenitor status being turned off. NGN3 expression is biphasic in mouse 
pancreas development with early NGN3-expressing progenitors appearing with primary 
transition of islet development and they become reactivated again just prior to secondary 
transition. The first wave of cells expressing NGN3 give rise mostly to α-cells while the later 
NGN3-expressing precursors give rise to all endocrine cell types (Villasenor et al., 2008; 
Johansson et al., 2007). Glucagon+ α-cells are the first to be expressed in islet development at 
E9.5 and Figure 3-12F show that NGN3 expression in most of the glucagon+ α-cells has been 
completely turned off, since they were negative for NGN3 at E18.5 when majority of α-cells had 
been formed (Johansson et al., 2007).  This is also true for δ-cells, as none of the somatostatin 
immunoreactivity colocalise with NGN3 in any cells (Figure 3-12H&I).  
 
To confirm the specificity of the NGN3 antibody that was used for IHC, wax-embedded mouse 
pancreas sections were subjected to the same IHC procedures in the absence of the NGN3 





primary antibody was specific to NGN3 and that the signals seen in Figure 3-12B, E&H were not 




Figure 3-11 Expression of insulin and NGN3+ endocrine progenitors in the pancreas at E18. Frozen 
pancreas sections were incubated with insulin and NGN3 antibodies. A) Insulin positive β-cells are already 
in clusters at E18, resembling the adult islet structure. B) Image shows that NGN3+ cells are restricted to 
an islet-like cluster at E18 (although there appears to be some NGN3+ duct cells), with no expression at 
the surrounding exocrine acinar cells. Subcellular localisation of NGN3 is both nuclear and cytoplasmic. C) 
Image shows colocalisation of insulin with NGN3+ cells in yellow and NGN3+ progenitor cells that are yet 
to differentiate. Scale bar = 100µm.   
 
Having established the expression pattern of NGN3 in the embryonic mouse pancreas, it was 
next determined whether NGN3 positive cells express GPR56. Double IHC staining for NGN3 
and GPR56 was performed on mouse pancreas sections at E13 and E16. At E13, most of the 
NGN3 positive cells co-express GPR56 (Figure 3-13), while at E16 most of the GPR56 positive 
cells no longer colocalise with NGN3 (Figure 3-15 A-C). As shown in Figure 3-14, GPR56 was 
expressed in cells that were positive for pancreatic and duodenal homeobox 1, a transcription 
factor that is important for pancreas development and functional maturity of β-cells (Romer and 
Sussel, 2015). In addition, as SOX9 is important in determining endocrine and ductal cell 
lineage fate, the expression of GPR56 was investigated in SOX9+ cells. It can be seen from 







Figure 3-12 Expression of NGN3 in developing islet endocrine cells. Paraffin embedded mouse pancreas 
sections were immunoprobed for insulin, glucagon, somatostatin and NGN3. A-C) Images show the 
expression of insulin and its colocalisatioin with NGN3. D-F) show glucagon+ cells, the majority of which 
do not express NGN3 (F).  G-I) show somatostatin positive cells that do not colocalise with NGN3. J-L) are 








Figure 3-13 Expression of GPR56 by NGN3+ progenitors at E13. Frozen mouse embryo was sectioned 
sagittally and immunoprobed for GPR56 and NGN3. A) Image shows the expression of GPR56 and B) 
NGN3 with C) colocalisation indicated in yellow. A’ – C’ are magnified images of A – C respectively. Scale 








Figure 3-14 Expression of GPR56 by PDX1+ pancreatic cells. Frozen mouse pancreas sections at E17 
were immunoprobed for PDX1 and GPR56. A) Image shows the expression of PDX1 and B) colocalisation 




Figure 3-15 Expression of GPR56 in NGN3+ and SOX9+ progenitors at E16. Double IHC for GPR56 and 
NGN3 or GPR56 and SOX9 was carried out on 10µm sections of E16 mouse pancreas.  A) GPR56 was 
expressed in mouse pancreas at E16. B) NGN3 was also detected. C) Image shows limited colocalisation 
of GPR56 and NGN3 in yellow. D-F Images show the expression of SOX9 in developing islet and ductal 







3.4.7 Effect of GPR56 deletion on differentiation of endocrine progenitors 
The effect of GPR56 on differentiation of endocrine progenitors was investigated by staining for 
NGN3 in embryonic pancreases retrieved from GPR56 WT and GPR56 KO mice. Prior to 
pancreas retrieval, pregnant dams were injected IP with BrdU, to label replicating cells. 
Immunostaining for NGN3 and BrdU was carried out and the number of NGN3+cells/mm2 and 
BrdU+ cells/mm2 were quantified by ImageJ (Figure 3-16A-D). At E16, there was an increased 
number of NGN3+ progenitors in GPR56 KO pancreas (NGN3+ cells/mm2; WT: 3,012 ± 211, 
KO: 3,880 ± 266, n=6-11 replicates, p=0.05), suggesting reduced differentiation (Figure 3-16E). 
However, there was no change in proliferation of progenitor cells at E16 (BrdU+ cells/mm2; WT: 
475.8 ± 44.6, KO: 448.2 ± 18.2, n=6-11 replicates, p>0.2) (Figure 3-16F). 
 
 
Figure 3-16 Effect of GPR56 deletion on differentiation and proliferation of endocrine progenitors at E16. 
Pregnant dams were given BrdU IP and pancreases were retrieved 2 h later and fixed frozen. 5µm 
sections were immunostained for NGN3 and BrdU in A-B) GPR56 WT pancreases and C-D) GPR56 KO 
pancreases. Scale bar = 100µm. E) There was a trend towards increased NGN3+ cells in GPR56 KO 
pancreas, p=0.05, Student’s t-test, n= 6 sections (KO) and 11 sections (WT). F) There was no difference in 
BrdU+ cells at E16, p>0.2, Student’s t-test, n= 6 sections (KO) and 11 sections (WT). Data are presented 






3.4.8  Detection of the GPR56 agonist, collagen III, in mouse and human islets 
Collagen III is a ligand for GPR56 in the developing brain (Luo et al., 2011). To find out whether 
it is also expressed in the pancreas, fluorescence IHC was carried out on adult mouse and 
human pancreas sections. Collagen III staining was seen around the lobar and acinar septa of 
the pancreas, at the peri-islet basement membrane and within islets, in both mouse and human 
pancreas (Figure 3-17 A, B, E & F). Collagen III did not colocalise with insulin+ β-cells (Figure 
3-17B &F). Immunostaining was also carried out for collagen IV to determine whether it has a 
similar pattern of expression as collagen III, since collagen IV has been reported to be present 
primarily in the basement membrane (Korpos et al., 2013) Collagen III and IV have similar 
staining pattern in human islets (Figure 3-17 E, & G), but in mouse pancreas there was marked 
intra-islet staining of collagen IV, perhaps reflecting its presence in the vascular network ECM. 
Overall, the IHC staining indicated that collagens III and IV are both found within and 







Figure 3-17 Detection of collagen III and IV in mouse and human pancreas. Upper panel: Wax-embedded 
sections of mouse pancreas showing expression of collagen III (A) and IV (C) and their non-colocalisation 
with insulin (B&D). Each image is representative of seven replicates. Lower panel: Wax-embedded 
sections of human pancreas showing expression of collagen III (E) and IV (G) and their non-colocalisation 





3.4.9 Collagen III is expressed by islet vascular endothelial cells 
In order to confirm that β-cells do not synthesise collagen III, RT-PCR was performed on cDNAs 
obtained from MIN6 β-cells, mouse and human islets, and exocrine cells. As shown in Figure 
3-18A, collagen III mRNA was not detected in MIN6 β cells, but it was amplified in cDNAs 
extracted from mouse and human islets, and pancreatic exocrine cells. It was confirmed that 
high quality MIN6 cell cDNA had been used in the PCR amplification since the expected 229bp 
product was generated when β-actin primers were used instead of collagen III primers. As 
expected, no products were obtained when MIN6 β-cell RNA or distilled water were used with 
collagen III primers instead of cDNA, indicating that the bands were not due to genomic DNA 
contamination. Given that collagen III is present in the blood vessels of human and rat pancreas 
(Deijnen et al., 1994), it is likely that the collagen III mRNA detected in the islets was due to its 
localisation to the vascular basement membrane. To confirm this, immunohistological staining of 
collagen III and CD31, a marker of vascular endothelial cells, was carried out on mouse 
pancreas sections. CD31 was detected in islets and blood vessels, and it colocalised with 
collagen III (Figure 3-18B, dotted circle), indicating that collagen III is produced by the vascular 






Figure 3-18 Collagen III is expressed by pancreatic vascular endothelial cells. A) Products of RT-PCR 
amplification using mouse and human col3a1 primers with cDNAs obtained from MIN6 β-cells, mouse and 
human islets and exocrine cells. Amplicons correspond to the predicted sizes of the nucleotide sequence 
generated using the chosen mouse and human primer pairs. No amplification was observed when cDNAs 
were replaced with RNA or distilled water. B) Images show the expression of collagen III and its 
colocalisation with CD31. Collagen III was detected in islets but it did not colocalise with insulin+ β-cells. 







3.4.10 Expression of other binding partners of GPR56 in islets 
The ability of the 1000+ GPCRs in the human genome to signal specifically through a limited 
number of heterotrimeric G-proteins has been shown to be mediated via scaffolding proteins 
such as the tetraspanins (Pierce et al., 2002). Tetraspanins are able to couple GPCRs to 
mediators of downstream signalling such as Gαq. For instance, GPR56 forms a stable complex 
with Gαq through CD81, a cell surface tetraspanin. Immunodepletion of CD81 from this complex 
led to complete dissociation of Gαq/11 from GPR56, suggesting that CD81 is important in 
stabilising the GPR56- Gαq/11 complex (Little et al., 2004). In islets, it is possible that CD81 
must be expressed on the cell surface for GPR56 to couple to Gαq/11. The expression of CD81 
mRNA was therefore investigated in mouse and human islets by RT-PCR using primers specific 
for CD81. The expression of CD81 mRNA was seen in MIN6 β-cells, mouse islets, mouse 
exocrine cells and human islets, but it was not expressed by human exocrine cells (Figure 
3-19). Distilled water used for diluting the cDNAs served as a negative control. The amplification 
of the mouse and human β-actin amplicons (227bp and 107bp respectively) in the cDNA 







Figure 3-19 Expression of CD81 mRNA in mouse and human islets. CD81 mRNA was detected in MIN6 β-
cells, mouse islets, and mouse exocrine cells. It was not detected in human exocrine cells but was faintly 
expressed in human islets. Amplicons correspond to the predicted sizes of the nucleotide sequence 




As a ‘split-personality receptor’, the N-terminal fragment of GPR56 can couple with the C-
terminal component of another adhesion GPCR, and vice versa, to form a functionally active 
complex. This has been demonstrated for GPR56 and latrophilin 1 in the brain (Silva et al., 
2009), so the expression of latrophilin 1 in mouse and human islets was therefore investigated. 
RNAs from MIN6 cells, mouse and human islets were reverse transcribed to cDNAs and the 
expression of latrophilin 1 was investigated by standard PCR. Latrophilin 1 mRNA was detected 
in all the tissues investigated, with strong expression in MIN6 β-cells, mouse and human islets 
compared with the exocrine cells (Figure 3-20). No amplification was seen when distilled water 









Figure 3-20 Expression of latrophilin1 mRNA in mouse and human islets. Images show products of RT-
PCR amplification using primers for latrophilin 1 and mouse and human β-actin primers. Amplicons 
correspond to the predicted sizes of the nucleotide sequences generated using the chosen primer pairs. 
Latrophilin1 mRNA was expressed in MIN6 β-cells, mouse and human islets and faintly in the exocrine 








In mouse, pancreas development starts as early as E9 and occurs in two phases. The first 
phase, which is also known as primary transition, takes place between E9 and E12.5. During 
this phase, the majority of the cells are multipotent progenitor cells (MPCs). As the nascent 
pancreas enlarges and buds, the MPCs, marked by their expression of transcription factors 
such as PDX1, Ptf1a and SOX9, undergo extensive proliferation. Towards the end of the 
primary transition, the first wave of differentiation begins, with the majority of the differentiated 
cells being glucagon-expressing α-cells. After E12.5, substantial differentiation occurs, giving 
rise to all the endocrine cell types, with β-cells appearing first, followed by δ-cells and then PP 
cells (Herrera et al, 1999). This is known as phase II or secondary transition (Jensen et al., 
2000).  
 
Whereas several studies have reported the role of GPR56 in brain development (Bae et al., 
2014; Iguchi et al., 2008; Piao et al., 2004; Li et al., 2008), nothing is known about the 
expression and function of GPR56 in developing and adult pancreas. The data presented in this 
chapter demonstrate that GPR56 is expressed in adult and embryonic pancreas, and it is 
colocalised with differentiating NGN3+ cells, SOX9+ cells, acini, ductal cells and mature β-cells. 
Consistent with a previous report that GPR56 maintains progenitors in a proliferative state 
(Giera et al., 2015), the images presented here show that GPR56 is strongly expressed at E11 
during MPC proliferation and it became downregulated during the differentiation stage, before 
E18. In addition, at the early stage of pancreas development, GPR56 was strongly expressed in 
cells that will later form islets and exocrine cells but became progressively downregulated in 
acinar cells as the pancreas develops. However, genetic lineage tracing would be required to 
show that the GPR56 expressing cells actually turned into islets or acinar cells. Since GPR56 is 
expressed before the appearance of β-cells, it is possible that the GPR56+/insulin- sup-
population are progenitor cells, while the GPR56-/insulin+ sup-population are cells in which 
GPR56 has been turned off after terminal differentiation to β-cells. After the cells have acquired 
β-cell identity, GPR56 expression is then turned back on. Once the mature islet structure has 
been formed at E18, GPR56 expression was upregulated in islets compared to the surrounding 






It is not yet clear what specifies the timing of GPR56 expression in the developing pancreas. 
However, the human GPR56 locus has 17 transcriptional start sites. In muscle cells and 
haematopoietic stem cells these sites are targets for transcription factors such as peroxisome 
proliferator-activated receptor gamma co-activator 1-alpha 4 (PGC-1α4) and heptad complex 
respectively (White et al., 2014; Solaimani Kartalaei et al., 2015). Although the instructive 
signals that initiate the expression of GPR56 in the developing pancreas are not known, 
transcription factors are likely to be involved, as Hobit, a homolog of blimp-1 in T cells, induces 
GPR56 expression in cytotoxic lymphocytes (Saito et al., 2013). This is further supported by the 
expression of GPR56 in NGN3+ cells in the pancreas, since NGN3 is a transcription factor 
necessary for the specification of endocrine cells. However, further experiment is required to 
determine whether NGN3 modulates the expression of GPR56 or not. 
 
The pancreas is largely made up of exocrine cells that secrete digestive enzymes into 
pancreatic ducts, with a minority of endocrine cells, comprising mainly α-, β-, and δ-cells, which 
secrete glucagon, insulin and somatostatin respectively. Genetic tracing has revealed that 
exocrine and endocrine cells have the same origin and arise from multipotent progenitor cells 
(Gu et al., 2002).  What governs the choice of progenitor cells to either become endocrine or 
exocrine is not completely understood, but transcription factors belonging to the basic-helix-loop 
family such as Ptf1a and Nkx6.1 have been implicated (Dong et al., 2008). Ptf1a is expressed in 
both exocrine and endocrine precursor cells. Downregulation of Ptf1a favours the conversion of 
pancreatic progenitors to an endocrine fate and vice versa (Dong et al., 2008). Given that 
GPR56 is strongly expressed in MPCs, and during lineage decision, cells with stronger 
expression follow the endocrine and ductal routes. In contrast, since it is downregulated in those 
cells that become acinar cells, GPR56 may be a novel contributor to the cell fate mechanism. 
Figure 3-21 shows a schematic that incorporates the data generated in this chapter to 
demonstrate the possible role for GPR56 in pancreas development.  
 
Mouse embryos at developmental stages before E11 were not available for the studies 
described here, so the earliest time point that was investigated was E11. GPR56 was detected 
in the pancreas at this early stage of development. It was strongly expressed by all the cells in 





function of GPR56 at this stage would be to keep the undifferentiated cells in a proliferative 
state, thereby maintaining a pool of progenitor cells. This is further supported by its 
coexpression with SOX9, a crucial transcription factor necessary for promoting proliferation and 
survival of progenitor cells and whose absence in mice leads to pancreatic hypoplasia 
(Seymour et al., 2007).  During cell fate decision, most of the MPCs at the trunk region that later 
differentiate to form endocrine and ductal cells (Romer and Sussel, 2015) retained stronger 
GPR56 expression while those at the tip region, which later form the exocrine acini, showed 
progressive downregulation of GPR56 expression.  
 
As the mouse matures, islet cells migrate from the epithelium to form clusters and they do not 
resemble adult islet structure until E18.5 (Bader et al., 2016; Villasenor et al., 2008). Figure 3-22 
shows a schematic of GPR56 expression at different stages of pancreas development in the 
mouse, based on the data generated in this chapter. During the period of differentiation and 
migration, GPR56 expression is reduced implying that GPR56 inhibits endocrine cell 
differentiation and migration. The increased number of NGN3+ cells in E16 pancreases from 
GPR56 KO mice further supports this, suggesting that in the absence of GPR56 there is 
reduced differentiation of these progenitor cells into β-cells. This inhibitory role is consistent with 
its function in preventing the differentiation of oligodendrocyte precursor cells in the brain (Giera 
et al., 2015). In the developing forebrain, GPR56 inhibits the migration of neural progenitor cells 
(Iguchi et al., 2008) and any defects in this process leads to cortical malformation (Li et al., 
2008). GPR56 may therefore play a role in allowing islet cells to migrate to form the three 
dimensional architecture as its expression is repressed during this process. Further work in 
which GPR56 is specifically deleted in β-cell, will be required to confirm this regulatory role of 
GPR56 in islet development. 
 
After the islets have formed, GPR56 expression was upregulated, coinciding with the phase 
where β-cells proliferate to increase islet mass. GPR56 was expressed exclusively by the β-
cells in islets, so it may be involved in regulating β-cell proliferation and islet mass. In addition, 
the expression of GPR56 postnatally in ductal cells is particularly intriguing, as ductal epithelium 
has long been speculated to be a reservoir for pancreatic progenitor cells, which may be 





diminished capacity to replicate, there are mounting evidences to support the existence of 
progenitor cells in ductal epithelium that can transdifferentiate to β-cells. Following pancreatic 
injury or ligation, insulin+ cells were identified in ductal tissues, indicating that β-cells may be 
formed from pre-existing ductal cells (Bonner-Weir et al., 2010). In human pancreas, insulin+ 
and glucagon+ cells have been reported in pancreatic ducts (Carpino et al., 2016) while obesity 
and T2D were found to increase ductal cell proliferation and the number of insulin+ cells in 
ductal epithelium (Butler et al., 2010). However, β-cell neogenesis from the pancreatic duct is a 
subject of on-going debate as other groups have failed to identify other sources of new β-cells 
apart from replication of pre-existing β-cells (Teta et al., 2007; Dor et al., 2004). 
 
Although a lot is known about transcription factors regulating islet differentiation and 
development, the signals that activate these processes are not clearly understood. It is thought 
that extracellular matrix components provide cues for cells to migrate during organ development 
(Langenhan et al., 2016) and they regulate branching morphogenesis during pancreas 
development (Shih et al., 2016). The detection of collagen III, a component of the basement 
membrane and the agonist of GPR56, and other GPR56 binding partners within the islet 
environment suggest that GPR56 may be activated in a paracrine manner to regulate pancreas 








Figure 3-21 A schematic showing the expression of GPR56 in pancreas development during lineage 
decisions. Between E9 and E12.5, transcription factors such as Pdx1, Sox9 and Ptf1a mark pancreas 
identity and they maintain the expansion of multipotent progenitor cells (MPC). During this period, GPR56 
is strongly expressed. As the MPCs decide their fate, GPR56 is strongly expressed by those progenitors at 
the trunk region that later form ductal and endocrine cells while it is progressively downregulated in the 
progenitors present in the tip region, that form the acini cells. As NGN3+ endocrine progenitors are 
unipotent cells, the progenitors that are strongly positive for GPR56 differentiate to form β-cells, while 
NGN3+ cells that are negative for GPR56 form the α and δ-cells. GPR56+++ = strongly positive for 









Figure 3-22 Expression pattern of GPR56 at different stages of pancreas development. This schematic is 
based on the immunohistochemical staining of embryonic mouse pancreas depicted in Figures 3-6-3-14. 
During the phase that marks the extensive proliferation of multipotent progenitor cells (MPCs) before E15, 
GPR56 is strongly expressed, while it is downregulated as the cells differentiate and migrate to form islet 
clusters. After the islet clusters are formed, GPR56 expression is upregulated, coinciding with the phase 






















































Chapter 4 The in vivo functions of GPR56 in glucose 
homeostasis, islet vascularisation and innervation 
 
4.1 Introduction 
Glucose homeostasis is a tightly controlled process in which blood glucose concentration is 
maintained within a normal range of 4-7mM. This is mainly achieved by feedback 
communication between islets and insulin-sensitive tissues. Following nutrient ingestion, β-cells 
are stimulated to release insulin, which facilitates glucose uptake into skeletal muscles and 
adipocytes and inhibits gluconeogenesis by the liver (Kahn et al., 2014). Information from the 
liver, skeletal muscles and fat on the other hand, either positively or negatively regulates the 
amount of insulin released from the β-cells, depending on blood glucose concentration. Thus, if 
insulin resistance is present, as is the case in obesity, insulin output is increased to maintain 
normal glucose levels.  The critical role played by the β-cells in the pathophysiology of diabetes 
is underscored by the observation that insulin resistance alone is not sufficient to cause T2D 
due to β-cell compensatory mechanisms of increased insulin secretion and increased β-cell 
mass (Ahrén, 2009). Failure of the β-cells to respond appropriately to increased insulin demand 
will mean that glucose concentration will continue to increase and this will culminate in 
uncontrolled hyperglycaemia and T2D. 
 
With the increasing rise in the incidence of T2D and the failure of the current therapies to 
prevent the progressive decline in β-cell function, several new treatment approaches are being 
developed. The aim of these novel therapies is to reduce hyperglycaemia and thus minimise the 
long-term microvascular and macrovascular complications. G-protein coupled receptors 
(GPCRs) are known to bind with high affinity to small molecules and are therefore attractive 
targets for drug development, and one of the recently implemented clinical therapies activates 
GLP-1R (Doyle and Egan, 2007). In addition, molecules targeting GPR40 and GPR119 are 
presently in clinical trials (Burant, 2013; Ritter et al., 2016). Interestingly, human islets express 





be established, indicating that an increased understanding of these receptors may lead to the 
discovery of new treatments for diabetes.  
 
The GPCR under investigation in this thesis, GPR56, may be involved in metabolic processes, 
as it is highly expressed in the hypothalamus and cerebral cortex (Piao et al., 2004; Haitina et 
al., 2008) – regions of the brain involved in regulating energy homeostasis and eating 
behaviour. It has been identified that outside the CNS, GPR56 expression was highest in 
mouse pancreas (Haitina et al., 2008), which fits with observations that this is the most 
abundant GPCR in islets (Amisten et al., 2013). Islets and hypothalamus are tightly connected 
by the neuro-entero-islet axis and there is evidence for direct involvement of hypothalamic 
neurons in modulating glucose-stimulated insulin secretion (GSIS) (Parton et al., 2007; Osundiji 
et al., 2012). GPR56 is exclusively expressed by the β-cells of mouse and human islets, as 
described in Chapter 3. It is coupled to the Gq subunit (Little et al., 2004), a protein that 
activates phospholipase C-mediated hydrolysis of phosphatidyl inositol bisphosphate (PIP2) and 
increased insulin secretion (Jones and Persaud, 2010). More recently, it has been suggested 
that GPR56 also activates the cAMP/PKA pathway in β-cells (Dunér et al., 2016), although this 
signal transduction coupling has not been identified in other cells types. 
 
In additional to neural regulation of β-cell function, blood vessels, which supply islets with 
oxygen and nutrients and distribute hormones secreted by the pancreas, also act as modulators 
of insulin secretion. During embryogenesis, endocrine cells lie in close proximity to blood 
vessels and the development of a properly vascularised islet is dependent on interactions 
between the islet cells and vascular endothelial cells (Lammert et al., 2003). In the early post 
natal phase of islet development, the characteristic rapid growth in islet mass has been 
associated with increased vascular density and a surge in the proliferation of vascular 
endothelial cells (Johansson et al., 2006). To further highlight the importance of the vascular 
bed in islet functions, abnormalities in islet perfusion have been observed in rodent models of 
diabetes mellitus (Iwase et al., 2002; Svensson et al., 2005).  
 
Adhesion GPCRs are thought to be important in blood vessel formation. Thirteen members of 





endothelium (Nolan et al., 2013), suggesting that they may play a role in endothelial cell 
functions. Notable among them is GPR124, which has been associated with embryonic death in 
endothelial-specific GPR124 null mice due to vascular malformations (Kuhnert et al., 2010). 
Adhesion GPCRs are important in cell migration, and the angiogenesis arrest seen in GPR124 
KO mice was due to deficiency in the migratory capabilities of the developing endothelial cells. 
As GPR56 is highly expressed in islets, it is hypothesised that it may contribute to the 
development of islet vasculature, which may be important in appropriate regulation of glucose 
homeostasis. 
 
In this chapter, the effect of GPR56 deletion on glucose homeostasis in mice was explored. The 
islet architecture, innervation and vascularisation in GPR56 KO mice and also in mice in which 
both GPR56 and one of its binding partners, transglutaminase 2 (TG2), had been deleted were 
also examined.  
 
4.2 Aims 
• Determine whether deletion of GPR56 has any effect on glucose homeostasis, insulin 
secretion and insulin content of mouse islets.  




















Mouse studies were performed during my research secondments to Dr Xianhua Piao’s lab in 
the Division of Newborn Medicine, Boston and were carried out according to the guidelines of 
the Animal Use and Care Committee of Boston Children’s Hospital. Adult male and female 
GPR56 WT and KO mice were bred and genotyped as described in Section 2.9.2.1. GPR56 
strain was maintained by Het X Het breeding and WT littermates were used as controls. In 
some of the experiments, pancreases from GPR56/TG2 double KO mice and WT littermates 
were used. 
 
4.3.2 Insulin secretion and insulin content quantification 
Islets were isolated from GPR56 KO and WT mice (Section 2.2.1) and incubated in the 
presence of buffers supplemented with either 2mM or 20mM glucose for 1 h at 370C. For the 
dynamic insulin secretion experiments, groups of 40 islets were initially perifused in the 
presence of 2mM glucose for 1 h in a temperature-controlled perifusion chamber. Perifusates 
were collected every 2 min for the next 10 min in physiological salt solution containing 2mM 
glucose, with a further 20 min in physiological buffer containing 20mM glucose. Insulin secretion 
in the static incubation and perifusion experiments was quantified by radioimmunoassay. To 
measure insulin content, groups of 10 size-matched islets were incubated in 200µl of acidified 
ethanol at -20°C until insulin was quantified by radioimmunoassay.  
 
4.3.3 Glucose tolerance test 
Glucose tolerance was measured in mice that had been fasted overnight for 16 hours by the 
intraperitoneal administration of 2 g glucose/kg body weight. Plasma glucose levels were 
measured prior to glucose administration and at  15, 30, 60, 90 and 120 min post injection using 
a glucometer.  
 
4.3.4 Immunohistochemistry 
Freshly retrieved mouse pancreases were fixed in 4% paraformaldehyde overnight before being 
cryoprotected in OCT medium and frozen. Immunohistochemistry was carried out on 10µm 





cells) or CD31 (endothelial cell marker) (Table 2-15). Each section was incubated with primary 
antibodies overnight after antigen retrieval was carried out in citrate buffer. For rat monoclonal 
CD31, antigen retrieval was not carried out since sections treated in citrate buffer prior to 
immunostaining were negative for CD31 signals, perhaps indicative of citrate-induced 
endothelial cell loss. Following incubation with fluorophore-coupled secondary antibodies, nuclei 
were stained with DAPI and images were acquired using a Nikon TE2000 or Nikon Eclipse Ti 
microscopes.  
 
4.3.5 Histomorphometrical analysis 
8-bit RGB photomicrographs of the immunostained pancreas sections, obtained from Nikon 
TE2000 or Nikon Eclipse Ti microscopes, were scored blindly before quantification. The total 
area of insulin staining, interpreted as islet area, was determined with Image J software. The 
total area of TUJ1 or CD31 staining within insulin+ islets was also quantified morphometrically in 























4.4.1 Confirmation of GPR56 gene knockout 
GPR56 KO mice were generated in Boston by targeted deletion of exons 2 and 3, producing a 
whole body knockout model. The genotypes of the mice were determined by PCR, carried out 
on genomic DNA extracted from the tails (Section 2.9.2). The primers were designed such that 
amplification of a 639bp product indicated WT mice. In the KO model, exons 2 and 3, which are 
270bp long, were deleted, thus, amplification of a 369bp amplicon indicated KO mice, while in 
the heterozygous mice both 639bp and 369bp products were amplified (Figure 4-1 A). To 
confirm that the GPR56 gene was deleted in the pancreas, immunohistochemistry was carried 
out on 10µm fixed-frozen, adult mouse pancreas sections using a previously validated GPR56 
antibody (Luo et al., 2011). Consistent with the data shown in Figure 3.3, GPR56 was detected 
in the pancreas of WT mice, where it colocalised with insulin produced by the β-cells (Figure 4-1 
B, C & D). As expected, GPR56 was not detected in the KO pancreas sections (Figure 4-1 E, F 









Figure 4-1 Confirmation of GPR56 gene knockout. A) Tail genomic DNA was subjected to PCR and 
resolved on a 1.5% agarose gel containing ethidium bromide. DNA was revealed under UV light. A 639bp 
product indicated WT mice, a 369bp product represented KO mice and the presence of both products is 
indicative of heterozygous mice. B – D) Representative images of pancreases from adult GPR56 WT mice 
showing the expression of GPR56 and its colocalisation with insulin. E – G) Representative images 







4.4.2 GPR56 KO islets have higher number of α-cells and less β-cells 
To determine whether the decreased differentiation of endocrine progenitors observed following 
GPR56 deletion, as reported in Chapter 3, had any effect on the number of terminally 
differentiated islet cells, wax-embedded pancreas sections from P9 WT and GPR56 KO mice 
were immunostained for insulin and glucagon. The number of insulin+ and glucagon+ cells per 
islet was counted manually. There were no striking morphological differences in pancreas 
cytoarchitecture between GPR56 WT and KO mice (Figure 4-2A-D).  However, GPR56 KO mice 
have less β-cells (% β-cells/islet; WT: 68.5±0.8, KO: 54.8±3.0, n=3 mice/genotype, p<0.05), but 
higher numbers of α-cells in KO islets (% α-cells/islet; WT: 17.7±0.9, KO: 33.7±2.8, n=3 
mice/genotype, p<0.01) (Figure 4-2 E & F). 
 
 
Figure 4-2 Effect of GPR56 deletion on the number of β- and α-cells per islet in P9 mice. Wax-embedded 
pancreas sections of A-B) GPR56 WT mice and C-D) GPR56 KO mice were immunoprobed for insulin and 
glucagon and the number of β-cells and α-cells were counted. Scale bar = 50µm E) Percentage insulin+ β-
cells per islet in GPR56 WT and KO pancreas were shown. Data are expressed as Mean + SEM, n=3 
mice/genotype, *p<0.05, Student’s t-test. F) The percentage of α-cells obtained from the number of 
glucagon+ cells per islet in GPR56 WT and KO pancreas were shown. Data are expressed as Mean + 








4.4.3 GPR56 KO mice have normal body weight and fasting glucose levels 
GPR56 KO and WT mice were maintained on a normal diet and measurement of body weight at 
8 weeks indicated that both genotypes were the same weight. This demonstrates that GPR56 
does not play a role in regulation of total body mass when mice were fed a standard diet (Figure 
4-3 A). To determine whether there were alterations in glucose metabolism upon GPR56 
deletion, plasma glucose levels were measured immediately before and after the mice were 
fasted overnight.  Similar to the lack of differences in body weight, glucose levels of WT mice 
were not significantly different from those quantified in the KO mice during the fasting conditions 








Figure 4-3 GPR56 KO mice have similar body weight and plasma glucose concentrations to WT mice. A) 
Total body weight of 8-week-old WT and KO mice. Data are represented as mean + SEM of 7 WT and 8 
KO mice. B) Plasma glucose concentrations were measured after an overnight fast. The means + SEM 















4.4.4 GPR56 mice are mildly glucose intolerant 
To further evaluate the role of GPR56 in glucose metabolism, male and female GPR56 WT and 
KO mice were injected IP with 2g/kg glucose, and plasma glucose concentrations were 
measured at 0, 15, 30, 60, 90 and 120 min post injection. In the male mice, there was a slight, 
but not statistically significant, increase in glucose concentration in the KO mice at all the time 
points measured after glucose administration (Figure 4-4 A), but there were no genotype-
dependent differences when the area under the curve (AUC) for the entire 120 min was 
evaluated (Figure 4-4 B). The trend of modest glucose intolerance was also observed in female 
mice (Figure 4-4 C), and there was a sharp decline in the glucose concentration at 30 min post 
injection in both female WT and KO mice that was not seen in the males (Figure 4-4 C). In 
addition, at 30 min post glucose injection there was a statistically significant increase (p<0.01) in 
glucose concentration in the female KO mice, suggesting that there may be gender-specific 
differences in glucose handling when the GPR56 gene is deleted as this was not observed for 
male mice. However, as for the observations made with the male mice, AUC measurements 








Figure 4-4 Glucose tolerance of male and female GPR56 KO mice. 2g/kg glucose was administered to 
overnight fasted (16h) mice at 8 weeks old. A) Glucose concentrations were measured at time 0, 15, 30, 
60, 90 and 120 min post glucose injection in male mice and B) area under the curve (AUC) was 
determined. C) Plasma glucose of female mice was also determined at the indicated time points. D) AUC 
was calculated from the glucose tolerance curve for the female mice. Data are mean ± SEM, n=5 male 





4.4.5 GPR56 KO islets respond appropriately to glucose  
Islets isolated from age-matched GPR56 WT and KO mice were matched for size, incubated in 
medium supplemented with either 2mM or 20mM glucose for 1hr at 370C and insulin secretion 
was quantified by radioimmunoassay. As shown in Figure 4-5 A (dark bars), there was a 5-fold 
increase in insulin secretion when GPR56 WT islets were exposed to medium supplemented 
with 20mM glucose and a similar magnitude of glucose-induced insulin secretion was observed 
from islets isolated from GPR56 KO mice (Figure 4-5 A, white bars).  Insulin content of isolated 
islets was determined by acidified ethanol extraction, which indicated that there was no 
significant difference in the amount of insulin per islet following GPR56 deletion (Figure 4-5 B).  
 
To investigate the dynamics of insulin secretion following GPR56 deletion, groups of 40 islets 
per genotype were continuously perifused at a constant temperature of 370C, simulating normal 
physiological conditions. After perifusing the islets in medium containing 2mM glucose for 1h, 
perifusates were collected every 2 min for 10 min in medium containing 2mM glucose and the 
next 20 min in buffer supplemented with 20mM glucose. In medium containing 2mM glucose, 
insulin secretion from WT islets was between 2-5pg/islet/min, which was not significantly 
different from the KO islets. Both WT and KO islets responded similarly when challenged with 
buffer containing 20mM glucose, with peak insulin secretion at 6 - 8 min after exposure to high 
glucose. The initial rapid initiation of insulin secretion followed by a period of sustained release 











Figure 4-5 Islets isolated from GPR56 KO mice responded similarly to a glucose challenge and have 
similar insulin content as islets from WT mice. A) Isolated islets from GPR56 WT and KO mice were 
incubated in buffer supplemented with either 2mM or 20mM glucose for 1 h at 370C and insulin secretion 
was quantified by radioimmunoassay. Data are mean + SEM, n=8, representing three independent 
experiments. B) Islets were matched for size and incubated overnight in acidified ethanol before being 
briefly sonicated and insulin content was determined by radioimmunoassay. Data are mean + SEM, n=3 








Figure 4-6 Insulin secretory kinetics of islets from GPR56 mice. A – C) Isolated islets were continuously 
perifused with buffer solution at 37°C in a temperature-controlled chamber. Data from three independent 





insulin secretion. Data are means + or – SEM, n=3-4 separate chambers, each containing 40 islets pooled 




4.4.6 GPR56 is not required for islet vascularisation 
Islets are able to adapt their vascular networks to cope with changes in metabolic demand, the 
failure of which may lead to impaired glucose homeostasis (Dai et al., 2013).  The requirement 
of GPR56 for appropriate islet vascularisation was investigated by immunohistochemical 
staining of pancreas sections from neonatal WT and GPR56 KO mice. Islet capillaries were 
identified by fluorescently staining for the vascular endothelial cell marker, CD31. Any 
fluorescently labelled endothelial cell or endothelial cell cluster, that was clearly distinct from 
adjacent cells, was counted as a single blood vessel, according to the method described by 
Weidner and colleagues (Weidner, 1995). In both WT and GPR56 KO pancreases, it was 
observed that islets have a richer supply of blood vessels than the surrounding exocrine tissues, 
but there were no differences in islet capillary density between the WT and KO mice (Figure 
4-7). 
 
To better understand the vascular phenotype of GPR56 deletion in islets, mice in which both 
GPR56 and tissue transglutaminase 2 had been deleted were employed. Transglutaminase 2 
was identified as a binding partner of GPR56 and together they regulate angiogenesis and 
tumour growth in cancer cells (Xu et al., 2006; Xu and Hynes, 2007). Immunohistochemistry 
was carried out on 10µm sections obtained from GRP56 WT/ TG2 KO and GPR56 KO/TG2 KO 
mice at P10 using insulin and CD31 antibodies. TG2 was deleted in both mouse strains; 
therefore any effect on the islet vasculature will not be due to contributions from TG2 signalling. 
Representative images revealed that islets are more highly vascularised than the surrounding 
acinar cells (Figure 4-8 A). Vascular parameters measured using Image J software revealed 
that there was no significant impact of GPR56 and TG2 deletion on the islet capillary density, 
represented by the number of blood vessels per islet, or on the area occupied by the blood 








Figure 4-7 Representative fluorescent images of GPR56 WT and KO pancreases from P9 mice, showing 
the expression of insulin and CD31. Scale bar = 50µm. B) Islet capillary density was quantified by 
determining the number of CD31+ blood vessels within the insulin+ islet area in the WT and KO mice. Data 




Figure 4-8 A) Representative fluorescent images of GPR56/TG2 WT/KO and KO/KO pancreases from P10 
mice, showing the expression of insulin and CD31. B) Islet capillary density was quantified by determining 





genotype  C) Quantification is shown for the area occupied by islet capillary vessels, as measured by the 
area of CD31+ blood vessels per insulin+ islet area. Data are represented as mean ± SEM, n = 3 mice per 




4.4.7 GPR56 is not required for islet innervation 
To determine the effect of GPR56 on islet innervation, pancreases from GPR56 WT and GPR56 
KO mice at E16 and P9 were immunostained for TUJ1, a neuron-specific structural protein 
present in axons. Neuronal axons were intensely fluorescent, confirming antibody specificity 
and tissue penetration (Figure 4-9 A & B). At E16 in GPR56 WT and GPR56 KO pancreases, 
TUJ1 positive nerve fibres were in close proximity to islets, with little or no staining in the 
exocrine cells (Figure 4-9 B & D). The pattern of innervation of islets in the pancreas sections 
from GPR56 KO mice was similar to that of the WT mice at both E16. Quantification of the total 
TUJ1 area in the pancreas revealed that there was no significant difference between GPR56 
WT and GPR56 KO mice at either stage of development (Figure 4-9 E).  
 
Islets were also strongly innervated in pancreases retrieved from both WT and GPR56 KO mice 
at P9. In the WT mice individual islets were surrounded by TUJ1+ nerve endings and TUJ1 
immunoreactivity was generally less prominent in the KO pancreas sections (Figure 4-10). 
However, analysis of multiple sections indicated that there was no significant difference in the 
percentage of TUJ1 positive area in the WT and KO pancreases (Figure 4-10). Few fine nerve 
fibres penetrated islets in both genotypes, but there was little evidence of colocalisation with 
insulin+ cells. Similar to the observations made in pancreases obtained from P9 WT mice, peri-
insular nerve endings appeared to be more pronounced around the islets in pancreas sections 
from P10 GPR56/TG2 WT/KO mice than in the KO/KO mice at P10 (Figure 4-11 A & B). The 
decrease in TUJ1 staining in pancreases from GPR56 null mice was not statistically significant 









Figure 4-9 Detection of TUJ1 positive neurons in E16 pancreases. 10µm pancreas sections were 
immunoprobed for TUJ1 and insulin. A – B) Images show the expression of TUJ1 and insulin in a 
pancreas section from a WT mouse. C – D) Images show the expression of TUJ1 and insulin in GPR56 
KO pancreases. E) Quantification of the area of TUJ1+ neurons per field is shown. Data are mean + SEM 





Figure 4-10 Representative images of GPR56 WT and KO pancreases showing expression of TUJ1 and 









difference in the nerve area between the two genotypes (p>0.2, Student’s t-test). Data are mean + SEM of 
n=3 mice per genotype, 10 sections per mouse. 
 
 
Figure 4-11 Representative fluorescent images of A) GPR56 WT/TG2 KO and B) GPR56 KO/TG2 KO 
pancreases at P10 showing the expression of insulin and TUJ1, a marker for nerve fibres. C) 
Quantification of the area occupied by the nerve fibre per islet area and D) nerve fibre densities in the 
WT/KO and KO/KO pancreases. Data are presented as mean ± S.E.M. Each dot represents a mouse, in 





4.4.8 GPR56 and peri-islet Schwann cells 
Islets are surrounded by a peri-insular capsule that is made up of a thin layer of collagens, 
fibroblasts and peri-islet Schwann cells (Sunami et al., 2001; Tsui et al., 2008). The peri-islet 
Schwann cells (pSc), characterised by their proximity to neurons and the expression of glial 
markers such as glial fibrillary acidic protein (GFAP) and S100β, are among the first cells to be 
selectively destroyed in T1D associated autoimmunity (Winer et al., 2003). The functions of pSc 
in the pancreas are not yet known, but they may be similar to the physiological roles played by 
peripheral Schwann cells, which form tight mantle around tissues (Winer et al., 2003). To 
investigate whether deletion of GPR56 has any effect on the pSc, immunostaining was carried 
out on E16 pancreases for glial fibrillary acidic protein (GFAP).  In both WT and KO pancreases, 
GFAP positive cells were seen mainly around islets or the endocrine trunk and there was less 
GFAP expression in the exocrine cells (Figure 4-12 A – D). Quantification of the area of GFAP+ 
Schwann cells b Image J analysis indicated that there was no significant difference between 








Figure 4-12 Expression of glial fibrillary acidic protein (GFAP) in GPR56 WT and KO pancreases. 10µm 
E16 mouse pancreas sections were immunoprobed for GFAP and insulin. A – C) Images show the 
expression of GFAP and insulin in GPR56WT pancreas. B– D) Images show the expression of GFAP and 
insulin in GPR56 KO pancreases. E) Quantification of the area of GFAP+ peri-islet Schwann cells per field 





























The data presented in this chapter demonstrate that deletion of GPR56 leads to less β-cells but 
higher numbers of α-cells in GPR56 KO islets. It was not possible to investigate the functional 
significance of the increased number of α-cells due to time constraints, but this is clearly an 
area of further research. For example, it is possible that there was dedifferentiation of β-cells to 
α-cells following GPR56 deletion, and this is something that could be investigated using lineage 
tracing. Under normal physiological conditions, GPR56 is not involved in whole body glucose 
homeostasis in adult mice, although a trend towards mild glucose intolerance was observed. 
The glucose excursion curve for the female mice showed a sharp decline at 30 min following 
glucose administration and there was a tendency for the GPR56 KO female mice towards 
glucose intolerance. This pattern was consistent with that reported for GLP-1 deficient female 
mice, where the excursion curve showed a sharp decline at 30 min and the female mice were 
more glucose intolerant than the males (Preitner et al., 2004). As glucose delivered by the 
intraperitoneal route does not pass through the GI tract, there was no contribution from the 
incretin effect or gastric emptying time to the glucose clearance pattern observed. In perifusion 
experiments, the classical biphasic pattern of insulin secretion was seen, where there is an 
initial rapid increase in insulin release followed by a sustained second phase. In T2D, first phase 
insulin secretion is almost completely abolished while the second phase is greatly reduced 
(Hosker et al., 1989). However, no defect was observed in GPR56 KO islets in these phases, 
indicating that islet GPR56 is not required for an appropriate insulin secretory response to 
increased glucose concentration. It was not possible to determine whether the mild glucose 
intolerance in the female mice was a result of reduced insulin secretion, because it was 
necessary to pool islets isolated from male and female mice to have sufficient quantities for the 
perifusion experiments. Nonetheless, there was no evidence of compromised insulin secretion 
in vitro, suggesting that the mild glucose intolerance is likely to be a consequence of reduced 
sensitivity of target tissues to insulin after GPR56 deletion.  
 
Some mice in which GPCRs have been deleted do show impaired fuel homeostasis under 
conditions of metabolic stress. For example, under standard conditions GPR39 KO mice have 
normal phenotypes (Tremblay et al., 2007) but they exhibit metabolic abnormalities when 





that different phenotypic characteristics may be observed if GPR56 KO mice are maintained 
under conditions of metabolic stress, such as high fat or high carbohydrate feeding. Under 
these conditions, β-cells will be forced to compensate for increased metabolic demand by 
increasing insulin output and islet mass, and the importance of GPR56 for these compensatory 
processes will be evident. 
 
Interestingly, a recent study found that GPR56 mRNA was decreased in isolated islets from 
T2D patients and from db/db mice – a rodent model of obesity and T2D, and the authors 
speculated that this downregulation may have a causal link to dysfunctional β-cells in T2D 
(Dunér et al., 2016). The researchers also found a reduction in insulin content and a decreased 
ability of β-cells to respond to glucose when GPR56 expression was reduced in the INS1 
insulin-secreting cell line. These findings are inconsistent with the data from GPR56 KO mice 
presented in this chapter. Thus, the data presented here demonstrate that there were no 
differences in the insulin content of islets isolated from KO and WT littermates and there were 
also no reductions in their insulin secretory response to glucose. However, it was found that 
GPR56 deletion resulted in a small reduction in pancreatic insulin content (WT: 117.1±18.4 ng 
insulin/mg protein, n=3; KO: 96.85, n=1). There was insufficient availability of pancreases from 
GPR56 KO mice to make any meaningful comparison, but given that the data in chapter 2 
implicated GPR56 in islet development it is perhaps not surprising that there was reduced 
insulin content after its deletion. This may not have been evident when insulin content was 
quantified in isolated islets since size-matched islets were used for this, which would have 
masked any reductions in overall content due to the overall smaller size of islets in the GPR56 
KO mice. In addition, several studies investigating glucose response profile of islets isolated 
from GPCR-null mice, such as GPR40, GPR119 and GLP-1R KO mice, found that GPCR 
deletion did not affect glucose-induced insulin secretion (Chu et al., 2007; Steneberg et al., 
2005; Latour et al., 2007; Flamez et al., 1998). This is not surprising, as glucose initiates insulin 
secretion through its metabolism while GPCRs are targets for agonists that potentiate this 
secretory response. Consistent with this, islets isolated from GPCR null mice failed to show an 
appropriate potentiation of glucose-induced insulin secretion. It is not clear why Dunér and 





knockdown, but it may be because they used INS1 cells, which are less reliable and less 
representative than primary islets. 
 
T2D is a complex disease that involves interaction between multiple genes and the 
environment. It is therefore instructive to note that single gene is directly important for glucose 
phosphorylation in β-cell, deletion does not usually result in overt diabetes. As islets express at 
least 293 GPCRs (Amisten et al., 2013), is it most likely that there is functional redundancy in 
case GPCRs are deleted, mutated or malfunctions. GPR56, for example, is on the same loci as 
genes encoding the adhesion GPCRs GPR114, GPR64 and GPR97 (Fredriksson et al., 2002; 
Peng et al., 2011) and GPR56/GPR97/GPR114 gene cluster has been postulated to possess 
functional redundancy in immune cells (Hamann et al., 2016). It is therefore possible that 
GPR114, GPR64 or GPR97 will compensate for the loss of function of GPR56, and in future 
studies it may be worthwhile quantifying the expression level of GPR114, GPR64 and GPR97 in 
islets from WT and GPR56 KO mice. 
 
GPR56 mRNA has been reported to undergo alternative splicing. Alternative splicing can occur 
in the non-coding region upstream of the transcriptional start site of GPR56, and this is thought 
to regulate cerebral cortex patterning in human (Bae et al., 2014). Alternative splicing has also 
been reported in GPR56 coding regions, resulting in four variants named S1 to S4 (Kim et al., 
2010). The targeting strategy for generating GPR56 KO mice used in this study deleted exons 2 
and 3, which are the regions that coincide with S1 to S3 variants. S4 variant has its start codon 
in exon 4, which meant that variant 4 was preserved in the current model of GPR56 KO. Indeed, 
S4 was recently detected in the current model of GPR56 KO mice and its presence was 
associated with increased basal activities (Salzman et al., 2016). To date, no studies have 
investigated the expression of these variants in the pancreas and the extent to which they may 
affect β-cell function is unknown. 
 
 
Islets require an abundant blood supply to allow them to rapidly sense changes in circulating 
glucose concentrations and distribute the insulin that they secrete. Islets are richly vascularised, 
and it is well established that blood vessel endothelial cells play crucial roles in maintaining 





during embryogenesis and requires the production of angiogenic factors such as vascular 
endothelial growth factor A (VEGF-A), which is critical for the recruitment of endothelial cells 
during islet vascularisation in the developing pancreas. The failure of this process leads to 
decreased islet mass and impaired glucose homeostasis (Reinert et al., 2013). Overexpression 
of GPR56 has been associated with increased expression of VEGF genes (Kim et al., 2010), 
suggesting that GPR56 may play a role in blood vessel formation. Although no study exists to 
support this notion in normal tissues, it has been established in cancerous cells that GPR56 can 
either promote or inhibit angiogenesis through VEGF signalling, depending on whether GPR56 
is expressed in a cleaved or full length form (Yang et al., 2011). In some cancer types, 
particularly in melanoma, downregulation of GPR56 is necessary for metastasis and disease 
progression. It is therefore possible that a GPR56 deficient islet, like a tumour mass, would 
increase the production of angiogenic factors such as VEGF and increase its vascular supply. 
To investigate the role of GPR56 in development of the islet vasculature, the endothelial CD31 
marker was used to quantify vascular density in GPR56 KO and WT pancreases. Surprisingly, 
there were no differences in islet vascular density and area in the absence of GPR56 
suggesting that this receptor is not essential for the formation of new blood vessels.  
 
The effect of GPR56 on angiogenesis in melanoma cells is potentiated by its interaction with 
transglutaminase 2, a cross-linking enzyme present in the ECM that inhibits tumour growth by 
restricting the formation of new blood vessels (Jones et al., 2006). It has been proposed that 
tumour growth and angiogenesis may be enhanced by degrading and internalising TG2 through 
the N-terminal domain of GPR56 (Yang et al., 2014). It was therefore hypothesised that if TG2 
and GPR56 act together to inhibit angiogenesis, mice in which both genes have been deleted 
might be hypervascularised. A double KO mouse model of GPR56 and TG2 was used to 
investigate this hypothesis. The mice used for these studies were those in which GPR56 was 
expressed and TG2 was deleted (WT/KO) and those in which both GPR56 and TG2 were 
deleted (KO/KO). Ideally, comparison should also have been made with the pancreases from 
WT/WT mice, but they were not available. In addition, limited availability of mice for these 
studies meant that it was only possible to quantify islet vascular density in pancreases retrieved 
from P10 mice. It was found that there were no differences in the area occupied by islet vessels 





in vascular density may not be surprising, as when islets adapt to metabolic demand during 
insulin resistance to increase oxygen supply, they do so not by generating new blood vessels 
but by dilatation of pre-existing blood vessels (Dai et al., 2013). It may therefore be worth 
measuring vessel diameter in future studies to determine whether this is altered following KO of 
GPR56 and TG2. Moreover, a compensatory mechanism may also be present to inhibit undue 
angiogenesis in normal tissues, in order to prevent tumour growth.  
 
During embryogenesis, islet vascular networks formed from VEGF signalling provide scaffolds 
for nerve fibre development, thus indicating that VEGF indirectly controls islet innervation 
(Reinert et al., 2014). Since islet nerve fibres fine-tune insulin secretion through the release of 
neurotransmitters (Ahrén, 2000), the requirement of GPR56 in islet innervation was determined. 
Although there was no difference in the innervation between GPR56 WT and KO islets, there 
was a 34% increase in fibre density in GPR56/TG2 KO/KO islets, indicating that TG2 may also 
be a binding partner of GPR56 in islets. It will be interesting to investigate the effect of deleting 
both GPR56 and TG2 on glucose homeostasis in the future, as at the time of this study, adult 
GPR56/TG2 KO/KO mice were not available. 
 
When comparing islet innervation and vascularisation, it could be observed that at P10 in 
GPR56/TG2 mice, there was a trend of increased fibre density in the double KO mice compared 
to the WT, while there was no trend in vascular density. This may be attributed to the different 
developmental age when innervation and vascularisation occur in mice. Islet vascularisation 
begins during the second phase of progenitor differentiation and is completed at birth while islet 
innervation starts during islet clustering around E15.5 and is not completed until during weaning 
at P21 (Reinert et al., 2014). When the quantifications were carried out at P10, nerve fibres are 
still developing whereas blood vessel formation has already been completed. The time at which 
innervation and vascularisation was investigated may therefore impact on the ability to detect 
any differences in the effect of GPR56 deletion, and ideally quantifications would have been 
carried out over a range of ages if the mice had been available.  
 
Finally, analysis of nerve processes in islet function should also consider the contribution of 





axons and Schwann cells (Ushiki and Watanabe, 1997). Schwann cells provide vital trophic 
support for neurons as they branch into a meshwork upon reaching islet surfaces, indicating 
that they may be important in neuroendocrine regulation of islet function. In NOD mice, it has 
been reported that infiltration of cells within islets by reactive T cells was not possible without 
the peri-islet glial sheath being compromised or destroyed (Winer et al., 2003). From the 
embryo to adult life, adhesion GPCRs are necessary for the proper function and signalling of 
Schwann cells (Sigoillot et al., 2016). GPR56 is important for CNS myelination (Giera et al., 
2015) but its role in the PNS is not yet documented. However, its close family member, 
GPR126, plays a crucial role in the normal functioning of Schwann cells in the PNS (Mogha et 
al., 2013). Since axons in the pancreas are mainly unmyelinated (Ushiki and Watanabe, 1997), 
GPR56 may have an indirect effect on peri-islet Schwann cells through other members of Group 
VIII adhesion GPCRs, possibly by interacting with GPR126. It was not possible to investigate 
this, as only one mouse per genotype was available for this work, which is too few to make any 
logical conclusion. 
 
In conclusion, this chapter has provided insights in to the role of GPR56 in the pancreas under 
normal physiological conditions. Deletion of GPR56 has no effect on insulin secretion, islet 
innervation and vascularisation in 8-week-old mice. Further studies are needed to clarify 
whether GPR56 KO mice will behave differently with ageing or under increased metabolic 
stress such as high fat feeding. It is also worth investigating the metabolic phenotype of islet-




































































Chapter 5 GPR56 regulates β-cell proliferation and islet mass 
 
5.1 Introduction 
Diabetes mellitus is characterised by loss of functional β-cells leading to decreased islet mass, 
with the resultant inability of sufficient insulin secretion to meet metabolic demands. In T1D, β-
cells are destroyed by autoimmune antibodies while in T2D the inability of β-cells to adapt 
appropriately to increased metabolic demand primarily drives the progressive loss of β-cells 
(Kahn, 2001). In addition, loss of β-cells may be underpinned by genetic defects. Data from 
genome wide association studies have shown that inherited abnormalities in β-cell mass and/or 
functions are critical to the onset of T2D, as many risk variants identified impact either on β-cell 
renewal or insulin secretion (McCarthy and Hattersley, 2008; Voight et al., 2010). 
 
Physiologically, β-cell mass is dependent on three main processes: replication of existing β-
cells, increase in size of individual cells, and formation of new β-cells through differentiation or 
neogenesis. Of these processes, β-cell replication is the primary determinant of β-cell mass 
postnatally (Georgia and Bhushan, 2004). The ability of pre-existing β-cells to proliferate is vital 
to the maintenance of adult islet mass (Dor et al., 2004) and for sustaining glucose homeostasis 
in the presence of insulin resistance (Cerf, 2013).  
 
In the past decades, research efforts have been geared towards understanding the 
physiological mechanisms regulating β-cell proliferation, with the intent of harnessing the 
information to increase islet mass in diabetes patients. Such efforts have led to the identification 
of the role played by gut hormones in maintaining islet neogenesis and β-cell proliferation. Thus, 
it was shown that chronic administration of exendin-4, an analogue of the gut hormone GLP-1, 
led to increased islet mass and cured rodent models of diabetes by activating a G-protein 
coupled receptor, GLP-1R (Xu et al., 1999; Tourrel et al., 2001; Ogawa et al., 2004). This 
breakthrough led to increased research interest in the role of islet GPCRs in regulating β-cell 
function and mass. As islets express many other GPCRs, some of which have no known 
functions, it is possible that some of them may have the appropriate characteristics for a next-






GPCRs are highly tractable drug targets. Currently, approximately 30-50% of all drugs in clinical 
use are directed at them (Cook, 2010). Indeed, novel T2D drugs must target the key 
dysfunctions associated with diabetes, one of which is reduced islet mass. Such drugs must 
prevent loss of β-cells by inhibiting cell death/de-differentiation, initiate the formation of new β-
cells or have the capacity to stimulate β-cells to proliferate. Increasing evidence points to islet-
expressed adhesion GPCRs as meeting at least some of these criteria. For instance, pancreas-
specific deletion of the adhesion GPCRs CELSR2 and CELSR3 produced mice that were 
glucose intolerant, because the absence of these adhesion GPCRs resulted in fewer β-cells as 
a consequence of decreased β-cell replication (Cortijo et al., 2012). CD97, another adhesion 
GPCR, enhanced cell survival by inhibiting intrinsic and extrinsic apoptosis in cancer cells 
(Hsiao et al., 2015). In addition, brain angiogenesis inhibitor 1 (BAl1) is an engulfment adhesion 
receptor on phagocytes that identifies and traps apoptotic cells (Park et al., 2007). 
Overexpression of BAI1 prevents tumour growth by initiating apoptosis while loss of BAI1 turns 
gliomas to aggressive glioblastoma (Nishimori et al., 1997; Kang et al., 2006). Regulation of 
proliferation and apoptosis may be a conserved function of the adhesion GPCRs.  
 
GPR56, the adhesion GPCR that is the subject of the experiments described in this thesis, has 
been implicated in many biological processes involving proliferation, apoptosis and organ mass. 
In the CNS, deletion of GPR56 resulted in fewer myelinated axons due to decreased 
proliferation of oligodendrocyte precursor cells (Giera et al., 2015). In leukaemia cells, and 
haematopoietic stem cells extracted from GPR56 KO mice, knockdown of GPR56 led to 
accumulation of apoptotic-related proteins such as p53 and cleaved caspase-3, due to DNA 
damage. The authors further concluded that GPR56 promotes cell survival by degrading p53 
(Saito et al., 2013). In addition, forced expression of GPR56 led to myotube hypertrophy and 
GPR56 signalling is important for maintaining muscle mass in models of muscle hypertrophy 
(White et al., 2014). From the foregoing, and because of the abundant expression of GPR56 in 
β-cells, it was hypothesised that GPR56 may play a role in β-cell proliferation and mass. Using 
gain-of-function and loss-of-function approaches, the role of GPR56 in β-cell mass expansion 







• Determine the effect of GPR56 overexpression on β-cell proliferation and apoptosis. 




5.3.1 siRNA-mediated downregulation of GPR56 expression in mouse islets 
Short interfering RNAs (siRNAs) employ the biological process of RNA interference, where the 
sequence of a protein-encoding gene is degraded by complementary RNA sequences, leading 
to directed silencing of gene expression and translation. Due to the three dimensional structure 
of islets, optimal delivery of siRNA to islets using the conventional delivery methods is 
challenging. Dharmacon Accell® siRNA technology, a self-deliverable RNAi method, that was 
used successfully to deliver siRNA into difficult-to-transfect leukaemia cells (Larsen et al., 
2011), was therefore tested in islets to knock down GPR56 expression. Uptake of siRNA was 
first assessed by incubating islets in RPMI supplemented with 2% fetal calf serum containing 
fluorescently labelled non-targeting siRNA (1µM) and monitored under a fluorescent microscope 
for 24 or 48 h. The target sequence for the negative control siRNA was 5’-
UGGUUUACAUGUCGACUAA-3’. In a separate tube, 200 mouse islets were incubated with 
1µM Accell SMARTpool GPR56 siRNAs containing the following sequences: 5’-
GUGUCAUCCACAGAGGUAG-3’, 5’-CCACUAUGAUCAAUCUUCA-3’, 5’-
UCCUCAUCUUCCUGUGGUA-3’ and 5’-CUCUUCAGCAUCAUAACUU-3’ in RPMI for 24 or 
48h before RNA was extracted and reversed transcribed. Expression of GPR56 was quantified 
by qPCR using the following GPR56 primers: forward primer 5’-TTGCAGCAGCTTAGCAGGTA-
3’ and reverse primer 5’-GATCCTCTAGACCGGCTGTG-3’. 
 
5.3.2 Overexpression of GPR56 by transient transfection 
Full-length GPR56 plasmid was a gift from Dr Xianhua Piao (Boston Children’s Hospital) and 
was shipped to London on filter papers. Plasmid DNAs were retrieved, expanded in E. coli 
(section 2.4) and the identities were confirmed by sequencing and BLAST searches. 3x105 





transiently transfected with 0 – 1200ng of full-length GPR56 plasmid for 24, 48 or 72 h using 
lipofectamine (Section 2.4.3), and the degree of transfection was determined by qPCR. In a 
parallel experiment, the efficiency of Lipofectamine and Viafect in delivering plasmids to MIN6 
cells was determined by incubating MIN6 cells for 24-72h with 0 – 1200ng of a plasmid 
encoding eGFP in the presence of these transfection reagents.  
 
5.3.3 In vitro measurement of β-cell proliferation following GPR56 overexpression 
The effect of GPR56 overexpression on β-cell proliferation was determined by quantifying BrdU 
incorporation into replicating DNA using a colometric BrdU ELISA kit. MIN6 cells transfected 
with empty pcDNA3 vector or MIN6 cells that were transiently transfected with GPR56 plasmids 
were cultured overnight in DMEM containing 10% fetal bovine serum. The cells were 
subsequently serum-starved for 24 h before being labelled with 100µM BrdU for 4 hours in 96 
well plates. Following fixation of the cells and addition of an anti-BrdU antibody, absorbance 
was read at 450nm as described in section 2.7.4.  
 
5.3.4 In vitro measurement of β-cell apoptosis following GPR56 overexpression 
Apoptosis was determined by measuring caspase 3/7 activities following transient 
overexpression of GPR56 in MIN6 cells. MIN6 cells transfected with empty pcDNA3 vector or 
MIN6 cells that were transiently transfected with GPR56 plasmids were cultured in medium 
containing 2% fetal bovine serum for 24 h with a further 20 h incubation in medium 
supplemented with a cytokine cocktail (1U/µl TNF-α, 0.05U/µl IL-1β and 1U/µl IFN-γ). Cells 
were incubated with Caspase 3/7 Glo working solution and caspase 3/7 activities were 
measured using a Veritas luminometer as described in section 2.7.2.  
 
5.3.5 Static insulin secretion 
Insulin secretion following GPR56 overexpression was determined by incubating 30,000 MIN6 
cells transfected with scrambled vector or GPR56 plasmids in 96 well plates in medium 







5.3.6 In vivo BrdU delivery 
Post-natal (P9) mice were given 50mg/kg BrdU intraperitoneally for 24 h prior to pancreas 
retrieval. To enable maximum labelling of replicating adult β-cells, age-matched WT and 
GPR56KO P56 mice were injected with 50mg/kg BrdU IP daily for 5 days.  
 
5.3.7 Assessment of β-cell proliferation and islet mass in vivo 
Pancreases were retrieved from WT and GPR56 KO mice that have received BrdU and either 
fixed-frozen or processed for paraffin embedding. Pancreases were cut at 5µm (fixed-frozen) or 
10µm thick (paraffin-embedded) and sections that were more than 100µm apart were 
immunoprobed for BrdU, insulin and Ki67 as described in section 2.5.5. Images were taken with 
a Nikon fluorescent microscope and scored blindly before quantification of BrdU+ β-cells and 

























5.4.1 Down regulation of GPR56 expression 
The discovery that short interfering RNAs transiently downregulate genes of interest has led to 
the development of exogenous siRNAs as biological tools for identifying the function of 
particular genes. However, for efficient downregulation to be achieved, optimal delivery of 
functional siRNA to the target of interest is essential. Accell siRNA employs a novel, chemically 
modified non-viral delivery method that has been used successfully to silence genes in difficult-
to-transfect cells such as primary leukemic cells (Larsen et al., 2011). The technology was tried 
on islets, which are also difficult to transfect, to investigate whether it is efficient in suppressing 
GPR56 expression. The method was validated by first evaluating the entry of scrambled siRNA 
into mouse islets. As shown in Figure 5-1 A and B, fluorescently labelled non-targeting siRNAs 
were detected in islet cells, with more cells fluorescing green after 48 h in culture (B) compared 
to when they were cultured for 24 h (A).  This indicated that the Accell siRNAs were able to 
penetrate the islets and reach cells in the interior. To confirm whether the uptake seen with non-
targeting siRNA could result in gene silencing when the siRNA was directed against GPR56, 
islets were incubated in a medium containing a mixture of GPR56 siRNAs and GPR56 mRNA 
downregulation was determined by qPCR. There was a significant reduction (p<0.001) in 
GPR56 mRNA expression when islets were incubated with Accell GPR56 siRNAs for 24 or 48 h 
compared to control. 1µM GPR56 siRNA induced a 31% knockdown when islets were cultured 
for 24 h, which was comparable to when islets were incubated for 48 h in the presence of 1µM 
GPR56 siRNA. Although there was a significant reduction in GPR56 expression following siRNA 
treatment, the 31% knockdown achieved was not sufficient to produce any functional effects on 
insulin secretion or β-cell proliferation. Other approaches to manipulate GPR56 expression in 
vitro, such as by transient overexpression and in vivo, by using GPR56 KO mice were employed 






Figure 5-1 siRNA-mediated knockdown of GPR56 expression in mouse islets. A – B) To follow the uptake 
of Accell siRNA, islets were incubated with Accell green negative control siRNA and images were taken 
after A) 24 h and B) 48 h. C) Mouse islets (150 each) were incubated in medium containing 1µM Accell 
siRNA targeting GPR56 for 0, 24 and 48 h. RNAs were extracted, reversed transcribed and the expression 
of GPR56 relative to GAPDH was quantified by qPCR. Data are presented as mean + SEM, n=4, p<0.001, 







5.4.2 Plasmid sequencing and BLAST search 
As indicated above, siRNA knockdown of GPR56 in β-cells was inefficient, therefore 
overexpression of GPR56 in MIN6 β-cells was carried out to investigate whether this would 
result in a gain of function. To carry out overexpression studies, plasmids encoding full length 
GPR56 were obtained from Dr Xianhua Piao of Boston Children’s Hospital. The plasmid DNA 
was extracted and sequenced. After translating the DNA sequence to protein, the identity of the 
sequence was confirmed by a protein Basic Local Alignment Search Tool (BLAST). Mouse 
GPR56 has 687 amino acids. The region amplified for sequencing covered the first 255 amino 
acids as shown in Figure 5-2. There was 100% similarity between the amino acids of GPR56 
full-length plasmid (Query) and mouse GPR56 in the reference database (Sbjct), confirming the 
plasmid identity and that it encodes for the mouse GPR56 protein. 
  
 
Figure 5-2 Sequencing of GPR56 encoded by plasmid DNA. GPR56 cDNA in pCMV-sport6 vector was 
expanded in E.coli and DNA was extracted for sequencing. Sequenced nucleotides were translated using 
ExPASy and protein identity was revealed by a BLAST search against the NCBI database. Sequencing 






5.4.3 Assessment of transfection efficiency  
Two commercial transfecting reagents, Lipofectamine and Viafect were available in our lab. To 
determine which of them yielded optimal transfection, they were used to deliver pcDNA3 
plasmids encoding enhanced green fluorescent protein (eGFP) to MIN6 cells. Equal numbers of 
MIN6 cells were incubated for 48 h with 1.25µg of eGFP in the presence of Lipofectamine (1:15) 
or Viafect (1:6) and the number of ‘green’ cells were counted under a fluorescent microscope. 
Transfection efficiency, defined as the percentage of the total number of MIN6 cells expressing 
eGFP, was determined. There were fewer MIN6 cells fluorescing green when Viafect was used 
as the transfecting reagent compared to Lipofectamine (Figure 5-3 A). As shown in Figure 5-3 
B, the transfection efficiency (TE) of Lipofectamine was about 26 times greater than Viafect (% 
TE; Lipofectamine: 78.0 ± 2.7; Viafect: 3.0 ± 1.0). Lipofectamine was therefore used for 



























































Phase-contrast Fluorescence A 
B 
Figure 5-3 Comparing transfection efficiency of two transfecting reagents using an eGFP plasmid. A) 
eGFP was transfected into MIN6 cells using lipofectamine or viafect. After 48hours, the number of cells 
expressing eGFP was determined by fluorescence microscopy. B) The bar graph shows the percentage of 





5.4.4 Overexpression of GPR56 plasmid in MIN6 cells 
Having established that Lipofectamine was a better transfecting reagent than Viafect it was 
used to transfect MIN6 cells with a GPR56 plasmid. MIN6 cells were transfected with empty 
vector (basal) or vectors containing 12, 120 or 1200ng of GPR56 plasmid and cultured for 24 to 
72 h. There was no change in GPR56 mRNA expression when MIN6 cells were transfected with 
12ng GPR56 plasmid, even after the cells were cultured for 72 hours, indicating that it was a 
sub-optimal concentration (Figure 5-4 A). At 120ng, there was an increase in GPR56 mRNA 
expression at 48 and 72 h post-transfection (Basal: 0.057 ± 0.005; 48h: 0.224 ± 0.017; 72h: 
0.442 ± 0.086), but these were not statistically significant elevations. At 1200ng of GPR56 
plasmid, there was a significant increase in GPR56 mRNA expression by MIN6 cells after 24 h 
in culture (p = 0.019). The high GPR56 expression continued to increase at 48 and 72 h post 
transfection (24h: 0.858 ± 0.46, 48h: 1.413 ± 0.063, 72h: 1.694 ± 0.086). At 72 h with 1200ng 
plasmid, there was an approximately 20-fold increase in GPR56 mRNA expression compared to 
basal. Melt-curve analysis revealed a single peak curve (Figure 5-4 B) and agarose gel 
electrophoresis of the amplified product produced single DNA bands of the expected size of 
96bp (Figure 5-4 C), indicating that there were no primer-dimer or nucleic acid contaminants. 
Western blot also revealed that the overexpressed GPR56 protein was of the predicted 
molecular weight of 70kDa (Figure 5-4 D). 1200ng GPR56 plasmid was therefore delivered to 








Figure 5-4 Evaluating GPR56 overexpression in MIN6 cells. A) Expression of GPR56 in MIN6 β-cells 
transfected with GPR56 plasmid is concentration-dependent. MIN6 cells were transiently transfected with 
different concentrations of GPR56 plasmid DNA using lipofectamine, and cultured for 24, 48 or 72 hours. 
cDNAs were prepared and expression of GPR56 mRNA was quantified by qPCR. Data are mean + SEM, 





qPCR showed a single band of GPR56 indicating that there was no primer dimer or other nucleic acid 
contaminations. B) Products of qPCR were subjected to agarose gel electrophoresis in the presence of 
ethidium bromide and DNA bands were revealed by UV light. The image shows single bands of GPR56 
amplicons at the appropriate product size of 98bp. C) Western blot image following GPR56 overexpression 
24h post incubation. β-actin was used as a loading control. 
 
 
5.4.5 Effect of GPR56 overexpression on β-cell proliferation, insulin secretion and 
apoptosis 
MIN6 β-cell proliferation, insulin secretion and apoptosis were evaluated following transient 
overexpression of 1200ng GPR56 plasmid. After 72 h culture in the presence of empty vector or 
the GPR56 plasmid, the cells were labelled with BrdU to measure DNA replication. MIN6 β-cells 
that were transfected with the GPR56 plasmid had a significantly higher number of cells with 
BrdU incorporated into their DNA compared to cells that were transfected with empty vector 
(p=0.04)  (Figure 5-5 A). Overexpression of GPR56 had no effect on basal insulin secretion at 
2mM glucose, suggesting that the secretory mechanisms of the β-cells were not disrupted 
(Figure 5-5 B). The number of β-cells undergoing basal apoptosis was significantly reduced 
following up-regulation of GPR56 (p=0.01), and while there was a trend towards protection 






Figure 5-5 Effect of GPR56 overexpression on β-cell proliferation, basal insulin secretion and apoptosis. 
MIN6 cells were transfected with empty vector (control) or 1200ng of full length GPR56 plasmid and 
cultured for 72 h. At 72 h, functional studies were carried out to determine the effect of overexpressing 
GPR56 on A) MIN6 cell proliferation using a BrdU ELISA, n=8, B) insulin secretion, n=8, C) basal 
apoptosis and D) cytokine-induced apoptosis by measuring caspase 3/7 activities, n=4. Data are mean + 








5.4.6 Effect of GPR56 deletion on β-cell proliferation in vivo 
To investigate the effect of GPR56 on β-cell proliferation in vivo, age-matched WT and 
GPR56KO mice were injected intraperitoneally with BrdU. Replicating β-cells were counted at 
two time points: post natal day 9 (P9) and P56. P9 was chosen to coincide with the period of a 
surge in β-cell proliferation that normally occurs between the 4th and 10th neonatal days in 
rodents (Kaung, 1994) while P56 represented young adult mice. BrdU delivery to the P9 mice 
was given as a single IP injection on that day, followed by culling of the mice twenty four hours 
later, while for adult mice BrdU was given daily for 5 days (P56-P61) to ensure maximal 
labelling of replicating β-cells. The number of BrdU-labelled β-cells was determined by 
immunostaining for insulin and BrdU.  
 
At P9, the number of replicating β-cells was significantly higher in the WT mice compared to the 
GPR56 KO littermates (p<0.001) (Figure 5-6 B). Since this decreased proliferation in the 
GPR56 KO neonatal mice could have resulted from β-cells exiting the cell cycle and being in the 
quiescent G0 phase (Teta et al., 2005), a cell cycle exit assay was conducted to determine 
whether the decreased β-cell proliferation in the KO mice was due to premature cell-cycle exit of 
the β-cells. This was carried out by dual staining for BrdU and Ki67 (Figure 5-6 A, lower panel). 
Ki67 is a proliferative marker that labels cells in all of the cell cycle phases except the resting 
phase G0. BrdU is incorporated into cells at S-phase during DNA replication and will not be 
detected in the preceding G1 phase. However, it will be detected at G1 in daughter cells that are 
re-entering the cell cycle since BrdU is passed on to daughter cells after mitosis (Kee et al., 
2002). Cells that are positive for both BrdU and Ki67 are therefore cells that are actively cycling 
and replicating while cells that are BrdU+/Ki67- are no longer in the cell cycle. Co-labelled 
BrdU+/Ki67+ cells from ten pancreas sections that were >100 µm apart were counted. It can be 
seen from Figure 5-6 C that significantly fewer numbers of pancreatic BrdU+/Ki67+ cells (p<0.05, 
n=3 mice per genotype) were seen in P9 GPR56 KO mice compared to their littermate controls, 
suggesting that the decreased proliferation in the KO mice is partly due to the cells exiting the 
cell cycle prematurely. 
 
In P56 adult mice, a similar trend was observed. The number of BrdU+/ β-cells was considerably 





Moreover, the rate of β-cell replication in P56 WT mice was twelve-fold lower than in P9 WT 
mice (BrdU+/ β-cells; P9 WT: 13.3 ± 5.5, P56 WT: 1.1 ± 0.3), consistent with published data that 
β-cell replication progressively declines with age (Teta et al., 2005; Finegood et al., 1995). 
 
 
Figure 5-6 Effect of GPR56 deletion on β-cell proliferation in P9 mice. Postnatal day 9 mice were given 
BrdU IP and pancreases were retrieved 24 hours later, fixed and embedded in paraffin. A) 5µm sections 
were immunostained for BrdU, insulin and Ki67. Scale bar = 100 µm. B) ***p<0.001, n = 37 islets per 








Figure 5-7 Effect of GPR56 deletion on β-cell proliferation in P56 adult mice. 8 week old GPR56 WT and 
KO mice were given BrdU IP daily for 5 days before pancreases were removed, fixed and embedded in 
paraffin. A) Pancreas sections were immunoprobed for insulin and BrdU. Scale bar = 50 µm. B) Data are 
presented as Mean + SEM, **p=0.005, n=33 islets from WT mice and 47 islets from KO mice, Mann 
Whitney test.  
 
 
5.4.7 Effect of GPR56 deletion on islet mass  
Postnatal islet mass is primarily driven by duplication of pre-existing β-cells (Dor et al., 2004). 
To investigate the extent to which the effect of GPR56 deletion on β-cell proliferation affects 
islet mass, the area occupied by insulin-positive β-cells was measured in pancreases retrieved 
from WT and GPR56KO mice (Figure 5-8 A). Islet size was determined at the same 
developmental stages of P9 and P56, where β-cell proliferation had been quantified. In P9 mice, 
GPR56 deletion resulted in islets being significantly smaller (p<0.01) compared to the littermate 
controls (Figure 5-8 B). There was also a small, non-significant reduction in islet size in the adult 
KO mice compared to the WT mice (Figure 5-8 C). Quantification of islet size distribution 
revealed that in P9 mice the majority of the islets were not bigger than 10 x 103 µm2 while in P56 
mice most of the islets were less than or equal to 18 x 103 µm2 in size. (Figure 5-9 A & B). 
GPR56 deletion was associated with increased numbers of islets of less than 2 x 103 µm2, in 





genotype, and so the chances of coincidence may not be ruled out, it is interesting to note that 
no islets were found within the size range of 10 x 103 µm2 and 18 x 103 µm2 in both P9 and P56 
KO mice. In the WT mice, 40% of islets were found within this size range in P56 mice, 
compared to 13% in P9 mice. Thus, from the pattern of the graphs in Figure 5-9 A & B, it 
appears that there is a relationship between cells that are less than 2 x 103 µm2 and cells in the 
10 – 18 x 103 µm2 size group. In P9 mice, about 50% of the β-cells were within the > 2 x103 µm2 




Figure 5-8 Islet sizes of P9 and P56 GPR56 WT and KO mice. Wax-embedded mouse pancreas sections 
were immunostained for insulin and the islet area was measured. B) Islet sizes of P9 WT and KO mice 
were significantly different. Data are mean+ SEM, **p<0.01. C) There was no difference in islet size at 








Figure 5-9 Size distribution of islets from P9 and P56 mice. Islet size was determined by measuring the 
area occupied by insulin positive β-cells and the percentage frequency of β-cells in the indicated size 
ranges in A) P9 and B) P56 mice was plotted. Data were obtained from 10 pancreas sections from a P9 




















The experiments carried out in this chapter demonstrate that GPR56 plays a role in regulating 
β-cell proliferation and islet mass. In the gain of function study in which GPR56 was 
overexpressed and constitutively activated in β-cells, its functional activity was investigated 
independently of agonists. Transient overexpression of GPR56 in MIN6 cells led to increased β-
cell proliferation and decreased apoptosis. These observations were consistent with data from 
GPR56 KO mice, indicating that deletion of GPR56 in vivo resulted in decreased islet mass as a 
consequence of decreased β-cell proliferation. In addition, a higher number of replicating β-cells 
exit the cell cycle prematurely in the KO islets compared to WT controls.  
 
Attempts to knock down islet GPR56 using siRNAs produced variable and unsatisfactory 
results, most likely as a result of poor accessibility of the siRNAs to the core of intact islets. The 
function of GPR56 in β-cells was therefore investigated using a receptor overexpression 
strategy. As expected, increasing the concentration of GPR56 plasmid delivered to β-cells 
produced a corresponding increase in GPR56 mRNA expression. The increased GPR56 
expression translated to enhanced β-cell survival and proliferation without any changes in basal 
insulin secretion.  
 
G-protein coupled receptors (GPCR) are the largest and most studied cell surface receptors in 
the human genome. They consist of seven transmembrane helices with N- and C-terminal 
domains at both ends. Binding of an agonist to the N-terminal domain leads to receptor 
activation and subsequent downstream signalling. However, some GPCRs have been found to 
be minimally active in the absence of an agonist (Lefkowitz et al., 1993), and this activity is 
termed basal or constitutive activity. Such basal activity can be increased to a point where 
downstream signalling can be detected either by introducing a mutation to the receptor or by 
overexpressing the wild-type strain. For β2-adrenoceptors, introducing a mutation to the C-
terminal segment of the third intracellular loop or overexpression of the wild-type receptor led to 
a marked increase in cAMP generation in the absence of an agonist (Samama et al., 1993).  
 
The constitutive activity of GPCRs arises from equilibrium between their active and inactive 





are overexpressed, the number of receptors in both active and inactive forms is increased, and 
once a certain threshold is reached, downstream signalling of the active receptors will be 
detected (Hamann et al., 2015). The concept of constitutive signalling has been investigated in 
adhesion GPCRs and it is now known that the majority of adhesion GPCRs are functionally 
activated when their wild-type receptors are overexpressed. Using this approach, direct 
evidence for adhesion GPCR coupling to G protein subunits has been uncovered. For example, 
overexpression of GPR133 caused an increase in cAMP signalling, providing the first evidence 
that it is Gs coupled (Bohnekamp and Schöneberg, 2011). Coupling to other G-protein subunits 
such as Gq, Gi and G12/13 have been demonstrated for several other adhesion GPCRs such as 
GPR126, GPR97, BAI1, GPR110 and GPR114 by overexpressing their wild-type strain (Gupte 
et al., 2012). 
 
To study the effect of GPR56 deletion on β-cell replication and islet mass in vivo, newly formed 
β-cells and islet sizes were examined using pancreases retrieved from GPR56KO mice at P9 
and P56. Shortly before birth, at E18, there is a dramatic increase in β-cell neogenesis and 
proliferation leading to increased islet mass. The islet mass enlargement in rodents continues 
after birth as a result of a rapid increase in β-cell replication: from P10, the rate of replication 
progressively declines until weaning at P28, where it remains fairly constant until adulthood 
(Kaung, 1994). As described in Chapter 3, a progressive increase in GPR56 expression was 
observed in islets between E18 and P9. As this period of increased GPR56 expression occurred 
when β-cell proliferation is at its peak, the absence of GPR56 may explain the decreased 
capacity of β-cells to proliferate at P9 in GPR56KO mice.  
 
Furthermore, the surge in perinatal β-cell proliferation reported in rodents between the 4th and 
10th days after birth is associated with increased expression of cyclin D2. Cyclin D2 is a 
proliferative gene that partners with cyclin dependent kinases (CDKs) to initiate cell cycle 
progression in β-cells (Cozar-Castellano, Fiaschi-Taesch, et al., 2006). Cyclin D2 KO mice have 
reduced β-cell replicative capacity with a resultant decrease in islet mass and they are glucose 
intolerant (Georgia and Bhushan, 2004). It has been reported that at P10, β-cells in islets of 
CDK-4 null mice showed about 60% reduction in their rate of proliferation (Martín et al., 2003). 





and CDKs in GPR56 KO islets, there has been a previous report of reduced CDK-2 protein in 
oligodendrocyte progenitor cells isolated from GPR56KO mouse brain (Giera et al., 2015), 
indicating that cell cycle regulators may play a part in the decreased replication of β-cells 
observed in the GPR56 KO islets. The decreased number of replicating and cycling BrdU+/Ki67+ 
cells observed in GPR56KO pancreas further supports this.  
 
Other cell cycle proteins that may account for the decreased number of BrdU+/Ki67+ cells seen 
in GPR56KO pancreas include E2F and nuclear factor of activated T cells (NFAT). Forced 
expression of GPR56 in HEK293T cells considerably induced the expression of E2F and NFAT 
(Kim et al., 2010), supporting a role for GPR56 signalling in influencing cell cycle progression. 
As replicating cells pass through the S phase of the cell cycle, their DNA contents are 
duplicated. The duplication process is under the control of a myriad of genes such as those 
encoding for ribosomal enzymes and enzymes for DNA synthesis, that can either slow down or 
increase cell progression through the S phase. The DNA replication genes are themselves 
under the control of E2F proteins (Cozar-Castellano et al., 2006a). Six members of the E2F 
protein family have been detected in murine islets (Cozar-Castellano et al., 2006b). NFAT and 
its upstream effector, calcineurin, also play critical role in postnatal β-cell proliferation, and β-
cell-specific loss of calcineurin/NFAT led to a significant decrease in β-cell proliferation in 
postnatal mice (Heit et al., 2006). Additional studies are required to confirm which cell cycle 
transcription factors are involved in the regulation of β-cell proliferation by GPR56 and their 
relative contributions. 
 
Although β-cell replication is the primary determinant of islet size postnatally (Georgia and 
Bhushan, 2004), elements of β-cell neogenesis have been described to take place shortly 
before weaning at P28, and this contribute to adult islet mass (Scaglia et al., 1997). The 
observation that islets in pancreases from P56 GPR56KO mice were not smaller than those 
from age-matched WT mice, while there was a significant reduction in size at P9 in the GPR56 
KO mice, suggests that other processes in addition to β-cell replication may contribute to adult 
islet mass. The first postnatal month is associated with many changes in the developing 
pancreas including a wave of increased apoptosis observed between P13 and P17. However, 





P2 and P20, suggesting that neogenesis is important for maintaining a constant β-cell mass 
(Scaglia et al., 1997). It was also reported that β-cell mass more than doubled between P2 and 
P5 but the cross-sectional area remained unchanged, indicating that increased β-cell number 
rather than size contributed to the increased mass (Bouwens et al., 1994). A sharp increase in 
β-cell mass was observed after P21 and based on islet mass at P31, data from mathematical 
modelling and duct-specific lineage tracing suggested that neogesis contributed between 30% 
to 50% of β-cell mass at the end of the first postnatal month (Finegood et al., 1995; Bonner-
Weir et al., 2010). It is likely that GPR56 does not contribute to β-cell neogenesis and further 
studies using markers of ductal cell differentiation is required to confirm this. 
 
The heterogeneity of islet cells, comprising, α, β, δ and PP cells, is well established (Steiner et 
al., 2010; Stanger and Hebrok, 2013). However, the heterogeneity is not limited to islet cell 
identity alone but it is now apparent that islets are made up of unique populations that are 
distinguishable based on size and function. This idea was first conceived by Bonner-Weir and 
colleagues, who classified islets into small and large based on their diameter (Bonner-Weir and 
Like, 1980), but the functional implication of this classification was not appreciated until recently. 
In addition, β-cells can be subdivided based on their ability to divide into proliferation-competent 
β-cells, expressing Fltp, a WNT/planar cell polarity effector gene and mature, proliferation-
incompetent β-cells, lacking Fltp gene (Bader et al., 2016). The pancreases of GPR56KO mice 
contain considerably more small islets (>2000µm2) than those from WT mice. In adult (P56) 
GPR56 KO mice, about 47% of all islets were less than 2000µm2 in size compared to about 7% 
in this size range in pancreases from GPR56WT mice. Small islets (both in situ and isolated) 
are reported to contain more insulin granules/area, have higher insulin content and they secrete 
more insulin upon glucose challenge than large islets in rats (Huang et al., 2011) and humans 
(Farhat et al., 2013). Small islets also yield superior islet graft outcomes than large islets in 
transplantation studies (Li et al., 2014; Lehmann et al., 2007). The high number of small islets in 
GPR56KO mouse pancreas may partly explain why GPR56KO mice were not glucose 
intolerant, as they will compensate by secreting more of their insulin content.  
 
The extent to which reduced β-cell mass contributes to T2D is an ongoing debate. It is not yet 





decrease of up to 60% in islet mass has been reported in pancreases obtained from people with 
T2D (Butler et al., 2003), but removal of 50% of the pancreas mass from patients with 
pancreatitis had little effect on glucose tolerance (Menge et al., 2008). Also, when half of the 
pancreas mass was removed from healthy donors only one-fifth of the patients developed 
impaired glucose tolerance (Kendall et al., 1990), indicating that a decrease in islet mass alone 
is not sufficient to cause T2D. Indeed, β-cell function rather than β-cell number may play a more 
crucial role in the onset of T2D, as when islets from T2D patients were normalised to insulin 
content, they still secreted less insulin compared to islets from healthy subjects (Ashcroft and 
Rorsman, 2012). The role of β-cell function is further supported by the reversal of diabetes 
following administration of GLP-1 analogues or bariatric surgery in patients with long standing 
T2D with reduced β-cell mass (Steven et al., 2015). 
 
In summary, the data presented in this chapter indicate that islet GPR56 plays an important role 
in fine-tuning β-cell proliferation and apoptosis, especially in the neonatal period, and suggest 





















































Chapter 6 The role of collagen III in islet functions 
 
6.1 Introduction 
The extracellular matrix (ECM) is a specialised structure of glycoproteins that, in addition to 
providing structural support and anchorage sites for cells, serves to mediate signal 
transductions from the immediate environment of cells to their intracellular environment. The 
signalling interaction between islets and ECM is complex and interdependent, and is key in 
maintaining normal islet physiology especially cell survival, adhesion and insulin secretion. 
Islets are surrounded by a capsule of ECM known as the peri-insular basement membrane 
(BM), and this is among the first structures to be compromised in T1D (Korpos et al., 2013). 
Following islet isolation, the peri-insular BM is lost and this can lead to increased islet apoptosis 
(Rosenberg et al., 1999). Within each islet are deposits of ECM produced by endothelial cells of 
the blood vessels, forming the peri-vasular BM (Otonkoski et al., 2008). The islet BM is a 
dynamic complex of proteins that is continually modified throughout life and it is composed 
primarily of laminin and collagens (Deijnen et al., 1994). As nearly all islet β-cell are in contact 
with the BM (Peiris et al., 2014), components of the BM can directly influence β-cell function. 
Collagen IV, for instance, promotes adhesion, migration and insulin secretion of human β-cells 
(Kaido et al., 2004). 
 
The potential of islet-matrix interactions to enhance islet survival and β-cell function has 
considerable translational impact on islet transplantation, which is increasingly becoming a 
popular treatment option for T1D. However, the current clinical procedure is associated with a 
high rate of early graft failure, especially during the first few weeks after transplantation (Saudek 
et al., 2010), thereby necessitating further grafts until euglycaemia is restored. In addition to 
immuno-rejection, one of the main reasons for graft failure is the uncontrolled and almost 
complete enzymatic digestion of the peri-islet matrix during the isolation process (Wang and 
Rosenberg, 1999). This is supported by the observation that transplantation of impure islets, 
such as those still attached to acinar or matrix tissues, has superior outcomes compared to the 
use of pure islet preparations possibly due to the trophic effect of the cell matrix on islet mass 





after several days in culture, the new matricellular proteins are of different compositions to those 
in vivo and the effect of matrix variability on graft failure is not yet known (Londono et al., 2016). 
In addition, loss of ECM leads to disruption of islet microvasculature, causing increased islet cell 
death in vitro as a result of reduced oxygen supply (Irving-Rodgers et al., 2014). Strategies that 
improve islet survival, such as incubating them on ECM derived from fibroblasts or tumour cells, 
have been reported (Jalili et al., 2011; Tsuchiya et al., 2015), but they do not effectively 
translate to improved clinical outcomes, possibly as a result of ECM variability and uncertainty 
in their compositions. 
 
Increased knowledge of individual ECM components, as well as the composition of the final 
transplant preparations is necessary to ensure that appropriate trophic support is supplied. 
Although the effect of complex matrices and the commonest members of the basement 
membrane on β-cell survival, proliferation and insulin secretion are well documented (Stendahl 
et al., 2009; Daoud et al., 2010; Weber et al., 2008; Wang and Rosenberg, 1999), the role of 
collagen III in islet function is not yet clear. It was reported in Chapter 3 that collagen III was not 
localised to the β cells but was found within the peri-islet capsule and islet blood vessels, 
supporting a previous report that collagens, including collagen III, are produced by the vascular 
endothelial cells (Nikolova et al., 2006). Collagen III is a ligand for GPR56 in the developing 
brain where it couples to Gα12/13 to elicit RhoA signalling (Iguchi et al., 2008; Luo et al., 2011). 
Since nearly all β cells are in contact with vascular endothelial cells and peri-vascular BM 
(Bonner-Weir, 1988; Peiris et al., 2014), and given the proximity of collagen III to the β cells, it 
was hypothesised that a paracrine activation of GPR56 by collagen III is likely, and GPR56-
collagen III interactions may be physiologically relevant in islet functions. 
 
6.2 Aims 
The aims of this chapter were to:  
• Determine whether GPR56 is necessary for β-cell adhesion. 






• Determine whether incubation of islets with collagen III potentiates glucose-induced 
insulin secretion and whether this is via activation of GPR56 using islets isolated from 
GPR56KO mice. 




6.3.1 Quantification of GPR56 mRNA expression in MIN6 pseudoislets 
Pseudoislets were formed by culturing 150,000 MIN6 β-cells in uncharged 9cm petri dishes for 
7 days in DMEM, supplemented with 10% fetal bovine serum. In parallel, 150,000 MIN6 β-cells 
were grown as adherent monolayers for 7 days. Total RNAs were extracted from pseudoislets 
and adherent MIN6 β-cells, and reversed transcribed to cDNAs. GPR56 expression in the 
pseudoislets and adherent MIN6 β-cells was quantified by qPCR as described in Section 2.3.5. 
 
6.3.2 Adhesion assay 
MIN6 β-cells of approximately 80% confluency were maintained in FBS-free DMEM for 8 h prior 
to the adhesion assay. To determine the number of cells required for adhesion assay, MIN6 β-
cells were seeded into a 96-well plate at densities ranging from 10,000 to 100,000 cells and 
allowed to adhere for 90 min at 370C. Unattached cells were washed off and adherent cells 
were fixed and quantified by a colorimetric assay of crystal violet binding to DNA as described in 
Section 2.7.1. The assay was then repeated using 96-well plates pre-coated with collagens I, III 
and IV. 
 
6.3.3 Apoptosis and proliferation assays  
Groups of 20,000 MIN6 β-cells per well were cultured in media containing 2% FBS in the 
presence or absence of 100nM collagen III for 48 h, with subsequent 20h incubation in the 
presence or absence of a cytokine cocktail (1U/µl TNF-α, 0.05U/µl IL-1β and 1U/µl IFN-γ). 
Apoptosis was determined by measuring caspase 3/7 activities as described in Section 2.7.2. 
Proliferation of β-cells in vitro was determined by BrdU incorporation using a colorimetric BrdU 





presence or absence of 100nM collagen III for 48 h before being labelled with 100µM BrdU for 
4h at 370C. For the proliferation assay, cells cultured in 10% FBS served as positive control. 
 
6.3.4 Single cell calcium microfluorimetry 
MIN6 β-cells were seeded at a density of 100,000 cells on acid-ethanol washed coverslips and 
incubated overnight at 370C in DMEM supplemented with 10% FBS. The cells were incubated 
with 5µM of the calcium fluorophore Fura-2AM for 30 min before being perifused with 
physiological solution containing 2mM or 20mM glucose in the presence or absence of collagen 
III or IV. Some experiments were carried out in the presence of 1mM EGTA to remove 
extracellular calcium from the buffer. Cells were alternatively exposed to light at 340nm and 
380nm and emitted light was filtered at 510nm to determine changes in [Ca2+]i (Section 2.8.1).  
 
6.3.5 Islet isolation 
For insulin secretion experiments, islets were isolated from ICR mice, GPR56KO mice and age-
matched GPR56WT mice using collagenase digestion of the pancreas (Bowe et al., 2013). 
Islets were cultured overnight in RPMI medium supplemented with 10% NCS and 100U/ml 
penicillin/0.1mg/ml streptomycin prior to use.  
 
6.3.6 Static insulin secretion 
To determine the acute effect of collagen III on insulin secretion, islets isolated from male ICR 
mice were incubated in physiological solution containing 2mM or 20mM glucose in the presence 
or absence of 100nM collagen III for 1 hour and insulin secretion was determined by 
radioimmunoassay. In parallel experiments to assess the chronic effect of collagen III on insulin 
secretion, islets were cultured on dishes coated with 100nM collagen III for 48 h before being 
retrieved and exposed to buffer supplemented with either 2mM or 20mM glucose for 1 hour. 
Insulin secretion was determined by radioimmunoassay. 
 
6.3.7 Dynamic insulin secretion 
To determine whether collagen III acts via GPR56 to increase insulin secretion, the dynamic 
secretory profile of islets isolated from GPR56KO mice and from their WT littermates to 2mM 





Perifusate was collected every 2 min and insulin secretion was quantified by 
radioimmunoassay. 
 
6.3.8 Statistical analysis 
Statistical analysis was determined either with Student’s t-test or ANOVA, as appropriate. Data 




6.4.1 Expression of GPR56 mRNA in MIN6 pseudoislets  
Adhesion receptors and ECM components provide cell-cell cohesion and are necessary for 
maintaining structural configuration of tissues (Nagata et al., 2001). Since islets are three-
dimensional organs of tightly packed cells, it is possible that adhesion GPCRs play a role in the 
adhesiveness of these cells. It was hypothesised that the expression of GPR56, being an 
adhesion receptor, will be higher in a model of β-cell aggregates known as pseudoislets 
compared to MIN6 β-cell monolayers. Pseudoislets are spherical ‘islet-like’ clusters that are 
formed when MIN6 β-cells are cultured on uncharged surfaces or on petri dishes coated with 
gelatin (Figure 6-1 B). Pseudoislets are known to have increased expression of adhesion 
receptors such as E-cadherin (Hauge-Evans et al., 1999). Using quantitative PCR, the 
expression of GPR56 mRNA in pseudoislets was found to be about 125% higher than in MIN6 
β-cells (Figure 6-1 C). However, the difference was not statistically significant when the means 
of three independent experiments were averaged (p=0.2). In future studies, deletion or 







Figure 6-1 Expression of GPR56 mRNA in MIN6 pseudoislets. A) Equal numbers of MIN6 β-cells were 
grown as adherent monolayers or B) on uncharged petri dishes to form pseudoislets after 7 days in 
culture. RNAs were extracted and reversed transcribed into cDNAs. Expression of GPR56 was quantified 
by qPCR. C) Bar graph shows the expression of GPR56 mRNA in MIN6 β-cells and pseudoislets relative 
to β-actin. Data are presented as Mean + SEM, n=3 independent experiments, p=0.2, Student’s t-test.  
 
6.4.2 Validation of the β-cell adhesion assay 
Given that GPR56 is an adhesion receptor activated by collagen III (Luo et al., 2011), it was 
investigated whether collagens increased the adhesiveness of β-cells. To do this, a crystal 
violet-based adhesion assay was first validated by determining the minimum density of MIN6 β-
cells required to yield optimum adhesion. Non-adherent cells were washed off while adherent β-
cells were quantified by a colorimetric method. As shown in Figure 6-2, there was a gradual 
increase in the absorbance of cells retaining the dye as the cell density increased. At a density 
of 30,000 cells, the absorbance of adherent cells was significantly higher (p<0.05) than at 





cell adhesion as measured by changes in absorbance, suggesting that 30,000 cells is the 




Figure 6-2 Determining the lowest density of MIN6 cells with optimum adhesion. Serum-starved MIN6 cells 
were seeded at densities ranging from 1 x104 to 9 x104 cells on 96-well plates and incubated for 90 min. 
Non-adherent cells were washed off while adherent MIN6 β-cells were fixed and quantified by a 
colorimetric assay involving crystal violet binding to DNA where absorbance was quantified at 595nm. 




6.4.3 Effects of collagens on β-cell adhesion 
Having validated that 30,000 cells is the optimum cell density for the MIN6 β-cell adhesion 
assay, the effect of collagens on β-cell adhesion was investigated. Collagens, being structural 
components of the ECM, may play a role in the three dimensional architecture of islets by 





vitro, MIN6 β-cells were seeded at a density of 30,000 cells on petri dishes pre-coated with 
100nM collagens I, III and IV. Collagens I and III did not have any effect on β-cell adhesion 
(p>0.2) at 100nM. However, collagen IV produced a statistically significant increase in β-cell 
adhesion (p<0.01) as measured by increased absorbance at 595nm as a result of crystal violet 
binding to DNA of adhered cells compared to the BSA control (Figure 6-3). This may highlight 
one of the differences between the three collagen subtypes: collagens I and III belong to the 
same class of fibre-forming collagens while collagen IV is a structural collagen of the basement 
membrane. 
 
In addition, when mouse islets were cultured on dishes coated with collagen III or IV for 72 h in 
serum-free media and observed via light microscopy, differences in islet morphology were 
evident (Figure 6-4). Islets cultured on uncharged petri dishes were intact but loosely attached 
cells were visible (Figure 6-4 A). Islets cultured on 100nM collagen III had the best morphology 
with few loose cells and no cell spreading (Figure 6-4 B). However, islets cultured on 100nM 
collagen IV exhibited cell recruitment to collagen IV although the overall islet integrity was not 
compromised (Figure 6-4 C). Cell recruitment was more pronounced at 200nM collagen IV 
(Figure 6-4 D) and at this higher concentration islets were strongly attached to the dishes and 








Figure 6-3 Adhesion of MIN6 β-cells to ECM components. Serum-starved MIN6 β-cells were seeded onto 
96-well plates coated with 100nM collagens I, III, IV, or 0.5% BSA at a density of 30,000 cells/well and 
allowed to adhere for 90 min. Non-adherent cells were washed off. Adherent MIN6 β-cells were fixed and 
quantified by a colorimetric assay involving crystal violet binding to DNA. Data are mean + SEM, n=3 







Figure 6-4: Phase contrast images of islets cultured in serum-free media for 72h on A) uncharged petri 
dishes B) uncharged petri dishes coated with 100nM collagen III C) uncharged petri dishes coated with 












6.4.4 Effect of collagen III on β-cell apoptosis 
Increased β-cell apoptosis is central to the progression of both T1D and T2D and it is one of the 
main drivers of decreased islet mass (Butler et al., 2003; Cernea and Dobreanu, 2013). Factors 
that promote cell survival are therefore beneficial for improved β-cell function in people with 
diabetes. To investigate whether collagen III had any effect on β-cell apoptosis, MIN6 β-cells 
were exposed to collagen III for 48 h, a time-course selected to ensure uniformity with the 
proliferation and chronic insulin secretion assays in this chapter. As shown in Figure 6-5, 
collagen III produced a modest decrease in basal apoptosis (p>0.2). However, when apoptosis 
was induced by a cocktail of cytokines in the continued presence of collagen III, there was a 
significant decrease in β-cell apoptosis (p<0.01), suggesting that collagen III may protect β-cells 
from environmental insults.  
 
 
Figure 6-5 Effect of collagen III on β-cell apoptosis. Groups of 20,000 MIN6 β-cells were cultured in media 
for 48 h in the presence or absence of collagen III. They were subsequently incubated for a further 20 h in 
the presence or absence of cytokines before caspase 3/7 activities were measured by a luminescence 
based method. Data are presented as mean + SEM, n=5, **p<0.01, Two-Way ANOVA with Bonferroni’s 






6.4.5 Effect of collagen III on β-cell proliferation 
Having demonstrated in Chapter 5 that loss of GPR56 led to decreased β-cell proliferation in 
postnatal mice, it was investigated whether collagen III, a GPR56 agonist, had any effect on β-
cell proliferation. MIN6 β-cells were serum-starved and cultured in media in the presence or 
absence of 100nM collagen III for 48 h. MIN6 β-cells cultured in the presence of 10% FBS 
served as a positive control. Replicating β-cells were labelled for 4 h with 100µM BrdU and 
quantified by a colorimetric ELISA method. 100nM collagen III had no effect on β-cell 
proliferation (Figure 6-6) whereas 10% FBS produced a significantly increased β-cell 




Figure 6-6 Effect of collagen III on β-cell proliferation. MIN6 cells were cultured in media containing 2% 
FBS in the presence or absence of collagen III for 48 h before being labelled with BrdU for 4 h.  Cells 
grown in media containing 10% FBS served as a positive control. Proliferating cells labelled with BrdU 
were determined with a BrdU ELISA. Data are presented as Mean + SEM, n=4 independent experiments, 







6.4.6 Effect of collagens III and IV on intracellular calcium levels 
It is well known that elevation of cytosolic calcium is critical for insulin release. To investigate 
whether collagen III had any effect on β-cell calcium levels, calcium microfluorimetry 
experiments were carried on MIN6 β-cells exposed to 1nM, 10nM, 100nM and 1µM of collagen 
III, and real-time changes in cytosolic calcium concentration ([Ca2+]i) were measured (Figure 
6-7). At 1nM collagen III, there was no change in [Ca2+]i. However, collagen III produced 
reversible increases in cytosolic calcium at 10nM, 100nM and 1µM. The effect of collagen III on 
[Ca2+]i  was not concentration-dependent as there was no difference in the basal to peak 
responses when 10, 100 and 1µM of collagen III were administered (p>0.2). Subsequent 
exposure of MIN6 β-cells to ATP produced a rapid and short-lived increase in cytosolic calcium 
while tolbutamide produced a more robust and sustained increase as expected. The ability of 
ATP and tolbutamide to elevate [Ca2+]i after the cells had been exposed to varying 
concentrations of collagen III indicated that the cells were viable and collagen III was not toxic to 
them. Since collagen III activates GPR56 at 84nM in neuronal cells (Luo et al., 2011), 
subsequent experiments were carried out with 100nM collagen III. Collagen IV also caused an 







Figure 6-7: Concentration-dependent effects of collagen III on cytosolic calcium levels in MIN6 β-cells. 
MIN6 cells were loaded with Fura-2 and perifused with physiological solutions supplemented with different 
concentrations of collagen III at the indicated time points. A) & B) Screenshots of fura-2-loaded MIN6 β-
cells at two fluorescence wavelengths, fura-short and fura-long respectively. C) A screenshot of the 
calcium imaging software showing the response of individual MIN6 β-cells to the various test agents. D). 





controls to check the viability of MIN6 cells at the end of the experiment. Changes in intracellular calcium 




Figure 6-8: Effect of collagens III and IV on [Ca2+]i in MIN6 β-cells. MIN6 β-cells were loaded with Fura-2 
and perifused with physiological buffers containing 100nM collagen III, 100nM collagen IV, 100µM ATP 
and 50µM tolbutamide at the indicated time points. ATP and tolbutamide were used as positive controls to 
check the viability of the MIN6 cells. Changes in intracellular calcium are expressed as 340/380nm 
ratiometric data. n=31 cells. 
 
 
6.4.7 Effects of collagens on preproinsulin gene expression 
Since the primary function of the β-cells is to secrete insulin, the effect of collagens on 
preproinsulin gene expression was investigated.  MIN6 β-cells were incubated with 100nM 
collagens I, III and IV for 7 days while equal numbers of MIN6 β-cells in culture in the absence 
of collagens served as a control. Since MIN6 β-cells were derived from mouse, expression of 
the Ins1 gene was evaluated since it is a rodent-specific retrogene, derived from the partially 
processed mRNA of Ins2 (Shiao et al., 2008). Quantification of Ins1 showed that irrespective of 









Figure 6-9 Effect of ECM components on insulin gene expression. MIN6 cells were cultured on dishes 
coated with 100nM of collagens I, III, or IV for 7 days. On day 7, RNAs were extracted from each sample 
and reverse-transcribed. Quantitative RT-PCR was carried out using the Pfaffl method of relative 
quantification. Results represent the mean change in Ins1 gene expression relative to GAPDH + SEM, 
n=3, **p<0.01, ***p<0.001, ****p<0.0001 compared to basal insulin expression, One-Way ANOVA with 
Bonferroni’s post-hoc test. 
 
 
6.4.8 Acute effect of collagen III on insulin secretion 
To investigate the effect of collagen III on insulin secretion, isolated mouse islets were 
incubated in physiological solution containing 2mM or 20mM glucose in the presence or 
absence of 100nM collagen III at 370C. After 1 h incubation, the tubes containing islets were 
placed on ice to inhibit further insulin release. Quantification of insulin secretion from the 
supernatant showed that collagen III had no effect on basal insulin secretion at 2mM glucose 
(Figure 6-10). The islets responded appropriately to 20mM glucose with a 5 fold increase over 








Figure 6-10 Acute effect of collagen III on insulin secretion from mouse islets. Insulin secretion was 
determined by radioimmunoassay. Data are presented as Mean + SEM, *p<0.05, n = 3 independent 
experiments, Two-way ANOVA with Bonferroni’s post-hoc test.  
 
 
6.4.9 Chronic effect of collagen III on insulin secretion 
Although β-cells interact directly with ECM in both mouse and human islets, mechanisms exist 
to prevent continuous activation of ECM receptors such as through the remodelling of ECM to 
either expose or hide ECM recognition sites. Since components of the ECM are in close 
proximity to the β-cells, the long-term effect of collagen III on insulin secretion was therefore 
investigated in vitro and it was also determined whether chronic incubation of islets with 
collagen III had any effect on insulin content. Islets were incubated on collagen III coated dishes 
or dishes coated with vehicle for 48 h, after which islets were retrieved and challenged with 
glucose. At 2mM glucose, there was no change in insulin secretion in islets pre-exposed to 
collagen III (Figure 6-11 A), similar to what was observed when islets were acutely challenged 





potentiation of glucose-induced insulin secretion in islets previously incubated with collagen III 
to a similar extent to that observed in the acute collagen III exposure experiment (Figure 6-11 
A). To determine whether the increased insulin secretion was as a result of changes in insulin 
content, islets were lysed in acidified ethanol to extract insulin. As shown in Figure 6-11 B, there 
was no change in insulin content of islets that were pre-treated for 48 h with collagen III at 2mM 
and 20mM glucose, suggesting that the increased secretion was as a result of increased 
release of pre-existing stored insulin rather than synthesis of new insulin.  
 
 
Figure 6-11 Chronic effect of collagen III on insulin secretion. A) Isolated islets were cultured on vehicle or 
collagen III-coated dishes for 48 h after which they were retrieved and challenged with 2mM or 20mM 
glucose for 1 h. Insulin secretion was quantified by radioimmunoassay. B) Groups of 10 islets from the 
treatment groups in A) were lysed in acidified ethanol to extract their insulin. Insulin content was 
determined by radioimmunoassay and normalised per islet. Data are presented as Mean + SEM, n=6-8 
replicates from 5 mice and representative of two independent experiments, ***p<0.001, ns = not 








6.4.10 Collagen III-induced insulin secretion depends on extracellular calcium influx 
Calcium-induced exocytosis of insulin granules is the primary determinant of insulin secretion 
(Rorsman and Renström, 2003). There are two sources of intracellular Ca2+ in β-cells: influx of 
calcium ions through voltage-dependent calcium channels following membrane depolarisation, 
which is the main route of Ca2+ entry and, secondly, mobilisation of Ca2+ ions from the 
endoplasmic reticulum store (Jones and Persaud, 2010). To test whether collagen III can 
augment the glucose-induced increase in cytosolic calcium, Fura-2 loaded MIN6 β-cells were 
perifused with physiological buffers supplemented with 20mM glucose, with or without 100nM 
collagen III. As shown in Figure 6-12 A (upper line), exposure of β-cells to 20mM glucose 
elicited an increase in [Ca2+]i followed by an additional ~50% increase in basal to peak ratio in 
the presence of collagen III (Figure 6-12 C). The increase in cytosolic Ca2+ concentration was 
reversible upon withdrawal of collagen III. Collagen III is therefore able to augment glucose-
induced [Ca2+]i  concentration and the cells also responded appropriately to ATP and 
tolbutamide indicating that they were still viable. 
 
To investigate the source of the cytosolic Ca2+, the experimental protocol was repeated by 
perifusing MIN6 β-cells with calcium-free physiological solution supplemented with 1mM EGTA, 
to chelate any available calcium in the buffer. In the absence of extracellular calcium, 20mM 
glucose, collagen III and tolbutamide were unable to increase cytosolic Ca2+, indicating that 
influx of extracellular calcium is the primary source of elevated [Ca2+]i with these agonists. ATP, 
on the other hand, caused an increase in cytosolic Ca2+ in the absence of extracellular calcium, 
indicating that it mobilises Ca2+ from internal stores consistent with its action as a purinergic 
receptor agonist (Figure 6-12 A: lower line). However, the magnitude of the peak was 
considerably lower compared to the presence of calcium, indicating that calcium-induced 
calcium release from the ER store is likely to play a role in ATP action.  
 
Using a temperature-controlled perifusion system, it was next investigated whether collagen III-
induced calcium influx is required for its stimulatory effects on insulin secretion, and whether 
removal of calcium had any effect on collagen III-induced insulin secretion.  Isolated mouse 
islets were perifused with physiological buffer containing 2mM or 20mM glucose with or without 





fold increase in insulin secretion. In the absence of calcium, insulin secretion was completely 
abolished, indicating that extracellular calcium is necessary for glucose-induced insulin 
secretion (Figure 6-13 A: t14 – t34 min). The increase in [Ca2+]i concentration caused by collagen 
III, as shown in Figure 6-12 A: upper line, corresponded to potentiation of glucose-induced 
insulin secretion in isolated islets (Figure 6-13 A: upper line). In the absence of extracellular 
calcium, collagen III was still able to stimulate insulin secretion albeit at a statistically lower AUC 
(Figure 6-13 C). Although collagen III could not increase [Ca2+]i in calcium-free media as shown 
in Figure 6-12 A: lower line, it is possible that the peak was too small to be detected, since 
collagen III was able to cause an increase in insulin secretion in the absence of calcium influx. 
Alternatively, it is possible that the elevation in [Ca2+]i in response to collagen III is not required 






Figure 6-12: Effect of collagen III on [Ca2+]i in the presence or absence of extracellular calcium. A) MIN6 β-
cells were loaded with Fura-2 and perifused with either calcium-free physiological buffers or buffers 
containing 2mM calcium, and supplemented with agonists as shown. ATP and tolbutamide were used as 
positive controls to check the viability of the MIN6 cells. Changes in intracellular calcium are expressed as 
340/380nm ratiometric data. Data are presented as mean ± SEM, n=19 cells, representative of three 
separate experiments.  B) Image shows fluorescent MIN6 β-cells loaded with Fura-2. C) Graph shows 
peak amplitude responses of MIN6 β-cells to the agonists in the presence or absence of extracellular 






Figure 6-13: Effect of collagen III on insulin secretion in the presence or absence of extracellular calcium. 
Isolated mouse islets were perifused with physiological buffers supplemented with 100nM collagen III and 
20mM glucose in the presence or absence of extracellular calcium. Islets were initially perifused with 
media containing 2mM glucose. Insulin secretion was quantified by radioimmunoassay. B) Area under the 
curve for collagen III-induced insulin secretion between time t34 and t54 min in the presence or absence of 
extracellular calcium. Data are presented as mean + SEM, n=4, *p<0.05, Student’s t-test. 
 
 
6.4.11 Collagen III increases insulin output via GPR56 activation 
Having established that collagen III potentiates glucose-stimulated insulin secretion, it was 
investigated whether it does this by activating GPR56 since collagen III is a ligand of GPR56 in 
the developing brain (Luo et al., 2011). Dynamic insulin secretion of islets isolated from 
GPR56KO and GPR56WT mice were determined using the physiologically relevant 
temperature-controlled perifusion system. In the presence of collagen III at 2mM glucose, there 
was no change in insulin secretion in either WT or KO islets; further confirming the result of the 
static insulin secretion experiments shown in Figure 6-10 that collagen III has no effect on basal 
insulin secretion. Exposure of the islets to a physiological solution containing 20mM glucose 
produced a robust increase in insulin secretion, characterised by the classical short-lived first 
phase and the sustained second phase of insulin secretion (Figure 6-14). There was no 
difference in the response of GPR56KO and GPR56WT islets to 20mM glucose (secretion at 60 





no effect on the capacity of β-cells to secrete insulin at stimulatory glucose concentration. When 
GPR56WT islets (closed circles) were exposed to 100nM collagen III in buffer containing 20mM 
glucose, there was potentiation of insulin secretion and this effect was fully reversible when 
collagen III was removed. This augmentation of insulin secretion was not observed when 
GPR56KO islets were exposed to 100nM collagen III in a physiological solution containing 
20mM glucose (open circles). This indicates that the potentiation of glucose-stimulated insulin 
secretion in the presence of 100nM collagen III was via activation of GPR56 and that collagen 





Figure 6-14 Collagen III potentiates glucose-induced insulin secretion via GPR56 activation. Islets isolated 
from GPR56 KO and WT mice were perifused with 2mM or 20mM glucose in the presence of 100nM 
collagen III at the indicated time points. Samples were collected every 2 min and insulin secretion was 
determined by radioimmunoassay. Data are presented as Mean + SEM, n=4 replicates of 40 islets each 
isolated from 5 mice per genotype and representative of three independent experiments, *p<0.05, 






6.4.12 Effect of collagen III on islet RhoA activation 
To investigate whether collagen III activation of GPR56 in islets signalled via the G12/13 pathway, 
activated downstream RhoA was measured. Groups of 400 islets were incubated in a 
physiological solution containing 20mM glucose in the presence or absence of 100nM collagen 
III for 10 min and activated RhoA was measured by immunoblotting as described in Section 
2.8.2. Exposure of islets to 20mM glucose and collagen III indicated the presence of total RhoA, 
but active RhoA could not be detected after a pull-down assay (Figure 6-15). Although the 
experiment was repeated with 600 islets, it was still not possible to detect active RhoA. It is 
therefore likely that the protein content in the samples was too low for active RhoA to be 
detected, since it has previously been reported that 20mM glucose activated RhoA in MIN6 β-
cells (Liu et al., 2016).  
 
 
Figure 6-15 Effect of collagen III on RhoA activation in mouse islets. Groups of 400 islets were incubated 
in a physiological solution containing 20mM glucose in the presence or absence of 100nM collagen III for 
10 min. Cells were lysed and incubated with 30µg rhotekin-RBD affinity beads to pull down active RhoA 











Novel data on the role of collagen III in islet functions have been presented in this chapter. 
Collagen III, a component of the peri-islet and peri-vascular basement membrane, promoted β-
cell survival, increased cytosolic calcium concentration and insulin gene expression, and 
potentiated glucose-stimulated insulin secretion. The integrin superfamily has five collagen 
receptors (White et al., 2004), so most earlier studies on the effect of collagens on islet 
functions have largely focused on collagen-integrin interactions (Krishnamurthy et al., 2008; 
Wang et al., 1999; Wang and Rosenberg, 1999; Kaido et al., 2004). Here, it was demonstrated 
that collagen III acts via the adhesion GPCR GPR56 to potentiate glucose-stimulated insulin 
secretion in mouse islets.  Evidence was also provided on the role of GPR56 and other islet 
ECM components on β-cell adhesion.  
 
The cellular organisation and the three dimensional structure of tissues are regulated by cells 
adhering to their neighbours and/or to the ECM (Heino, 2007; Liu et al., 1997; Rozario and 
DeSimone, 2010). Cell adhesion is important for the correct movement of progenitor cells during 
brain development and in ensuring that cells are situated in their proper locations (Jeong et al., 
2012). With the unique 3D architecture of islets, and the peri-insular basement membrane 
partially encasing each islet, cell adhesion may play crucial roles in islet organogenesis, and 
this may be achieved through the individual ECM proteins. Indeed, ECM proteins control 
branching of the developing pancreas by modulating adhesiveness of the early progenitor cells 
(Shih et al., 2016). The effect of collagens on β cell adhesion was therefore investigated and it 
was found that only collagen IV promoted adhesion of MIN6 β-cells out of the three collagen 
sub-types investigated. It was not possible to determine whether this is due to activation of 
GPR56 but this should be investigated in future studies.  
 
Considering that GPR56 has sticky motifs in its N-terminal and can form homo- or heterodimers 
(Langenhan et al., 2013), it was hypothesised that it could play a part in the adherent nature of 
β cells. To investigate the role of GPR56 in β-cell adhesion, GPR56 expression in MIN6 β-cells 
grown as monolayers, was compared with its expression in MIN6 islet-like clusters known as 
pseudoislets. The ability of β-cells to aggregate and form pseudoislets provides a useful tool to 





clusters formed when MIN6 β-cells are grown in suspension and they are largely comparable in 
function to primary islets (Persaud et al., 2010; Hauge-Evans et al., 1999). An increase in 
GPR56 expression in pseudoislets indicated that GPR56 might improve the capacity of β-cells 
to adhere to each other, but since the expression was not statistically significant, other adhesion 
molecules such as E-cadherin may play more important roles in pseudoislet formation. 
However, experiments involving knockdown or deletion of GPR56 are necessary to confirm 
whether GPR56 is required for pseudoislet formation. GPR56 may also prevent β-cell migration, 
enabling them to cluster together, as brain studies have shown that activation of GPR56 
prevents migration of developing neurons (Li et al., 2008), which is an important step in the 
normal formation of the cerebral cortex (Jeong et al., 2012).  Mutations that prevent the 
expression of GPR56 in the brain lead to over-migration of neurons resulting in a rare disorder 
known as bilateral frontoparietal polymicrogyra (Piao et al., 2004). Cancer studies have also 
indicated that GPR56 prevents cell migration by inhibiting metastasis (Xu and Hynes, 2007). 
Taken together, GPR56 may play a role in islet development ensuring β-cell compactness and 
contributing to the 3D nature of islets. Further studies are required to determine whether GPR56 
plays any role in islet structural arrangement.  
 
Collagens I and III belong to the same class of fibrillar collagen and they have been implicated 
in maintaining elasticity and distensibility of tissues (Leitinger and Hohenester, 2007). Loss of 
collagens I and III in vivo causes skin blistering and aortic rupture (Liu et al., 1997). Collagen IV, 
on the other hand, is a structural collagen important for maintaining cohesiveness. The 
difference in functions of collagen III and IV was highlighted by the increased adhesion of MIN6 
β-cells observed with collagen IV treatment but not with collagen III. The ability of collagens to 
cause tissues to adhere or to distend is likely a physical property and not necessarily due to 
downstream genomic activation. Another difference observed between collagen III and IV is 
their effect on mouse islet morphology. Islets cultured on collagen III had good integrity with few 
loosely attached cells while those cultured on collagen IV exhibited cell spreading and they 
were difficult to retrieve after few days in culture. Collagen III may therefore have beneficial 
effects on islets maintained in culture prior to transplantation. Indeed, collagen III preserved β-
cells by suppressing cytokine-induced apoptosis. This is in agreement with a recent report, 





caspase 3 activities. The ability of collagen III to reduce apoptosis was lost once GPR56 was 
down-regulated (Dunér et al., 2016), indicating that it signals via this receptor in β-cells, 
consistent with the data shown in this thesis using islets for GPR56 KO mice. 
 
GPR56 is both Gq and G12/13 coupled (Little et al., 2004; Iguchi et al., 2008); pathways that are 
associated with elevation of intracellular calcium. The effect of collagen III on β-cell [Ca2+]i was 
therefore investigated and elevations in intracellular calcium were observed at 10nM, 100nM 
and 1µM collagen III with calcium profiles similar to those obtained with tolbutamide.  
Tolbutamide is a sulphonylurea that closes KATP channels and the subsequent depolarisation of 
the cell membrane leads to calcium influx through voltage-gated calcium channels. It cannot 
elevate [Ca2+]i without calcium influx as shown by the complete loss of its effects on calcium 
when extracellular calcium was removed from the physiological buffer. Removal of extracellular 
calcium when MIN6 β-cells were exposed to collagen III led to a complete loss of response, 
suggesting that the increase in [Ca2+]i requires calcium.  
 
Although the effect of collagen III to increase [Ca2+]i was lost when MIN6 β-cells were perifused 
with calcium-free media, collagen III was able to significantly potentiate glucose-stimulated 
insulin release in the absence of extracellular calcium, suggesting that collagen III can promote 
insulin secretion independently from its effects to promote calcium influx.  However, the amount 
of insulin released in response to collagen III was lower than when islets were perifused with 
physiological solution containing 2mM calcium. These data suggest that collagen III may be 
acting via a different cascade to promote insulin release in the absence of calcium influx. One 
possibility is the activation of protein kinases PKA and PKC. Activation of PLC from Gq 
stimulation produces simultaneous increase in IP3 and DAG. While IP3 causes Ca2+ release 
from the internal store, DAG activates PKC, which in turn regulates insulin secretion by 
modulating cell excitability, calcium influx and it can directly enhance non-calcium mediated 
exocytosis (Hille et al., 1999). In addition, collagen III can activate PKA through the Gs/cAMP 
pathway to increase insulin secretion (Dunér et al., 2016) 
 
Acute exposure of islets to 100nM collagen III potentiated glucose-stimulated insulin secretion 





insulin secretion when islets were retrieved and challenged with 20mM glucose. In both cases, 
there was no increase in basal insulin secretion indicating that collagen III functions to regulate 
the magnitude of insulin exocytosis in response to a physiological response. The most logical 
reason for the increase in insulin secretion when islets pre-cultured on collagen III-coated plates 
were exposed to high glucose is a direct increase in insulin exocytosis, since there was no 
increase in insulin content. This is similar to the effect of exogenous administration of the 
phospholipid PIP2 on β-cells, which causes increased insulin secretion as a result of priming 
and increased insulin granule docking (Tomas et al., 2010). PIP2 is hydrolysed to the second 
messengers IP3 and DAG after Gq mediated activation of PLC and its level is modulated by 
ECM (Takenawa and Itoh, 2001). Although there was no increase in insulin content after 48 h 
exposure to collagen III, incubation of β-cells on collagen III-coated dishes for 7 days led to 
increased preproinsulin gene expression. It is therefore likely that collagen III has a time-
dependent effect on insulin synthesis. 
  
To determine whether collagen III acted via GPR56 to increase insulin release, dynamic 
perifusion of isolated islets from GPR56KO mice and their WT littermates was used. Molecules 
such as serotonin, amylin, and nucleotides that can activate GPCRs are known to be co-
secreted with insulin upon a glucose challenge (Fehmann et al., 1990; Sassmann et al., 2010). 
In static secretion experiments, these substances can have a paracrine effect on the β-cells, 
thus a perifusion system that prevents accumulation of secreted substances is preferred. Using 
a temperature-controlled perifusion system, it was demonstrated that collagen III reversibly 
potentiated glucose-stimulated insulin secretion in a GPR56-dependent manner. The 
mechanisms downstream of GPR56 that mediate collagen III-induced insulin secretion are not 
yet clear but they may include Ca2+ signalling and interplay between Gq/PIP2 (Little et al., 
2004), G12/13/RhoA (Iguchi et al., 2008; Kanda et al., 2006) and more recently the Gs/PKA 
pathway has been implicated (Dunér et al., 2016). The effect of collagen III on insulin secretion 
may also be linked to remodelling of actin cytoskeleton via RhoA signalling. The effect of 
collagen III was investigated on RhoA pathway, but activated RhoA was not detected. Further 






In summary, this chapter demonstrated the beneficial effects of collagen III on β-cell function in 
terms of improving cell survival and insulin secretion. It also established that collagen III acts by 
activating GPR56 to potentiate glucose-stimulated insulin secretion. Taken together, these data 
provided insights into the role played by the ECM protein collagen III and GPR56 in regulating 
islet functions, which may be useful in optimising islet function prior to transplantation in T1D 
patients, or in targeting GPR56 for new therapies for T2D. Since collagen products are 
commercially available and are generally well tolerated during clinical trials (Borumand and 
Sibilla, 2014), it may be worth investigating whether people consuming collagen  supplements 
have improved metabolic functions, especially as ingestion of collagen peptides derived from 
fish has been shown to reduce fasting blood glucose and Hb1Ac in randomised Chinese 
patients with T2D (Zhu et al., 2010). However, ingested collagens would have been digested in 
the GI tract, so any beneficial effects that they may have on glucose homeostasis would not be 














































Chapter 7 General Discussion 
With the current trend of globalisation, physical inactivity, increasing obesity and people living 
longer, T2D will continue to pose considerable health challenges for the foreseeable future. 
Indeed, it is projected that by 2040, diabetes will affect more than 0.6 billion people, which 
translates to one in every ten adults having diabetes if urgent actions are not taken. The 
situation is particularly gloomy for developing countries, where two-thirds of the people living 
with diabetes are undiagnosed and 80% of deaths arising from diabetes-related complications 
occur in this region alone (International Diabetes Federation, 2015). Diabetes is also likely to 
impact detrimentally on the economies of many nations: its cost to the UK is currently at 10% of 
the NHS budget, translating to over £1.5m every hour (Kanavos et al., 2012), while the USA 
spends 20% of its health care budget on diabetes (American Diabetes Association, 2013). To 
put the cost into perspective, the estimated annual global expenditure associated with diabetes 
is equal to the gross domestic product (GDP) of Switzerland and twice the GDP of South Africa 
(da Rocha Fernandes et al., 2016; International Monetary Fund, 2016). The real cost to society 
is likely to be even higher than estimated, as the figures quoted above excluded care provided 
by family members of patients, pain and suffering, and the costs associated with undiagnosed 
diabetes and pre-diabetes.  
 
Moreover, another issue of considerable concern is that some of the currently available drugs 
for T2D are failing or are associated with serious side effects. For instance, one of the most 
recent therapies for T2D, Byetta, targets GLP-1 receptors on β-cells to stimulate insulin 
secretion, and studies in mice suggest that it also increases β-cell mass (Chon and Gautier, 
2016). However, Byetta has been associated with pancreatitis and kidney dysfunction in some 
individuals (Elashoff et al., 2011; Butler et al., 2013; Monami et al., 2017) so there is a need for 
development of novel therapies with minimal side-effects. G-protein coupled receptors (GPCRs) 
play important roles in modern medicine, and they are the targets of approximately 50% of all 
prescription drugs (Cook, 2010). Interestingly, many pharmaceutical companies are investing 
heavily in developing new T2D therapies that act via GPCRs (Filmore, 2004; Nguyen et al., 
2011). In our lab, we have shown that human islets express nearly 300 GPCRs, the majority of 





generation T2D therapy. This led us to focus on GPR56, which we have shown to be the most 
abundant GPCR in human islets (Amisten et al., 2013).  
 
As described previously, GPR56 is a member of the adhesion GPCRs and it is one of the few 
GPCRs to be associated with a human disease. Germline mutation in GPR56 causes bilateral 
frontoparietal polymicrogyra (BFPP), a deformity of the cerebral cortex, which presents as 
seizure, mental retardation and developmental difficulties in children (Chiang et al., 2011; Luo et 
al., 2011; Fujii et al., 2013; Piao et al., 2004). GPR56 has a wide tissue distribution and is 
involved in cell migration, organ development, cell adhesion, muscle hypertrophy, proliferation 
and inhibition of apoptosis (Shashidhar et al., 2005; White et al., 2014; Ke et al., 2007; Saito et 
al., 2013; Iguchi et al., 2008; Chen et al., 2010; Giera et al., 2015). The expression and function 
of GPR56 was therefore investigated from the embryonic stage of pancreas development to 
adulthood, with a focus on β-cell adhesion, proliferation and apoptosis.  
 
7.1 GPR56 and embryonic pancreas development 
GPR56, being a developmental gene, is critical for the proper formation of the cerebellum as it 
allows the developing neurons to adhere to the extracellular matrix of the pial basement 
membrane. Ectopia and numerous small gyri are characteristic features of the cerebral cortex of 
BFPP patients, and they arise as a result of mutations in GPR56 (Singer et al., 2013; Parrini et 
al., 2009; Piao et al., 2004). Moreover, loss of GPR56 during embryogenesis leads to 
decreased male fertility and hypomyelination of the CNS as a result of defective development of 
oligodendrocyte precursor cells (Chen et al., 2010; Bahi-Buisson et al., 2010; Giera et al., 
2015). Since GPR56 mRNA is robustly expressed in NGN3+ endocrine progenitors in the 
pancreas (Gu et al., 2004), it was hypothesised that GPR56 may play a role in islet 
development. The expression of GPR56 was therefore investigated in developing mouse 
pancreas at E11 to P9.  
 
Pancreas development involves a carefully orchestrated series of molecular activities that 
transform the single epithelium of the primitive foregut into two morphologically distinct 
structures: exocrine and endocrine segments of the mature pancreas. At post-conception day 9 





pancreas is specified in mice by condensation of the mesenchyme. This is followed by 
evagination, proliferation and branching morphogenesis to form dorsal and ventral buds 
(Stanger and Hebrok, 2013; Jørgensen et al., 2007). As a result of gut rotation and elongation, 
the dorsal and ventral buds come into contact and fuse to form a single entity at around E12 to 
E13. This stage, known as the primary transition, is characterised by extensive proliferation of 
multipotent progenitor cells (MPCs) and it coincided with high GPR56 expression by pancreatic 
progenitors, as reported in Chapter 3. At this stage, GPR56 was strongly expressed by cells 
expressing PDX1, which is a marker for uncommitted MPCs (Gittes, 2009; Marty-Santos and 
Cleaver, 2016). As the pancreas develops, up to E18, GPR56 expression was progressively 
downregulated. GPR56 may act during the primary transition to keep undifferentiated cells in a 
proliferative state, thereby maintaining a pool of progenitor cells. This role is supported by the 
observations that GPR56 expression was downregulated during the secondary transition from 
E14 to E18, when MPCs differentiate to the various pancreatic cell types. This is similar to what 
was observed in the brain, where GPR56 was strongly expressed in oligodendrocyte precursor 
cells (OPCs) but its expression gradually decreased as the OPCs matured into myelinating 
oligodendrocytes (Giera et al., 2015). 
 
In addition, the results from chapter 3 indicated that in the developing mouse pancreas GPR56 
was also co-localised with SOX9+ and NGN3+ cells, markers for ductal cells and endocrine 
progenitors respectively (Gu et al., 2002; Seymour, 2014). However, there were NGN3+ cells 
that were negative for GPR56, indicating that some terminally differentiated endocrine cells will 
not express GPR56. Among the major endocrine cell types, GPR56 was only expressed by the 
β-cells. At E16, there was an increased number of NGN3+ progenitors in pancreases from 
GPR56 KO mice, suggesting reduced differentiation, but there was no difference in the number 
of proliferating progenitor cells between GPR56 WT and KO mice at E16. This implies that islet 
development involves a tight regulation of endocrine precursor cell proliferation and 
differentiation, and that progenitor cells cannot be differentiating and proliferating at the same 
time. There were no striking morphological differences between the embryonic pancreases of 
GPR56 KO and WT mice, suggesting that GPR56 is not an instructive signal in islet 





studies using lineage tracing and β-cell specific deletion of GPR56 are required to confirm the 
role of GPR56 at key stages of embryonic islet development.  
 
7.2 The role of GPR56 in developing post-natal pancreas 
As described in Chapter 3, GPR56 expression was upregulated three days prior to birth, at E18, 
and maintained at a high level until P9, the latest time point when GPR56 expression was 
studied. This phase of increased GPR56 expression coincided with the period of increased β-
cell replication. Since the rate of replication declines progressively from P10 until weaning at 
P28, where it remains fairly constant until adulthood (Kaung, 1994), the requirement of GPR56 
for β-cell proliferation, β-cell number and mass was investigated at P9. Deletion of GPR56 in 
vivo resulted in decreased islet size at P9 as a result of decreased β-cell proliferation. The 
number of cells proliferating and still in the cell cycle was significantly lower at P9, leading to 
less β-cells but higher numbers of α-cells in GPR56 KO islets. It was not possible to investigate 
the functional significance of the increased number of α-cells due to time constraints, but this is 
clearly an area of further research. For example, it is possible that there was dedifferentiation of 
β-cells to α-cells following GPR56 deletion, and this is something that could be investigated 
using lineage tracing. Interestingly, there was no difference in islet area between GPR56 KO 
and WT mice at P56, although there was a higher proportion of small islets of less than 2 x 103 
µm2 in P56 KO pancreases. 
 
The observation that islets in pancreases from P56 GPR56 KO mice were not smaller than 
those from age-matched WT mice, while there was a significant reduction in size at P9 in the 
GPR56 KO mice, suggests that other processes in addition to β-cell replication may contribute 
to adult islet mass. The first postnatal month is associated with many changes in the developing 
pancreas, including a wave of increased apoptosis observed between P13 and P17 (Figure 
7-1). However, it has been reported that β-cell mass in rats was stable between P2 and P20 
despite increased apoptosis and decreased proliferation, suggesting that neogenesis is 
important for maintaining a constant β-cell mass (Scaglia et al., 1997). It was also reported that 
β-cell mass was more than doubled between P2 and P5 but the cross-sectional area remained 
unchanged, indicating that increased β-cell number rather than size contributed to the increased 





tracing suggested that neogenesis contributed between 30% to 50% of β-cell mass at the end of 
the first postnatal month (Finegood et al., 1995; Bonner-Weir et al., 2010). It is therefore likely 
that neogenesis enables GPR56 KO islets to catch up in size with their WT counterparts at 
adulthood or that GPR56 is not required for the formation of new β-cells postnatally. The extent 
to which GPR56 contributes to postnatal β-cell neogenesis warrants further studies using 









Figure 7-1: A schematic representing the various factors contributing to β-cell mass postnatally (not drawn 
to scale). β-cell replication is at its peak in the first week of birth and accounts for about 50%-70% of islet 
mass at the first postnatal month. GPR56 is strongly expressed between E18 and P9, coinciding with the 
phase of increased β-cell replication and minimal neogenesis. A wave of apoptosis between P13 and P17 
precedes a period of substantial neogenesis, which overall accounts for 30% to 50% of β-cell mass at P31. 
Data on β-cell replication, apoptosis, neogenesis and β-cell mass were adapted from (Bonner-Weir et al., 
2016; Scaglia et al., 1997).  
 
 
7.3 Functions of GPR56 in mature islets 
To date, the majority of studies on the beneficial effects of ECM on β-cell survival and function 
have focused on the roles of integrins (Kaido et al., 2004; White et al., 2004; Weber et al., 2008; 
Shih et al., 2016; Jiang and Harrison, 2002). However, the sheer complexity of ECM 
interactions with the many variants of integrin heterodimers has made it difficult to translate the 
understanding of β-cell-ECM interaction into novel therapeutic targets. It is therefore necessary 
to identify other, more tractable, targets through which the effect of ECM on β-cell function may 
be manipulated. A recent report using siRNA-mediated silencing of gene expression suggests 
that GPR56 could be one of the mechanisms through which ECM may influence β-cell function 
(Dunér et al., 2016). Using GPR56 KO mice, this thesis confirmed that GPR56 is a β-cell sensor 
for ECM-mediated effects on islet function.  
 
Collagen III, the primary agonist of GPR56, was identified within the peri-islet and peri-vascular 
basement membranes of mature mouse and human islets, as described in Chapter 3. However, 
collagen III mRNA was not detected in MIN6 β-cells and this was supported by IHC, indicating 
that β-cells do not lay down collagen III but this ECM protein is produced by fibroblasts and 
endothelial cells of islet blood vessels. Studying the requirement of collagen III on islet function 
in vivo was not possible as collagen III deletion in mice results in perinatal lethality, with only 5% 
of mutant mice surviving beyond P2 (Liu et al., 1997). The effect of collagen III on islet function 
was therefore studied in vitro using isolated mouse islets as described in Chapter 6. 100nM 





against cytokine-induced apoptosis, but it had no effect on β-cell adhesion. Acute and chronic 
exposure of islets to 100nM collagen III potentiated glucose-stimulated insulin secretion in static 
incubation assays. In both cases, there was no increase in basal insulin secretion indicating that 
collagen III functions to regulate the magnitude of insulin exocytosis in response to nutrients. 
The most logical reason for the increase in insulin secretion, when islets pre-cultured on 
collagen III-coated plates were exposed to high glucose, is a direct increase in insulin 
exocytosis, since there was no increase in insulin content. In addition, the perifusion data in 
Chapter 6 demonstrate that GPR56 is not required for appropriate insulin secretion in response 
to increased glucose concentration, but that it is essential for collagen III-induced potentiation of 
insulin secretion. The mechanisms by which collagen III activates GPR56 in β-cells to augment 
insulin release are not yet known but they may include Ca2+ signalling and interplay between 
Gq/PIP2 (Figure 7-2) (Little et al., 2004), G12/13/RhoA (Iguchi et al., 2008; Kanda et al., 2006), 
and, more recently, the Gs/PKA pathway has been suggested (Dunér et al., 2016).  
 
Chapter 4 showed that GPR56 is not involved in whole body glucose homeostasis in adult mice 
fed on a normal chow diet, although a trend towards mild glucose intolerance was observed. 
The glucose excursion curve for the female mice showed a sharp decline at 30 minutes 
following glucose administration and there was a tendency for the GPR56 KO female mice 
towards glucose intolerance. Nonetheless, there was no evidence of compromised insulin 
secretion in vitro, suggesting that the mild glucose intolerance is likely to be a consequence of 
reduced sensitivity of target tissues to insulin after GPR56 deletion. Furthermore, deletion of 
GPR56 had no effect on islet innervation and vascularisation. Further studies are needed to 
clarify whether GPR56 KO mice will behave differently with ageing or under increased metabolic 








Figure 7-2: Schematic summary of the signalling pathways downstream of GPR56 in the regulation of β-
cell function. Collagen III activates GPR56 to stimulate insulin secretion, possibly through elevations in 
cytosolic calcium via PKC phosphorylation of voltage-dependent calcium channels. The increased 
intracellular calcium stimulates insulin exocytosis. GPR56 also promotes β-cell proliferation and inhibits 
differentiation perhaps via the G12/13/RhoA pathway in islet development, but further experiments are 







7.4 Future studies 
7.4.1 Perspectives on future translational potential 
The experiments described in this thesis have established that GPR56/agonist interaction in β-
cells might have translational potential for T1D and T2D. It is possible that maintenance of islets 
with collagen III may improve transplantation outcomes for T1D since islet integrity and survival 
were improved when mouse islets were incubated with collagen III for 48 h. In addition, pre-
exposure of islets to collagen III before they were challenged with glucose led to potentiation of 
glucose-stimulated insulin secretion. However, future work should first determine whether the 
protective effect of collagen III on mouse islets and its ability to stimulate insulin secretion can 
be demonstrated in human islets, since species differences exist in the response of GPCRs to 
agonists (Amisten et al., 2017). The requirement of GPR56 for the improved insulin secretion 
observed after 48 h exposure of mouse islets to collagen III should also be investigated by 
using islets isolated from GPR56 KO mice and appropriate controls from WT mice. 
 
GPR56 may also be a novel target for T2D therapy. Reduction in islet mass is a hallmark 
feature of T2D and two separate reports have indicated that GPR56 expression is reduced in 
islets obtained from T2D donors (Taneera et al., 2012; Dunér et al., 2016). The size distribution 
of islets from GPR56 KO mice indicated a higher proportion of small islets as a result of 
decreased β-cell proliferation, as evidenced by the number of replicating BrdU+ β-cells in 
GPR56 KO and WT pancreases. This suggests that GPR56 may be a promising target for 
improving functional β-cell mass in T2D. It may be worth investigating whether activation of 
GPR56 offers a therapeutic target for maintaining functional β-cell mass by using mice with β-
cell-specific deletion of GPR56, under metabolic stress. In this condition, the requirement for 
GPR56 in the islet adaptive response to stress imposed by high fat feeding would be 
determined. It is conceivable that mice with β-cell-specific GPR56 deletion will be unable to 
compensate appropriately to increased metabolic demand. It may also be worth investigating 
the mechanisms by which collagen III stimulates insulin secretion. Moreover, a GPR56-specific 
agonist, TYFAVLM, is now available commercially, and it activates GPR56 with an EC50 of 
35µM (Stoveken et al., 2015). It will be interesting to know whether TYFAVLM replicates the 






7.4.2 GPR56 may be involved in the crosstalk between β-cells and intra-islet endothelial 
cells.  
As mentioned earlier, islets of Langerhans are highly vascularised, with a blood vessel density 
five times higher than exocrine cells and they make use of about 15% of the total pancreas 
blood supply, despite contributing only 2% to the pancreas mass (Zanone et al., 2008). The 
interaction between islet endocrine cells and this large vascular bed has been of great interest 
recently. Thus, it has been suggested that there is crosstalk between the endocrine cells and 
the vascular endothelial cells. This crosstalk regulates ECM protein production, angiogenesis 
and insulin secretion (Cao and Wang, 2014). ECM is an important islet component as the peri-
islet basement membrane has been shown to serve as a protective mantle against inflammatory 
leucocytes (Korpos et al., 2013). As islet β-cells do not produce ECM, they rely on 
communication with the vascular endothelial cells to produce this important component (Figure 
7-3). On the other hand, the endothelial cells depend on vascular endothelial growth factor 
(VEGF) secreted from the β-cells for angiogenesis and vascularisation (Nikolova et al., 2007). 
Since VEGF attracts endothelial cells to the β-cells and lays a network of blood capillaries near 
the β-cells, any factor that distorts the balance between ECM production and angiogenesis may 
therefore cause pathologic features in islets.  
 
 It has been reported that a progressive deposition of collagen I and III occurs at the islet-
exocrine cell interface and within the islets of the Zucker rat obese model of T2D as 
inflammation and fibrosis progresses (Jones et al., 2013). Evidence from cancer studies and 
idiopathic lung fibrosis, where the microenvironment is characterised by excessive deposition of 
ECM, suggest that GPR56 may play a role in T2D by modulating fibrosis and ECM composition. 
In those disease conditions, expression of GPR56 was downregulated and over-expression of 
GPR56 in a mouse model of lung fibrosis was able to rescue the phenotype (Yang et al., 2011; 
Yang et al., 2014). It may therefore be worth investigating the expression level of GPR56 in an 
obese mouse model of T2D since it might be expected that low levels of GPR56 expression 
may contribute to islet fibrosis. The mechanism by which GPR56 may regulate ECM production 
is hypothesised to be secondary to VEGF production via a PKCα signalling pathway (Figure 
7-3), since it has been reported that VEGF production in melanoma cells is regulated by GPR56 








Figure 7-3: Proposed crosstalk between islet β-cells and vascular endothelial cells. Endothelial cells are 
known to produce the islet basement membrane that contains collagen III, laminins, etc. The secreted 
factors stimulate β-cells to produce VEGF, which in turn induces endothelial cell-mediated vascularisation. 
This may be mediated via GPR56: Activation of GPR56 leads to VEGF production, which attracts 
endothelial cells to β-cells and causes new blood vessel formation and secretion of collagen III. The 
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